Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A cell line derived from cultured tumor cells.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
The action of a drug in promoting or enhancing the effectiveness of another drug.
Compounds with triple bonds to each side of a double bond. Many of these are CYTOTOXINS and are researched for use as CYTOTOXIC ANTIBIOTICS.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Transplantation between animals of different species.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Injections introduced directly into localized lesions.
Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Antibodies produced by a single clone of cells.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
Tumors or cancer of the LUNG.
Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY.
Tumors or cancer of the COLON.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Pyrido-CARBAZOLES originally discovered in the bark of OCHROSIA ELLIPTICA. They inhibit DNA and RNA synthesis and have immunosuppressive properties.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (ANTIGENS, CD28) and CD80 antigens (ANTIGENS, CD80).
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA.
An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
An experimental lymphocytic leukemia of mice.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Processes required for CELL ENLARGEMENT and CELL PROLIFERATION.
A tricyclic pentaglycosidic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA. It is used as a fluorescent dye and as an antineoplastic agent, especially in bone and testicular tumors. Plicamycin is also used to reduce hypercalcemia, especially that due to malignancies.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Tumors or cancer of the human BREAST.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Elements of limited time intervals, contributing to particular results or situations.
Agents that inhibit PROTEIN KINASES.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
A malignant epithelial tumor with a glandular organization.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Acridines which are substituted in any position by one or more amino groups or substituted amino groups.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells such as the GOBLET CELLS.
Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall.
Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID.
Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Tumors or cancers of the KIDNEY.
Proteins prepared by recombinant DNA technology.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
An encapsulated lymphatic organ through which venous blood filters.
Tumors or cancer of the PROSTATE.
Tumors or cancer of the LIVER.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
Angiostatic proteins that are formed from proteolytic cleavage of COLLAGEN TYPE XVIII.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Established cell cultures that have the potential to propagate indefinitely.
Compounds based on ANTHRACENES which contain two KETONES in any position. Substitutions can be in any position except on the ketone groups.
The giving of drugs, chemicals, or other substances by mouth.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
A general term for various neoplastic diseases of the lymphoid tissue.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A group of XANTHENES that contain a 9-keto OXYGEN.
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
The introduction of functional (usually cloned) GENES into cells. A variety of techniques and naturally occurring processes are used for the gene transfer such as cell hybridization, LIPOSOMES or microcell-mediated gene transfer, ELECTROPORATION, chromosome-mediated gene transfer, TRANSFECTION, and GENETIC TRANSDUCTION. Gene transfer may result in genetically transformed cells and individual organisms.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE.
Benzene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
Antimetabolites that are useful in cancer chemotherapy.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Complex cytotoxic antibiotic obtained from Streptomyces flocculus or S. rufochronmogenus. It is used in advanced carcinoma and causes leukopenia.
Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Experimentally induced tumors of the LIVER.
Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).
Glycoproteins found on the membrane or surface of cells.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
Organic compounds which contain platinum as an integral part of the molecule.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
A pyrano-acridone alkaloid found in RUTACEAE plants.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Compounds that include the amino-N-phenylamide structure.
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
Organic salts and esters of benzenesulfonic acid.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.

A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells. (1/3906)

We have evaluated the cytotoxicities of the combinations of calcium mobilizers and PKC inhibitors against human acute lymphoblastic leukemia (ALL) cells. Here we report that calcium mobilizers alone or PKC inhibitors alone do not induce apoptosis in human ALL cells. However, the combinations of calcium mobilizers with potent inhibitors of PKC cause significant apoptosis in ALL cells. Our results provide experimental evidence that PKC blocks Ca2+-triggered apoptosis in human ALL cells. Thus, PKC inhibitors can be used to enhance the antileukemic activity of chemical or biological agents that trigger an apoptotic calcium signal in ALL cells. The exquisite sensitivity of ALL cells to calcium-dependent apoptosis in the presence of PKC inhibitors could provide the basis for new treatment programs against ALL.  (+info)

Novel selective inhibitors for human topoisomerase I, BM2419-1 and -2 derived from saintopin. (2/3906)

Compounds BM2419-1 and -2 were isolated from a culture broth of a fungus Paecilomyces sp. BM2419. It was shown that these novel compounds were artifacts derived from saintopin, a dual inhibitor of topoisomerase I and II by independent processes. In the human topoisomerase I inhibition assay using the recombinant Saccharomyces cerevisiae, BM2419-1 and -2 inhibited selectively the yeast growth dependent on human topoisomerase I induction with IC50 values of 0.3 ng/ml and 6.0 ng/ml, respectively.  (+info)

Apicularens A and B, new cytostatic macrolides from Chondromyces species (myxobacteria): production, physico-chemical and biological properties. (3/3906)

A novel macrolide, apicularen A, was produced by several species of the genus Chondromyces. Initially it was discovered by bioassay-guided RP-HPLC-fractionation of culture extracts of Chondromyces robustus, strain Cm a13. Apicularen A showed no antimicrobial activity, but was highly cytotoxic for cultivated human and animal cells, with IC50 values ranging between 0.1 and 3 ng/ml. A cometabolite of apicularen A, the N-acetylglucosamine glycoside apicularen B, was distinctly less cytotoxic with IC50 values between 0.2 and 1.2 microg/ml, and showed weak activity against a few Gram-positive bacteria. Apicularen A is chemically closely related to the salicylihalamides A and B from the marine sponge Haliclona sp.  (+info)

BE-31405, a new antifungal antibiotic produced by Penicillium minioluteum. I. Description of producing organism, fermentation, isolation, physico-chemical and biological properties. (4/3906)

A new antifungal antibiotic, BE-31405, was isolated from the culture broth of a fungal strain, Penicillium minioluteum F31405. BE-31405 was isolated by adsorption on high porous polymer resin (Diaion HP-20), followed by solvent extraction, precipitation and crystallization. BE-31405 showed potent growth inhibitory activity against pathogenic fungal strains such as Candida albicans, Candida glabrata and Cryptococcus neoformans, but did not show cytotoxic activity against mammalian cells such as P388 mouse leukemia. The mechanism studies indicated that BE-31405 inhibited the protein synthesis of C. albicans but not of mammalian cells.  (+info)

Diperamycin, a new antimicrobial antibiotic produced by Streptomyces griseoaurantiacus MK393-AF2. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. (5/3906)

Antibacterial antibiotics, diperamycin (1) was produced in the culture broth of Streptomyces griseoaurantiacus MK393-AF2. Various spectroscopic analyses of 1 suggested that 1 belonged to a member of cyclic hexadepsipeptide antibiotic. Antibiotic 1 had potent inhibitory activity against various Gram-positive bacteria including Enterococcus seriolicida and methicillin-resistant Staphylococcus aureus.  (+info)

Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. (6/3906)

Resveratrol, a plant constituent enriched in the skin of grapes, is one of the most promising agents for the prevention of cancer. However, the mechanism of the anti-carcinogenic activity of resveratrol is not well understood. Here we offer a possible explanation of its anti-cancer effect. Resveratrol suppresses tumor promoter-induced cell transformation and markedly induces apoptosis, transactivation of p53 activity and expression of p53 protein in the same cell line and at the same dosage. Also, resveratrol-induced apoptosis occurs only in cells expressing wild-type p53 (p53+/+), but not in p53-deficient (p53-/-) cells, while there is no difference in apoptosis induction between normal lymphoblasts and sphingomyelinase-deficient cell lines. These results demonstrate for the first time that resveratrol induces apoptosis through activation of p53 activity, suggesting that its anti-tumor activity may occur through the induction of apoptosis.  (+info)

Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. (7/3906)

We have previously reported that the retinoids, 4-(hydroxyphenyl)retinamide (4-HPR) and 9-cis-retinoic acid (RA) prevented azoxymethane (AOM)-induced colon tumors and along with 2-(carboxyphenyl)retinamide (2-CPR) prevented aberrant crypt foci (ACF). In this study, we evaluated the effect of 2-CPR on AOM-induced colon tumors and the effect of the three retinoids on apoptosis and cell proliferation. Male F344 rats were administrated 15 mg/kg AOM at weeks 7 and 8 of age. 2-CPR (315 mg/kg) was administered in the diet starting either 1 week before or at week 12 after the first dose of AOM. The rats continued to receive the 2-CPR until killed at week 46. Unlike the demonstrated prevention of colon cancer by the other two retinoids, both dosing schedules of 2-CPR resulted in an approximate doubling of the yield of colon tumors. In adenomas, 2-CPR, 4-HPR and 9-cis-RA were equally effective in reducing mitotic activity, while only 4-HPR and 9-cis-RA but not 2-CPR enhanced apoptosis. When administered for only the 6 days prior to killing 4-HPR but not 2-CPR decreased the Mitotic Index and increased the Apoptotic Index in adenomas. In non-involved crypts, chronic exposure to 4-HPR and 9-cis-RA in contrast to 2-CPR reduced the Mitotic Index and enhanced the Apoptotic Index. In concurrence with our previous study, both 2-CPR and 4-HPR were very potent in preventing ACF when administered in the diet starting 1 week before the first dose of AOM and continuing for the 5 weeks of the study. Hence, unlike the other two retinoids, 2-CPR, although very potent in preventing ACF, enhanced rather than prevented AOM-induced colon cancer. Furthermore, our results suggest that the effect of 2-CPR on tumor yield is different from 4-HPR and 9-cis-RA because, unlike them, it does not enhance apoptosis.  (+info)

Synthesis, anti-HIV and anticancer activities of new 4-(2-mercaptobenzenesulfonyl)perhydro-1,2,4-triazin-3-ones. (8/3906)

Syntheses of N-(6-chloro-1,1-dioxo-7-R1-1,4,2-benzodithiazyn-3-yl)-N'-(2- hydroxyethyl)hydrazines (IIa-d], N-(6-chloro-1,1-dioxo-7-methyl-1,4,2-benzodithiazyn-3-yl)-N'-(2- chloroethyl)hydrazine [IV], 4-(4-chloro-5-R1-2-mercaptobenzenesulfonyl)perhydro-1,2,4-triaz in-3-ones [IIIa-d] and 5-chloro-4-methyl-2-(3-oxoperhydro-1,2,4-triazin-4- ylsulfonyl)phenylthioacetic acid [V] have been described. Preliminary screening data have indicated that compounds [IIIa-d] exhibit either a moderate or a high anti-HIV activity and a moderate anticancer activity in some human tumor cell lines.  (+info)

In the medical field, Leukemia P388 is defined as a subline of leukemia cells that exhibits a specific set of genetic alterations and characteristics, including the ability to grow and proliferate in culture and in vivo, resistance to certain drugs and therapies, and the presence of specific markers and mutations.

Leukemia P388 is commonly used in research to study the biology of leukemia and to develop new treatments for this disease. It is also sometimes used as a model to study other types of cancer, such as lymphoma and solid tumors.

Overall, Leukemia P388 is an important tool in the study of cancer biology and is used to advance our understanding of the disease and to develop new treatments for patients with leukemia and other types of cancer.

The term "Sarcoma 180" was coined by a German surgeon named Otto Kunkel in the early 20th century. He described this type of cancer as a highly malignant tumor that grows slowly but is resistant to treatment with surgery, radiation therapy, and chemotherapy.

The exact cause of Sarcoma 180 is not known, but it is believed to be linked to genetic mutations and exposure to certain chemicals or radiation. The disease typically affects middle-aged adults and is more common in men than women.

The symptoms of Sarcoma 180 can vary depending on the location of the tumor, but they may include pain, swelling, redness, and limited mobility in the affected area. If left untreated, the cancer can spread to other parts of the body and be fatal.

Treatment for Sarcoma 180 usually involves a combination of surgery, radiation therapy, and chemotherapy. In some cases, amputation of the affected limb may be necessary. The prognosis for this disease is generally poor, with a five-year survival rate of less than 50%.

In summary, Sarcoma 180 is a rare and aggressive form of cancer that affects connective tissue and has a poor prognosis. It is important for medical professionals to be aware of this condition and its symptoms in order to provide proper diagnosis and treatment.

Types of experimental neoplasms include:

* Xenografts: tumors that are transplanted into animals from another species, often humans.
* Transgenic tumors: tumors that are created by introducing cancer-causing genes into an animal's genome.
* Chemically-induced tumors: tumors that are caused by exposure to certain chemicals or drugs.

The use of experimental neoplasms in research has led to significant advances in our understanding of cancer biology and the development of new treatments for the disease. However, the use of animals in cancer research is a controversial topic and alternatives to animal models are being developed and implemented.

2. Our research focuses on identifying the genetic mutations that contribute to experimental melanoma and developing targeted therapies.
3. The patient's experimental melanoma had spread to her lungs and liver, so we recommended chemotherapy and immunotherapy treatments.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

The tumor cells are typically small, uniform, and well-differentiated, with a distinct cell border and a central nucleus. The tumor cells are often arranged in a glandular or tubular pattern, which is characteristic of this type of cancer.

Carcinoma, Lewis lung usually affects older adults, with the median age at diagnosis being around 60 years. Men are slightly more likely to be affected than women. The main risk factor for developing this type of cancer is smoking, although it can also occur in people who have never smoked.

The symptoms of Carcinoma, Lewis lung can vary depending on the location and size of the tumor, but they may include:

* Chest pain or discomfort
* Coughing up blood
* Shortness of breath
* Fatigue
* Weight loss

If you suspect you may have Carcinoma, Lewis lung or are experiencing any of these symptoms, it is important to consult a healthcare professional for an accurate diagnosis and appropriate treatment.

The post Definition of 'Carcinoma, Lewis Lung' in the medical field appeared first on Healthy Life Tips.

Example sentence: The patient was diagnosed with experimental sarcoma and underwent a novel chemotherapy regimen that included a targeted therapy drug.

There are several types of melanoma, including:

1. Superficial spreading melanoma: This is the most common type of melanoma, accounting for about 70% of cases. It usually appears as a flat or slightly raised discolored patch on the skin.
2. Nodular melanoma: This type of melanoma is more aggressive and accounts for about 15% of cases. It typically appears as a raised bump on the skin, often with a darker color.
3. Acral lentiginous melanoma: This type of melanoma affects the palms of the hands, soles of the feet, or nail beds and accounts for about 5% of cases.
4. Lentigo maligna melanoma: This type of melanoma usually affects the face and is more common in older adults.

The risk factors for developing melanoma include:

1. Ultraviolet (UV) radiation exposure from the sun or tanning beds
2. Fair skin, light hair, and light eyes
3. A history of sunburns
4. Weakened immune system
5. Family history of melanoma

The symptoms of melanoma can vary depending on the type and location of the cancer. Common symptoms include:

1. Changes in the size, shape, or color of a mole
2. A new mole or growth on the skin
3. A spot or sore that bleeds or crusts over
4. Itching or pain on the skin
5. Redness or swelling around a mole

If melanoma is suspected, a biopsy will be performed to confirm the diagnosis. Treatment options for melanoma depend on the stage and location of the cancer and may include surgery, chemotherapy, radiation therapy, or a combination of these. Early detection and treatment are key to successful outcomes in melanoma cases.

In conclusion, melanoma is a type of skin cancer that can be deadly if not detected early. It is important to practice sun safety, perform regular self-exams, and seek medical attention if any suspicious changes are noticed on the skin. By being aware of the risk factors, symptoms, and treatment options for melanoma, individuals can take steps to protect themselves from this potentially deadly disease.

The exact cause of fibrosarcoma is not known, but it is believed to be linked to genetic mutations that occur during a person's lifetime. Some risk factors for developing fibrosarcoma include previous radiation exposure, chronic inflammation, and certain inherited conditions such as neurofibromatosis type 1 (NF1).

The symptoms of fibrosarcoma can vary depending on the location and size of the tumor. In some cases, there may be no symptoms until the tumor has grown to a significant size. Common symptoms include pain, swelling, and limited mobility in the affected limb. If the tumor is near a nerve, it can also cause numbness or tingling sensations in the affected area.

Diagnosis of fibrosarcoma typically involves a combination of imaging tests such as X-rays, CT scans, and MRI scans, as well as a biopsy to confirm the presence of cancer cells. Treatment options for fibrosarcoma may include surgery, radiation therapy, and chemotherapy, depending on the size and location of the tumor, as well as the patient's overall health.

Prognosis for fibrosarcoma is generally good if the tumor is caught early and treated aggressively. However, if the cancer has spread to other parts of the body (metastasized), the prognosis is generally poorer. In some cases, the cancer can recur after treatment, so it is important for patients to follow their doctor's recommendations for regular check-ups and follow-up testing.

Overall, fibrosarcoma is a rare and aggressive form of cancer that can be challenging to diagnose and treat. However, with early detection and appropriate treatment, many people with this condition can achieve long-term survival and a good quality of life.

There are several types of lung neoplasms, including:

1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.

Lung diseases can also be classified based on their cause, such as:

1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.

Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.

There are several types of colonic neoplasms, including:

1. Adenomas: These are benign growths that are usually precursors to colorectal cancer.
2. Carcinomas: These are malignant tumors that arise from the epithelial lining of the colon.
3. Sarcomas: These are rare malignant tumors that arise from the connective tissue of the colon.
4. Lymphomas: These are cancers of the immune system that can affect the colon.

Colonic neoplasms can cause a variety of symptoms, including bleeding, abdominal pain, and changes in bowel habits. They are often diagnosed through a combination of medical imaging tests (such as colonoscopy or CT scan) and biopsy. Treatment for colonic neoplasms depends on the type and stage of the tumor, and may include surgery, chemotherapy, and/or radiation therapy.

Overall, colonic neoplasms are a common condition that can have serious consequences if left untreated. It is important for individuals to be aware of their risk factors and to undergo regular screening for colon cancer to help detect and treat any abnormal growths or tumors in the colon.

Pathologic neovascularization can be seen in a variety of conditions, including cancer, diabetic retinopathy, and age-related macular degeneration. In cancer, for example, the formation of new blood vessels can help the tumor grow and spread to other parts of the body. In diabetic retinopathy, the growth of new blood vessels in the retina can cause vision loss and other complications.

There are several different types of pathologic neovascularization, including:

* Angiosarcoma: a type of cancer that arises from the cells lining blood vessels
* Hemangiomas: benign tumors that are composed of blood vessels
* Cavernous malformations: abnormal collections of blood vessels in the brain or other parts of the body
* Pyogenic granulomas: inflammatory lesions that can form in response to trauma or infection.

The diagnosis of pathologic neovascularization is typically made through a combination of physical examination, imaging studies (such as ultrasound, CT scans, or MRI), and biopsy. Treatment options vary depending on the underlying cause of the condition, but may include medications, surgery, or radiation therapy.

In summary, pathologic neovascularization is a process that occurs in response to injury or disease, and it can lead to serious complications. It is important for healthcare professionals to be aware of this condition and its various forms in order to provide appropriate diagnosis and treatment.

Examples of 'Mammary Neoplasms, Experimental' in a sentence:

1. The researchers studied the effects of hormone therapy on mammary neoplasms in experimental animals to better understand its potential role in human breast cancer.
2. The lab used mice with genetic mutations that predispose them to developing mammary neoplasms to test the efficacy of new cancer drugs.
3. In order to investigate the link between obesity and breast cancer, the researchers conducted experiments on mammary neoplasms in rats with diet-induced obesity.

The signs and symptoms of CE can vary depending on the location of the tumor, but they may include:

* Lumps or swelling in the neck, underarm, or groin area
* Fever
* Fatigue
* Weight loss
* Night sweats
* Swollen lymph nodes
* Pain in the affected area

CE is caused by a genetic mutation that leads to uncontrolled cell growth and division. The exact cause of the mutation is not fully understood, but it is believed to be linked to exposure to certain viruses or chemicals.

Diagnosis of CE typically involves a combination of physical examination, imaging tests such as CT scans or PET scans, and biopsy to confirm the presence of cancer cells. Treatment options for CE depend on the stage and location of the tumor, but may include:

* Chemotherapy to kill cancer cells
* Radiation therapy to shrink the tumor
* Surgery to remove the tumor
* Immunotherapy to boost the immune system's ability to fight the cancer

Overall, CE is a rare and aggressive form of cancer that requires prompt diagnosis and treatment to improve outcomes.

The Leukemia L5178 cell line has been used in numerous studies to investigate the molecular mechanisms underlying cancer development and progression. For example, researchers have used these cells to study the role of specific genes and proteins in tumorigenesis, as well as the effects of environmental factors such as radiation and chemical carcinogens on cancer development.

In addition to its use in basic research, the Leukemia L5178 cell line has also been used as a model system for testing the efficacy of new anti-cancer drugs. These cells are often implanted into mice and then treated with different drug regimens to assess their ability to inhibit tumor growth and induce apoptosis (programmed cell death).

Overall, the Leukemia L5178 cell line is a valuable tool for cancer researchers, providing a reliable and well-characterized model system for studying various aspects of cancer biology. Its use has contributed significantly to our understanding of the molecular mechanisms underlying cancer development and progression, and has helped to identify potential therapeutic targets for the treatment of this disease.

Examples of experimental leukemias include:

1. X-linked agammaglobulinemia (XLA): A rare inherited disorder that leads to a lack of antibody production and an increased risk of infections.
2. Diamond-Blackfan anemia (DBA): A rare inherited disorder characterized by a failure of red blood cells to mature in the bone marrow.
3. Fanconi anemia: A rare inherited disorder that leads to a defect in DNA repair and an increased risk of cancer, particularly leukemia.
4. Ataxia-telangiectasia (AT): A rare inherited disorder characterized by progressive loss of coordination, balance, and speech, as well as an increased risk of cancer, particularly lymphoma.
5. Down syndrome: A genetic disorder caused by an extra copy of chromosome 21, which increases the risk of developing leukemia, particularly acute myeloid leukemia (AML).

These experimental leukemias are often used in research studies to better understand the biology of leukemia and to develop new treatments.

There are different types of Breast Neoplasms such as:

1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.

2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.

3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.

4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.

5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.

Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.

Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.

It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:

1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)

The symptoms of adenocarcinoma depend on the location of the cancer and can include:

1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)

The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.

Treatment options for adenocarcinoma depend on the location of the cancer and can include:

1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.

The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.

Neoplastic metastasis can occur in any type of cancer but are more common in solid tumors such as carcinomas (breast, lung, colon). It is important for cancer diagnosis and prognosis because metastasis indicates that the cancer has spread beyond its original site and may be more difficult to treat.

Metastases can appear at any distant location but commonly found sites include the liver, lungs, bones, brain, and lymph nodes. The presence of metastases indicates a higher stage of cancer which is associated with lower survival rates compared to localized cancer.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

Symptoms of Kidney Neoplasms can include blood in the urine, pain in the flank or abdomen, weight loss, fever, and fatigue. Diagnosis is made through a combination of physical examination, imaging studies such as CT scans or ultrasound, and tissue biopsy. Treatment options vary depending on the type and stage of the neoplasm, but may include surgery, ablation therapy, targeted therapy, or chemotherapy.

It is important for individuals with a history of Kidney Neoplasms to follow up with their healthcare provider regularly for monitoring and check-ups to ensure early detection of any recurrences or new tumors.

Malignant prostatic neoplasms are cancerous tumors that can be aggressive and spread to other parts of the body (metastasize). The most common type of malignant prostatic neoplasm is adenocarcinoma of the prostate, which accounts for approximately 95% of all prostate cancers. Other types of malignant prostatic neoplasms include sarcomas and small cell carcinomas.

Prostatic neoplasms can be diagnosed through a variety of tests such as digital rectal examination (DRE), prostate-specific antigen (PSA) test, imaging studies (ultrasound, CT scan or MRI), and biopsy. Treatment options for prostatic neoplasms depend on the type, stage, and grade of the tumor, as well as the patient's age and overall health. Treatment options can include active surveillance, surgery (robotic-assisted laparoscopic prostatectomy or open prostatectomy), radiation therapy (external beam radiation therapy or brachytherapy), and hormone therapy.

In summary, Prostatic Neoplasms are tumors that occur in the prostate gland, which can be benign or malignant. The most common types of malignant prostatic neoplasms are adenocarcinoma of the prostate, and other types include sarcomas and small cell carcinomas. Diagnosis is done through a variety of tests, and treatment options depend on the type, stage, and grade of the tumor, as well as the patient's age and overall health.

Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.

There are several types of liver neoplasms, including:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.

The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.

Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.

Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

Mast cell sarcoma is most commonly seen in the skin, but it can also arise in other parts of the body such as the spleen, liver, or gastrointestinal tract. The tumors are usually large, irregularly shaped masses that can be firm or soft to the touch. They may ulcerate and bleed easily, leading to swelling and discomfort.

The symptoms of mast cell sarcoma can vary depending on the location and size of the tumor. They may include:

* A lump or mass that may be painless or tender to the touch
* Swelling in the affected area
* Abdominal pain
* Diarrhea or constipation
* Fatigue
* Fevers
* Night sweats

Mast cell sarcoma is rare and accounts for only about 1-2% of all skin tumors. It is more common in dogs than cats and tends to affect older animals. The exact cause of mast cell sarcoma is not known, but genetic factors and environmental triggers may play a role.

Treatment options for mast cell sarcoma depend on the location and stage of the tumor. Surgery is often the first line of treatment to remove the tumor and any affected tissue. Additional therapies such as radiation, chemotherapy, or immunotherapy may be recommended based on the severity of the disease and the patient's overall health.

Prognosis for mast cell sarcoma varies depending on several factors, including the size and location of the tumor, the effectiveness of treatment, and the patient's overall health. In general, the prognosis is guarded and early detection and treatment are important to improve outcomes. With prompt and appropriate therapy, some patients with mast cell sarcoma can achieve long-term remission or even cure. However, in advanced cases or those that are resistant to treatment, the prognosis may be poorer.

Brain neoplasms can arise from various types of cells in the brain, including glial cells (such as astrocytes and oligodendrocytes), neurons, and vascular tissues. The symptoms of brain neoplasms vary depending on their size, location, and type, but may include headaches, seizures, weakness or numbness in the limbs, and changes in personality or cognitive function.

There are several different types of brain neoplasms, including:

1. Meningiomas: These are benign tumors that arise from the meninges, the thin layers of tissue that cover the brain and spinal cord.
2. Gliomas: These are malignant tumors that arise from glial cells in the brain. The most common type of glioma is a glioblastoma, which is aggressive and hard to treat.
3. Pineal parenchymal tumors: These are rare tumors that arise in the pineal gland, a small endocrine gland in the brain.
4. Craniopharyngiomas: These are benign tumors that arise from the epithelial cells of the pituitary gland and the hypothalamus.
5. Medulloblastomas: These are malignant tumors that arise in the cerebellum, specifically in the medulla oblongata. They are most common in children.
6. Acoustic neurinomas: These are benign tumors that arise on the nerve that connects the inner ear to the brain.
7. Oligodendrogliomas: These are malignant tumors that arise from oligodendrocytes, the cells that produce the fatty substance called myelin that insulates nerve fibers.
8. Lymphomas: These are cancers of the immune system that can arise in the brain and spinal cord. The most common type of lymphoma in the CNS is primary central nervous system (CNS) lymphoma, which is usually a type of B-cell non-Hodgkin lymphoma.
9. Metastatic tumors: These are tumors that have spread to the brain from another part of the body. The most common types of metastatic tumors in the CNS are breast cancer, lung cancer, and melanoma.

These are just a few examples of the many types of brain and spinal cord tumors that can occur. Each type of tumor has its own unique characteristics, such as its location, size, growth rate, and biological behavior. These factors can help doctors determine the best course of treatment for each patient.

There are several subtypes of RCC, including clear cell, papillary, chromophobe, and collecting duct carcinoma. The most common subtype is clear cell RCC, which accounts for approximately 70-80% of all RCC cases.

RCC can be difficult to diagnose as it may not cause any symptoms in its early stages. However, some common symptoms of RCC include blood in the urine (hematuria), pain in the flank or abdomen, weight loss, and fatigue. RCC is typically diagnosed through a combination of imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans, along with a biopsy to confirm the presence of cancer cells.

Treatment for RCC depends on the stage and location of the cancer. Surgery is the primary treatment for localized RCC, and may involve a partial or complete nephrectomy (removal of the affected kidney). For more advanced cases, treatment may involve a combination of surgery and systemic therapies such as targeted therapy or immunotherapy. Targeted therapy drugs, such as sunitinib and pazopanib, work by blocking specific molecules that promote the growth and spread of cancer cells. Immunotherapy drugs, such as checkpoint inhibitors, work by stimulating the body's immune system to attack cancer cells.

The prognosis for RCC is generally good if the cancer is detected early and treated promptly. However, the cancer can be aggressive and may spread to other parts of the body (metastasize) if left untreated. The 5-year survival rate for RCC is about 73% for patients with localized disease, but it drops to about 12% for those with distant metastases.

There are several risk factors for developing RCC, including:

* Age: RCC is more common in people over the age of 50.
* Gender: Men are slightly more likely to develop RCC than women.
* Family history: People with a family history of RCC or other kidney diseases may be at increased risk.
* Chronic kidney disease: Patients with chronic kidney disease are at higher risk for developing RCC.
* Hypertension: High blood pressure is a common risk factor for RCC.
* Smoking: Smoking may increase the risk of developing RCC.
* Obesity: Being overweight or obese may increase the risk of developing RCC.

There are several complications associated with RCC, including:

* Metastasis: RCC can spread to other parts of the body, such as the lymph nodes, liver, and bones.
* Hematuria: Blood in the urine is a common complication of RCC.
* Pain: RCC can cause pain in the flank or abdomen.
* Fatigue: RCC can cause fatigue and weakness.
* Weight loss: RCC can cause weight loss and loss of appetite.

There are several treatment options for RCC, including:

* Surgery: Surgery is often the first line of treatment for RCC that is localized and has not spread to other parts of the body.
* Ablation: Ablation therapies, such as cryotherapy or radiofrequency ablation, can be used to destroy the tumor.
* Targeted therapy: Targeted therapies, such as sunitinib or pazopanib, can be used to slow the growth of the tumor.
* Immunotherapy: Immunotherapies, such as checkpoint inhibitors, can be used to stimulate the immune system to attack the tumor.
* Chemotherapy: Chemotherapy may be used in combination with other treatments or as a last resort for patients with advanced RCC.

The prognosis for RCC varies depending on the stage and location of the cancer, but in general, the earlier the cancer is detected and treated, the better the outcome. According to the American Cancer Society, the 5-year survival rate for RCC is about 73% for patients with localized disease (cancer that has not spread beyond the kidney) and about 12% for patients with distant disease (cancer that has spread to other parts of the body).

Examples of experimental liver neoplasms include:

1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and can be induced experimentally by injecting carcinogens such as diethylnitrosamine (DEN) or dimethylbenz(a)anthracene (DMBA) into the liver tissue of animals.
2. Cholangiocarcinoma: This type of cancer originates in the bile ducts within the liver and can be induced experimentally by injecting chemical carcinogens such as DEN or DMBA into the bile ducts of animals.
3. Hepatoblastoma: This is a rare type of liver cancer that primarily affects children and can be induced experimentally by administering chemotherapy drugs to newborn mice or rats.
4. Metastatic tumors: These are tumors that originate in other parts of the body and spread to the liver through the bloodstream or lymphatic system. Experimental models of metastatic tumors can be studied by injecting cancer cells into the liver tissue of animals.

The study of experimental liver neoplasms is important for understanding the underlying mechanisms of liver cancer development and progression, as well as identifying potential therapeutic targets for the treatment of this disease. Animal models can be used to test the efficacy of new drugs or therapies before they are tested in humans, which can help to accelerate the development of new treatments for liver cancer.

Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.

Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.

Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.

The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.




There are several types of gliomas, including:

1. Astrocytoma: This is the most common type of glioma, accounting for about 50% of all cases. It arises from the star-shaped cells called astrocytes that provide support and nutrients to the brain's nerve cells.
2. Oligodendroglioma: This type of glioma originates from the oligodendrocytes, which are responsible for producing the fatty substance called myelin that insulates the nerve fibers.
3. Glioblastoma (GBM): This is the most aggressive and malignant type of glioma, accounting for about 70% of all cases. It is fast-growing and often spreads to other parts of the brain.
4. Brain stem glioma: This type of glioma arises in the brain stem, which is responsible for controlling many of the body's vital functions such as breathing, heart rate, and blood pressure.

The symptoms of glioma depend on the location and size of the tumor. Common symptoms include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality, memory, or speech.

Gliomas are diagnosed through a combination of imaging tests such as CT or MRI scans, and tissue biopsy to confirm the presence of cancer cells. Treatment options for glioma depend on the type and location of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment to remove as much of the tumor as possible, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells.

The prognosis for glioma patients varies depending on the type and location of the tumor, as well as the patient's overall health. In general, the prognosis is better for patients with slow-growing, low-grade tumors, while those with fast-growing, high-grade tumors have a poorer prognosis. Overall, the 5-year survival rate for glioma patients is around 30-40%.

There are several risk factors for developing HCC, including:

* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity

HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:

* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss

If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:

* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope

Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:

* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer

Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.

Neuroblastoma is caused by a genetic mutation that affects the development and growth of nerve cells. The cancerous cells are often sensitive to chemotherapy, but they can be difficult to remove surgically because they are deeply embedded in the nervous system.

There are several different types of neuroblastoma, including:

1. Infantile neuroblastoma: This type of neuroblastoma occurs in children under the age of one and is often more aggressive than other types of the cancer.
2. Juvenile neuroblastoma: This type of neuroblastoma occurs in children between the ages of one and five and tends to be less aggressive than infantile neuroblastoma.
3. Adult neuroblastoma: This type of neuroblastoma occurs in adults and is rare.
4. Metastatic neuroblastoma: This type of neuroblastoma has spread to other parts of the body, such as the bones or liver.

Symptoms of neuroblastoma can vary depending on the location and size of the tumor, but they may include:

* Abdominal pain
* Fever
* Loss of appetite
* Weight loss
* Fatigue
* Bone pain
* Swelling in the abdomen or neck
* Constipation
* Increased heart rate

Diagnosis of neuroblastoma typically involves a combination of imaging tests, such as CT scans and MRI scans, and biopsies to confirm the presence of cancerous cells. Treatment for neuroblastoma usually involves a combination of chemotherapy, surgery, and radiation therapy. The prognosis for neuroblastoma varies depending on the type of cancer, the age of the child, and the stage of the disease. In general, the younger the child and the more aggressive the treatment, the better the prognosis.

Glioblastomas are highly malignant tumors that can grow rapidly and infiltrate surrounding brain tissue, making them difficult to remove surgically. They often recur after treatment and are usually fatal within a few years of diagnosis.

The symptoms of glioblastoma can vary depending on the location and size of the tumor but may include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality, memory or cognitive function.

Glioblastomas are diagnosed through a combination of imaging tests such as CT or MRI scans, and a biopsy to confirm the presence of cancerous cells. Treatment typically involves surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy to slow the growth of any remaining cancerous cells.

Prognosis for glioblastoma is generally poor, with a five-year survival rate of around 5% for newly diagnosed patients. However, the prognosis can vary depending on factors such as the location and size of the tumor, the patient's age and overall health, and the effectiveness of treatment.

The symptoms of Sarcoma, Yoshida can vary depending on the location of the tumor, but may include pain, swelling, and limited mobility in the affected limb. The diagnosis of this condition is based on a combination of imaging studies such as CT or MRI scans, and a biopsy to confirm the presence of cancer cells.

Treatment for Sarcoma, Yoshida usually involves a combination of surgery, chemotherapy, and radiation therapy. The prognosis for this condition is generally poor, with a five-year survival rate of around 30%. However, early detection and aggressive treatment can improve outcomes.

There are several types of skin neoplasms, including:

1. Basal cell carcinoma (BCC): This is the most common type of skin cancer, and it usually appears as a small, fleshy bump or a flat, scaly patch. BCC is highly treatable, but if left untreated, it can grow and invade surrounding tissue.
2. Squamous cell carcinoma (SCC): This type of skin cancer is less common than BCC but more aggressive. It typically appears as a firm, flat, or raised bump on sun-exposed areas. SCC can spread to other parts of the body if left untreated.
3. Melanoma: This is the most serious type of skin cancer, accounting for only 1% of all skin neoplasms but responsible for the majority of skin cancer deaths. Melanoma can appear as a new or changing mole, and it's essential to recognize the ABCDE signs (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving size, shape, or color) to detect it early.
4. Sebaceous gland carcinoma: This rare type of skin cancer originates in the oil-producing glands of the skin and can appear as a firm, painless nodule on the forehead, nose, or other oily areas.
5. Merkel cell carcinoma: This is a rare and aggressive skin cancer that typically appears as a firm, shiny bump on the skin. It's more common in older adults and those with a history of sun exposure.
6. Cutaneous lymphoma: This type of cancer affects the immune system and can appear as a rash, nodules, or tumors on the skin.
7. Kaposi sarcoma: This is a rare type of skin cancer that affects people with weakened immune systems, such as those with HIV/AIDS. It typically appears as a flat, red or purple lesion on the skin.

While skin cancers are generally curable when detected early, it's important to be aware of your skin and notice any changes or unusual spots, especially if you have a history of sun exposure or other risk factors. If you suspect anything suspicious, see a dermatologist for an evaluation and potential biopsy. Remember, prevention is key to avoiding the harmful effects of UV radiation and reducing your risk of developing skin cancer.

Gliosarcoma typically grows slowly over time, but it can be difficult to diagnose because its symptoms are often similar to those of other conditions. The cancer usually starts in one part of the brain and then spreads to other areas, which is why it is important for doctors to monitor patients closely and perform regular scans to detect any changes.

Surgery is often the first line of treatment for gliosarcoma, followed by radiation therapy and chemotherapy. Depending on the location and size of the tumor, a surgical procedure may be performed to remove as much of the cancerous tissue as possible. If the cancer has spread to other parts of the brain, doctors may use a combination of radiation and chemotherapy to shrink the tumor before surgery.

Gliosarcoma is a rare type of brain cancer, but researchers are working to learn more about its causes and develop new treatments. In recent years, advances in surgical techniques and radiation therapy have improved survival rates for patients with gliosarcoma, and clinical trials are ongoing to investigate the use of targeted therapies and immunotherapy for this rare and aggressive form of cancer.

Thymoma can be broadly classified into two main types:

1. Benign thymoma: This type of thymoma is non-cancerous and does not spread to other parts of the body. It is usually small in size and may not cause any symptoms.
2. Malignant thymoma: This type of thymoma is cancerous and can spread to other parts of the body, including the lungs, liver, and bone marrow. Malignant thymomas are more aggressive than benign thymomas and can be life-threatening if not treated promptly.

The exact cause of thymoma is not known, but it is believed to arise from abnormal cell growth in the thymus gland. Some risk factors that may increase the likelihood of developing thymoma include:

1. Genetic mutations: Certain genetic mutations, such as those affecting the TREX1 gene, can increase the risk of developing thymoma.
2. Radiation exposure: Exposure to radiation, such as from radiation therapy, may increase the risk of developing thymoma.
3. Thymic hyperplasia: Enlargement of the thymus gland, known as thymic hyperplasia, may increase the risk of developing thymoma.

The symptoms of thymoma can vary depending on the size and location of the tumor. Some common symptoms include:

1. Chest pain or discomfort
2. Shortness of breath
3. Coughing
4. Fatigue
5. Weight loss
6. Fever
7. Night sweats
8. Pain in the arm or shoulder

Thymoma is diagnosed through a combination of imaging tests, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), and biopsy, which involves removing a sample of tissue from the thymus gland for examination under a microscope. Treatment options for thymoma depend on the stage and aggressiveness of the tumor, and may include:

1. Surgery: Removing the tumor through surgery is often the first line of treatment for thymoma.
2. Radiation therapy: High-energy beams can be used to kill cancer cells and shrink the tumor.
3. Chemotherapy: Drugs can be used to kill cancer cells and shrink the tumor.
4. Targeted therapy: Drugs that target specific molecules involved in the growth and spread of cancer cells can be used to treat thymoma.
5. Immunotherapy: Treatments that use the body's immune system to fight cancer, such as checkpoint inhibitors, can be effective for some people with thymoma.

Overall, the prognosis for thymoma is generally good, with a 5-year survival rate of about 70% for people with localized disease. However, the prognosis can vary depending on the stage and aggressiveness of the tumor, as well as the effectiveness of treatment.

SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.

SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.

Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.

Plasmacytoma is a type of plasma cell dyscrasia, which is a group of diseases that affect the production and function of plasma cells. Plasma cells are a type of white blood cell that produces antibodies to fight infections. In plasmacytoma, the abnormal plasma cells grow and multiply out of control, leading to a tumor.

There are several subtypes of plasmacytoma, including:

* solitary plasmacytoma: A single tumor that occurs in one location.
* multiple myeloma: A type of cancer that affects the bones and is characterized by an overgrowth of malignant plasma cells in the bone marrow.
* extramedullary plasmacytoma: A tumor that occurs outside of the bone marrow, such as in soft tissue or organs.

Plasmacytoma is usually diagnosed through a combination of physical examination, imaging tests such as X-rays or CT scans, and biopsy. Treatment typically involves chemotherapy and/or radiation therapy to destroy the abnormal cells. In some cases, surgery may be necessary to remove the tumor.

Plasmacytoma is a relatively rare cancer, but it can be aggressive and potentially life-threatening if left untreated. It is important for patients with symptoms of plasmacytoma to seek medical attention as soon as possible to receive an accurate diagnosis and appropriate treatment.

There are several subtypes of lymphoma, B-cell, including:

1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.

The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.

Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.

Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.

Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.

Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.

Some common types of head and neck neoplasms include:

1. Oral cavity cancer: Cancer that develops in the mouth, tongue, lips, or floor of the mouth.
2. Oropharyngeal cancer: Cancer that develops in the throat, including the base of the tongue, soft palate, and tonsils.
3. Hypopharyngeal cancer: Cancer that develops in the lower part of the throat, near the esophagus.
4. Laryngeal cancer: Cancer that develops in the voice box (larynx).
5. Paranasal sinus cancer: Cancer that develops in the air-filled cavities around the eyes and nose.
6. Salivary gland cancer: Cancer that develops in the salivary glands, which produce saliva to moisten food and keep the mouth lubricated.
7. Thyroid gland cancer: Cancer that develops in the butterfly-shaped gland in the neck that regulates metabolism and growth.

The risk factors for developing head and neck neoplasms include tobacco use, heavy alcohol consumption, human papillomavirus (HPV) infection, poor diet, and exposure to environmental carcinogens such as asbestos or radiation. Symptoms of head and neck neoplasms can vary depending on the location and size of the tumor, but may include a lump or swelling, pain, difficulty swallowing, bleeding, and changes in voice or breathing.

Diagnosis of head and neck neoplasms typically involves a combination of physical examination, imaging tests such as CT scans or MRI, and biopsy to confirm the presence of cancer cells. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, depending on the type, location, and stage of the cancer.

Overall, head and neck neoplasms can have a significant impact on quality of life, and early detection and treatment are important for improving outcomes. If you suspect any changes in your head or neck, it is essential to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.

Adenocarcinoma is the most common subtype of NSCLC and is characterized by malignant cells that have glandular or secretory properties. Squamous cell carcinoma is less common and is characterized by malignant cells that resemble squamous epithelium. Large cell carcinoma is a rare subtype and is characterized by large, poorly differentiated cells.

The main risk factor for developing NSCLC is tobacco smoking, which is responsible for approximately 80-90% of all cases. Other risk factors include exposure to secondhand smoke, radon gas, asbestos, and certain chemicals in the workplace or environment.

Symptoms of NSCLC can include coughing, chest pain, shortness of breath, and fatigue. The diagnosis is typically made through a combination of imaging studies such as CT scans, PET scans, and biopsy. Treatment options for NSCLC can include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for NSCLC depends on several factors, including the stage of the cancer, the patient's overall health, and the effectiveness of treatment.

Overall, NSCLC is a common and aggressive form of lung cancer that can be treated with a variety of therapies. Early detection and treatment are critical for improving outcomes in patients with this diagnosis.

There are several subtypes of carcinoma, including:

1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.

The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:

* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding

The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.

In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.

References:

1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from

The causes of colorectal neoplasms are not fully understood, but factors such as age, genetics, diet, and lifestyle have been implicated. Symptoms of colorectal cancer can include changes in bowel habits, blood in the stool, abdominal pain, and weight loss. Screening for colorectal cancer is recommended for adults over the age of 50, as it can help detect early-stage tumors and improve survival rates.

There are several subtypes of colorectal neoplasms, including adenomas (which are precancerous polyps), carcinomas (which are malignant tumors), and lymphomas (which are cancers of the immune system). Treatment options for colorectal cancer depend on the stage and location of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Research into the causes and treatment of colorectal neoplasms is ongoing, and there has been significant progress in recent years. Advances in screening and treatment have improved survival rates for patients with colorectal cancer, and there is hope that continued research will lead to even more effective treatments in the future.

Treatment options for ascites include medications to reduce fluid buildup, dietary restrictions, and insertion of a catheter to drain the fluid. In severe cases, a liver transplant may be necessary. It is important to seek medical attention if symptoms persist or worsen over time.

Ascites is a serious condition that requires ongoing management and monitoring to prevent complications and improve quality of life.

There are several different types of leukemia, including:

1. Acute Lymphoblastic Leukemia (ALL): This is the most common type of leukemia in children, but it can also occur in adults. It is characterized by an overproduction of immature white blood cells called lymphoblasts.
2. Acute Myeloid Leukemia (AML): This type of leukemia affects the bone marrow's ability to produce red blood cells, platelets, and other white blood cells. It can occur at any age but is most common in adults.
3. Chronic Lymphocytic Leukemia (CLL): This type of leukemia affects older adults and is characterized by the slow growth of abnormal white blood cells called lymphocytes.
4. Chronic Myeloid Leukemia (CML): This type of leukemia is caused by a genetic mutation in a gene called BCR-ABL. It can occur at any age but is most common in adults.
5. Hairy Cell Leukemia: This is a rare type of leukemia that affects older adults and is characterized by the presence of abnormal white blood cells called hairy cells.
6. Myelodysplastic Syndrome (MDS): This is a group of disorders that occur when the bone marrow is unable to produce healthy blood cells. It can lead to leukemia if left untreated.

Treatment for leukemia depends on the type and severity of the disease, but may include chemotherapy, radiation therapy, targeted therapy, or stem cell transplantation.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

These tumors can be benign or malignant, and their growth and behavior vary depending on the type of cancer. Malignant tumors can invade the surrounding tissues and spread to other parts of the body through the bloodstream or lymphatic system, causing serious complications and potentially life-threatening consequences.

The risk factors for developing urinary bladder neoplasms include smoking, exposure to certain chemicals, recurrent bladder infections, and a family history of bladder cancer. The symptoms of these tumors can include blood in the urine, pain during urination, frequent urination, and abdominal pain.

Diagnosis of urinary bladder neoplasms is typically made through a combination of imaging tests such as ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI), and cystoscopy, which involves inserting a flexible tube with a camera into the bladder to visualize the tumor.

Treatment options for urinary bladder neoplasms depend on the type of cancer, stage, and location of the tumor. Treatment may include surgery to remove the tumor, chemotherapy, radiation therapy, or a combination of these modalities. Early detection and treatment can improve the prognosis for patients with urinary bladder neoplasms.

Examples of mammary neoplasms in animals include:

* Mammary adenocarcinoma: A type of tumor that develops in the mammary gland of animals and is characterized by the growth of abnormal cells that produce milk.
* Mammary fibroadenoma: A benign tumor that develops in the mammary gland of animals and is characterized by the growth of fibrous and glandular tissue.
* Inflammatory mammary carcinoma: A type of tumor that develops in the mammary gland of animals and is characterized by the presence of inflammatory cells and abnormal cells.

These tumors can be caused by a variety of factors, including genetic mutations, hormonal imbalances, and exposure to certain environmental agents. They can also be induced experimentally using chemical carcinogens or viruses.

The study of mammary neoplasms in animals is important for understanding the molecular mechanisms underlying breast cancer development and progression, as well as for identifying potential therapeutic targets and developing new treatments.

There are two main types of mastocytoma: cutaneous mastocytoma, which affects the skin, and systemic mastocytosis, which can affect multiple organs throughout the body. Cutaneous mastocytoma typically appears as a firm, raised bump or nodule on the skin, and may be accompanied by itching or other symptoms. Systemic mastocytosis is more serious and can cause a wide range of symptoms, including abdominal pain, diarrhea, fatigue, and anemia.

The exact cause of mastocytoma is not known, but it is believed to be linked to genetic mutations and environmental factors such as exposure to toxins or allergens. Diagnosis is typically made through a combination of physical examination, biopsy, and laboratory tests. Treatment options for mastocytoma include surgery, chemotherapy, and medications to reduce histamine levels.

Prognosis for mastocytoma varies depending on the type and severity of the disease, but in general, the prognosis is good for most patients with this condition. With proper treatment, many patients can achieve long-term remission or even be cured. However, in some cases, mastocytoma can progress to more aggressive forms of cancer, such as mast cell leukemia, which can be difficult to treat and has a poorer prognosis.

Necrosis is a type of cell death that occurs when cells are exposed to excessive stress, injury, or inflammation, leading to damage to the cell membrane and the release of cellular contents into the surrounding tissue. This can lead to the formation of gangrene, which is the death of body tissue due to lack of blood supply.

There are several types of necrosis, including:

1. Coagulative necrosis: This type of necrosis occurs when there is a lack of blood supply to the tissues, leading to the formation of a firm, white plaque on the surface of the affected area.
2. Liquefactive necrosis: This type of necrosis occurs when there is an infection or inflammation that causes the death of cells and the formation of pus.
3. Caseous necrosis: This type of necrosis occurs when there is a chronic infection, such as tuberculosis, and the affected tissue becomes soft and cheese-like.
4. Fat necrosis: This type of necrosis occurs when there is trauma to fatty tissue, leading to the formation of firm, yellowish nodules.
5. Necrotizing fasciitis: This is a severe and life-threatening form of necrosis that affects the skin and underlying tissues, often as a result of bacterial infection.

The diagnosis of necrosis is typically made through a combination of physical examination, imaging studies such as X-rays or CT scans, and laboratory tests such as biopsy. Treatment depends on the underlying cause of the necrosis and may include antibiotics, surgical debridement, or amputation in severe cases.

There are several types of osteosarcomas, including:

1. High-grade osteosarcoma: This is the most common type of osteosarcoma and tends to grow quickly.
2. Low-grade osteosarcoma: This type of osteosarcoma grows more slowly than high-grade osteosarcoma.
3. Chondrosarcoma: This is a type of osteosarcoma that arises in the cartilage cells of the bone.
4. Ewing's family of tumors: These are rare types of osteosarcoma that can occur in any bone of the body.

The exact cause of osteosarcoma is not known, but certain risk factors may increase the likelihood of developing the disease. These include:

1. Previous radiation exposure
2. Paget's disease of bone
3. Li-Fraumeni syndrome (a genetic disorder that increases the risk of certain types of cancer)
4. Familial retinoblastoma (a rare inherited condition)
5. Exposure to certain chemicals, such as herbicides and industrial chemicals.

Symptoms of osteosarcoma may include:

1. Pain in the affected bone, which may be worse at night or with activity
2. Swelling and redness around the affected area
3. Limited mobility or stiffness in the affected limb
4. A visible lump or mass on the affected bone
5. Fractures or breaks in the affected bone

If osteosarcoma is suspected, a doctor may perform several tests to confirm the diagnosis and determine the extent of the disease. These may include:

1. Imaging studies, such as X-rays, CT scans, or MRI scans
2. Biopsy, in which a sample of tissue is removed from the affected bone and examined under a microscope for cancer cells
3. Blood tests to check for elevated levels of certain enzymes that are produced by osteosarcoma cells
4. Bone scans to look for areas of increased activity or metabolism in the bones.

Some common types of bone neoplasms include:

* Osteochondromas: These are benign tumors that grow on the surface of a bone.
* Giant cell tumors: These are benign tumors that can occur in any bone of the body.
* Chondromyxoid fibromas: These are rare, benign tumors that develop in the cartilage of a bone.
* Ewing's sarcoma: This is a malignant tumor that usually occurs in the long bones of the arms and legs.
* Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow.

Symptoms of bone neoplasms can include pain, swelling, or deformity of the affected bone, as well as weakness or fatigue. Treatment options depend on the type and location of the tumor, as well as the severity of the symptoms. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these.

The symptoms of mesothelioma can vary depending on the location of the cancer, but they may include:

* Shortness of breath or pain in the chest (for pleural mesothelioma)
* Abdominal pain or swelling (for peritoneal mesothelioma)
* Fatigue or fever (for pericardial mesothelioma)
* Weight loss and night sweats

There is no cure for mesothelioma, but treatment options may include surgery, chemotherapy, and radiation therapy. The prognosis for mesothelioma is generally poor, with a five-year survival rate of about 5% to 10%. However, the outlook can vary depending on the type of mesothelioma, the stage of the cancer, and the patient's overall health.

Asbestos exposure is the primary risk factor for developing mesothelioma, and it is important to avoid exposure to asbestos in any form. This can be done by avoiding old buildings and products that contain asbestos, wearing protective clothing and equipment when working with asbestos, and following proper safety protocols when handling asbestos-containing materials.

In summary, mesothelioma is a rare and aggressive form of cancer that develops in the lining of the heart or abdomen due to exposure to asbestos. It can be difficult to diagnose and treat, and the prognosis is generally poor. However, with proper medical care and avoidance of asbestos exposure, patients with mesothelioma may have a better chance of survival.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Sarcomas can arise in any part of the body, but they are most common in the arms and legs. They can also occur in the abdomen, chest, or head and neck. There are many different types of sarcoma, each with its own unique characteristics and treatment options.

The causes of sarcoma are not fully understood, but genetic mutations, exposure to radiation, and certain chemicals have been linked to an increased risk of developing the disease. Sarcomas can be challenging to diagnose and treat, as they often grow slowly and may not cause symptoms until they are advanced.

Treatment for sarcoma typically involves a combination of surgery, radiation therapy, and chemotherapy. The specific treatment plan will depend on the type of sarcoma, its location, and the stage of the disease. In some cases, amputation may be necessary to remove the tumor.

Prognosis for sarcoma varies depending on the type of cancer, the size and location of the tumor, and the stage of the disease. In general, the prognosis is best for patients with early-stage sarcoma that is confined to a small area and has not spread to other parts of the body.

Overall, sarcoma is a rare and complex form of cancer that requires specialized treatment and care. While the prognosis can vary depending on the specific type of cancer and the stage of the disease, advances in medical technology and treatment options have improved outcomes for many patients with sarcoma.

There are several types of stomach neoplasms, including:

1. Adenocarcinoma: This is the most common type of stomach cancer, accounting for approximately 90% of all cases. It begins in the glandular cells that line the stomach and can spread to other parts of the body.
2. Squamous cell carcinoma: This type of cancer begins in the squamous cells that cover the outer layer of the stomach. It is less common than adenocarcinoma but more likely to be found in the upper part of the stomach.
3. Gastric mixed adenocarcinomasquamous cell carcinoma: This type of cancer is a combination of adenocarcinoma and squamous cell carcinoma.
4. Lymphoma: This is a cancer of the immune system that can occur in the stomach. It is less common than other types of stomach cancer but can be more aggressive.
5. Carcinomas of the stomach: These are malignant tumors that arise from the epithelial cells lining the stomach. They can be subdivided into adenocarcinoma, squamous cell carcinoma, and others.
6. Gastric brunner's gland adenoma: This is a rare type of benign tumor that arises from the Brunner's glands in the stomach.
7. Gastric polyps: These are growths that occur on the lining of the stomach and can be either benign or malignant.

The symptoms of stomach neoplasms vary depending on the location, size, and type of tumor. Common symptoms include abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. Diagnosis is usually made through a combination of endoscopy, imaging studies (such as CT or PET scans), and biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these. The prognosis for stomach neoplasms varies depending on the type and stage of the tumor, but early detection and treatment can improve outcomes.

Without more information about the context in which this term is being used, it is difficult to provide a clear definition or interpretation of its meaning. However, based on the name "Walker" and the fact that it is followed by a number (256), it is possible that this term may refer to a specific type of cancer or tumor that has been identified in a patient with the last name Walker.

It's important to note that the diagnosis and treatment of cancer can be complex and highly individualized, and any medical information or terminology should only be interpreted and applied by qualified healthcare professionals who have access to the relevant clinical context and patient information.

Peritoneal neoplasms are relatively rare, but they can be aggressive and difficult to treat. The most common types of peritoneal neoplasms include:

1. Peritoneal mesothelioma: This is the most common type of peritoneal neoplasm and arises from the mesothelial cells that line the abdominal cavity. It is often associated with asbestos exposure.
2. Ovarian cancer: This type of cancer originates in the ovaries and can spread to the peritoneum.
3. Appendiceal cancer: This type of cancer arises in the appendix and can spread to the peritoneum.
4. Pseudomyxoma peritonei: This is a rare type of cancer that originates in the abdominal cavity and resembles a mucin-secreting tumor.
5. Primary peritoneal cancer: This type of cancer originates in the peritoneum itself and can be of various types, including adenocarcinoma, squamous cell carcinoma, and sarcoma.

The symptoms of peritoneal neoplasms vary depending on the location and size of the tumor, but may include abdominal pain, distension, and difficulty eating or passing stool. Treatment options for peritoneal neoplasms depend on the type and stage of the cancer, but may include surgery, chemotherapy, and radiation therapy. Prognosis for peritoneal neoplasms is generally poor, with a five-year survival rate of around 20-30%.

* Peripheral T-cell lymphoma (PTCL): This is a rare type of T-cell lymphoma that can develop in the skin, lymph nodes, or other organs.
* Cutaneous T-cell lymphoma (CTCL): This is a type of PTCL that affects the skin and can cause lesions, rashes, and other skin changes.
* Anaplastic large cell lymphoma (ALCL): This is a rare subtype of PTCL that can develop in the lymph nodes, spleen, or bone marrow.
* Adult T-cell leukemia/lymphoma (ATLL): This is a rare and aggressive subtype of PTCL that is caused by the human T-lymphotropic virus type 1 (HTLV-1).

Symptoms of T-cell lymphoma can include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Skin lesions or rashes

Treatment options for T-cell lymphoma depend on the subtype and stage of the cancer, but may include:

* Chemotherapy
* Radiation therapy
* Immunotherapy
* Targeted therapy

Prognosis for T-cell lymphoma varies depending on the subtype and stage of the cancer, but in general, the prognosis for PTCL is poorer than for other types of non-Hodgkin lymphoma. However, with prompt and appropriate treatment, many people with T-cell lymphoma can achieve long-term remission or even be cured.

1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.

Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.

The exact cause of RMS is not known, but it is believed to be linked to genetic mutations that occur during fetal development. These mutations can lead to the growth of abnormal cells that can eventually form a tumor.

There are several subtypes of RMS, including:

1. Embryonal rhabdomyosarcoma: This is the most common type of RMS and typically affects children under the age of 6.
2. Alveolar rhabdomyosarcoma: This type of RMS is more aggressive than embryonal RMS and tends to affect older children and teenagers.
3. Pleomorphic rhabdomyosarcoma: This is the least common subtype of RMS and can occur in any age group.

The symptoms of RMS vary depending on the location of the tumor, but may include:

* Lumps or swelling in the neck, abdomen, or extremities
* Painless lumps or swelling in the scrotum (in boys)
* Difficulty swallowing or breathing (if the tumor is located in the throat)
* Abdominal pain (if the tumor is located in the abdomen)
* Fever
* Fatigue
* Weight loss

If RMS is suspected, a doctor may perform a physical exam, take a medical history, and order imaging tests such as X-rays, CT scans, or MRI scans to confirm the diagnosis. A biopsy, in which a small sample of tissue is removed from the body and examined under a microscope, may also be performed to confirm the presence of cancer cells.

Treatment for RMS typically involves a combination of surgery, chemotherapy, and radiation therapy. The specific treatment plan will depend on the location and size of the tumor, as well as the age and overall health of the patient. In some cases, the tumor may be completely removed with surgery, while in other cases, the cancer cells may be difficult to remove and may require ongoing treatment to manage the disease.

Overall, RMS is a rare and aggressive form of cancer that can affect children and adults. While the prognosis for RMS varies depending on the location and size of the tumor, early diagnosis and treatment are critical for improving outcomes.

Also known as Burkitt's Lymphoma.

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

In medical terminology, nausea is sometimes used interchangeably with the term "dyspepsia," which refers to a general feeling of discomfort or unease in the stomach, often accompanied by symptoms such as bloating, belching, or heartburn. However, while nausea and dyspepsia can be related, they are not always the same thing, and it's important to understand the specific underlying cause of any gastrointestinal symptoms in order to provide appropriate treatment.

Some common causes of nausea include:

* Gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastritis
* Motion sickness or seasickness
* Medication side effects, including chemotherapy drugs, antibiotics, and painkillers
* Pregnancy and morning sickness
* Food poisoning or other infections
* Migraines and other headaches
* Anxiety and stress

Treatment for nausea will depend on the underlying cause, but may include medications such as antihistamines, anticholinergics, or anti-nausea drugs, as well as non-pharmacological interventions such as ginger, acupressure, or relaxation techniques. In severe cases, hospitalization may be necessary to manage symptoms and prevent dehydration or other complications.

There are several possible causes of lymphopenia, including:

1. Viral infections: Many viral infections can cause lymphopenia, such as HIV/AIDS, hepatitis B and C, and influenza.
2. Bacterial infections: Some bacterial infections, such as tuberculosis and leprosy, can also cause lymphopenia.
3. Cancer: Certain types of cancer, such as Hodgkin's disease and non-Hodgkin's lymphoma, can cause lymphopenia by destroying lymphocytes.
4. Autoimmune disorders: Autoimmune disorders, such as rheumatoid arthritis and lupus, can cause lymphopenia by attacking the body's own tissues, including lymphocytes.
5. Radiation therapy: Radiation therapy can destroy lymphocytes and cause lymphopenia.
6. Medications: Certain medications, such as chemotherapy drugs and antibiotics, can cause lymphopenia as a side effect.
7. Genetic disorders: Some genetic disorders, such as X-linked lymphoproliferative disease, can cause lymphopenia by affecting the development or function of lymphocytes.

Symptoms of lymphopenia can include recurring infections, fatigue, and swollen lymph nodes. Treatment of lymphopenia depends on the underlying cause and may involve antibiotics, antiviral medications, or immunoglobulin replacement therapy. In some cases, a bone marrow transplant may be necessary.

Overall, lymphopenia is a condition that can have a significant impact on quality of life, and it is important to seek medical attention if symptoms persist or worsen over time. With proper diagnosis and treatment, many people with lymphopenia can experience improved health outcomes and a better quality of life.

The exact cause of adenosarcoma is not known, but it is believed to be linked to genetic mutations that occur during the development of soft tissue cells. The risk of developing adenosarcoma increases with age, and it is more common in men than women.

Symptoms of adenosarcoma may include:

* Painless lumps or swelling in the affected area
* Pain or discomfort in the affected area
* Limited range of motion in the affected limb
* Night sweats
* Fever

If adenosarcoma is suspected, a doctor may perform a series of tests to confirm the diagnosis, including:

* Imaging tests, such as X-rays, CT scans, or MRI scans, to visualize the tumor and determine its size and location.
* Biopsy, where a sample of tissue is taken from the affected area and examined under a microscope for cancer cells.
* Blood tests to check for certain substances in the blood that are associated with adenosarcoma.

Treatment options for adenosarcoma may include:

* Surgery to remove the tumor and surrounding tissue.
* Radiation therapy to kill cancer cells using high-energy rays.
* Chemotherapy to kill cancer cells using drugs.
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of cancer cells.

The prognosis for adenosarcoma is generally good if the tumor is small and has not spread to other parts of the body. However, the cancer can be challenging to treat if it has spread to surrounding tissues or organs. The 5-year survival rate for adenosarcoma is approximately 70%.

Epidemiology:

* Incidence: Small cell carcinoma (SCC) accounts for approximately 10%-15% of all skin cancers, but it is more common in certain populations such as fair-skinned individuals and those with a history of sun exposure.
* Prevalence: The prevalence of SCC is difficult to determine due to its rarity, but it is believed to be more common in certain geographic regions such as Australia and New Zealand.

Clinical features:

* Appearance: Small cell carcinoma usually appears as a firm, shiny nodule or plaque on sun-exposed areas of the skin, such as the face, ears, lips, and hands. It can also occur in other parts of the body, including the mucous membranes.
* Color: The color of SCC can range from pink to red to purple, and it may be covered with a crust or scab.
* Dimensions: SCC usually measures between 1-5 cm in diameter, but it can be larger in some cases.
* Surface: The surface of SCC may be smooth or rough, and it may have a "pearly" appearance due to the presence of small, white, and shiny nodules called "heidlebergs."

Differential diagnosis:

* Other types of skin cancer, such as basal cell carcinoma and squamous cell carcinoma.
* Other diseases that can cause similar symptoms and appearance, such as psoriasis, eczema, and actinic keratosis.

Treatment:

* Surgical excision: Small cell carcinoma is usually treated with surgical excision, which involves removing the tumor and some surrounding tissue.
* Radiation therapy: In some cases, radiation therapy may be used after surgical excision to ensure that all cancer cells are eliminated.
* Topical treatments: For more superficial SCC, topical treatments such as imiquimod cream or podofilox solution may be effective.

Prognosis:

* The prognosis for small cell carcinoma is generally good if it is detected and treated early.
* However, if left untreated, SCC can invade surrounding tissues and organs, leading to serious complications and potentially fatal outcomes.

Complications:

* Invasion of surrounding tissues and organs.
* Spread of cancer cells to other parts of the body (metastasis).
* Scarring and disfigurement.
* Infection and inflammation.

There are several subtypes of B-cell leukemia, including:

1. Chronic lymphocytic leukemia (CLL): This is the most common type of B-cell leukemia, and it typically affects older adults. CLL is a slow-growing cancer that can progress over time.
2. Acute lymphoblastic leukemia (ALL): This is a fast-growing and aggressive form of B-cell leukemia that can affect people of all ages. ALL is often treated with chemotherapy and sometimes with bone marrow transplantation.
3. Burkitt lymphoma: This is an aggressive form of B-cell leukemia that typically affects older adults in Africa and Asia. Burkitt lymphoma can be treated with chemotherapy and sometimes with bone marrow transplantation.
4. Hairy cell leukemia: This is a rare type of B-cell leukemia that is characterized by the presence of hair-like projections on the surface of cancer cells. Hairy cell leukemia can be treated with chemotherapy and sometimes with bone marrow transplantation.

The diagnosis of B-cell leukemia is based on a combination of physical examination, medical history, laboratory tests, and biopsies. Treatment options for B-cell leukemia include chemotherapy, bone marrow transplantation, and in some cases, targeted therapy with drugs that specifically target cancer cells. The prognosis for B-cell leukemia varies depending on the subtype of the disease and the patient's overall health.

Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

Body weight is an important health indicator, as it can affect an individual's risk for certain medical conditions, such as obesity, diabetes, and cardiovascular disease. Maintaining a healthy body weight is essential for overall health and well-being, and there are many ways to do so, including a balanced diet, regular exercise, and other lifestyle changes.

There are several ways to measure body weight, including:

1. Scale: This is the most common method of measuring body weight, and it involves standing on a scale that displays the individual's weight in kg or lb.
2. Body fat calipers: These are used to measure body fat percentage by pinching the skin at specific points on the body.
3. Skinfold measurements: This method involves measuring the thickness of the skin folds at specific points on the body to estimate body fat percentage.
4. Bioelectrical impedance analysis (BIA): This is a non-invasive method that uses electrical impulses to measure body fat percentage.
5. Dual-energy X-ray absorptiometry (DXA): This is a more accurate method of measuring body composition, including bone density and body fat percentage.

It's important to note that body weight can fluctuate throughout the day due to factors such as water retention, so it's best to measure body weight at the same time each day for the most accurate results. Additionally, it's important to use a reliable scale or measuring tool to ensure accurate measurements.

Explanation: Neoplastic cell transformation is a complex process that involves multiple steps and can occur as a result of genetic mutations, environmental factors, or a combination of both. The process typically begins with a series of subtle changes in the DNA of individual cells, which can lead to the loss of normal cellular functions and the acquisition of abnormal growth and reproduction patterns.

Over time, these transformed cells can accumulate further mutations that allow them to survive and proliferate despite adverse conditions. As the transformed cells continue to divide and grow, they can eventually form a tumor, which is a mass of abnormal cells that can invade and damage surrounding tissues.

In some cases, cancer cells can also break away from the primary tumor and travel through the bloodstream or lymphatic system to other parts of the body, where they can establish new tumors. This process, known as metastasis, is a major cause of death in many types of cancer.

It's worth noting that not all transformed cells will become cancerous. Some forms of cellular transformation, such as those that occur during embryonic development or tissue regeneration, are normal and necessary for the proper functioning of the body. However, when these transformations occur in adult tissues, they can be a sign of cancer.

See also: Cancer, Tumor

Word count: 190

Examples of delayed hypersensitivity reactions include contact dermatitis (a skin reaction to an allergic substance), tuberculin reactivity (a reaction to the bacteria that cause tuberculosis), and sarcoidosis (a condition characterized by inflammation in various organs, including the lungs and lymph nodes).

Delayed hypersensitivity reactions are important in the diagnosis and management of allergic disorders and other immune-related conditions. They can be detected through a variety of tests, including skin prick testing, patch testing, and blood tests. Treatment for delayed hypersensitivity reactions depends on the underlying cause and may involve medications such as antihistamines, corticosteroids, or immunosuppressants.

It is also known as mouth inflammation.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

Examples of hormone-dependent neoplasms include:

1. Breast cancer: Many breast cancers are estrogen receptor-positive (ER+), meaning that they grow in response to estrogen. These cancers can be treated with selective estrogen receptor modulators (SERMs) or aromatase inhibitors, which block the effects of estrogen on cancer growth.
2. Prostate cancer: Some prostate cancers are androgen-dependent, meaning that they grow in response to androgens such as testosterone. These cancers can be treated with androgen deprivation therapy (ADT), which reduces the levels of androgens in the body to slow or stop cancer growth.
3. Uterine cancer: Some uterine cancers are estrogen-dependent, meaning that they grow in response to estrogen. These cancers can be treated with hormone therapy to reduce estrogen levels.

Hormone-dependent neoplasms are often characterized by the presence of hormone receptors on the surface of the cancer cells. These receptors can bind to specific hormones and trigger signals that promote cancer growth and progression. Targeting these hormone receptors with hormone therapy can be an effective way to slow or stop the growth of these cancers.

The tumor develops from immature cells in the cerebellum called granule cells, and it can grow rapidly and spread to other parts of the brain. Medulloblastoma is usually diagnosed in the early stages, and treatment typically involves surgery, chemotherapy, and radiation therapy.

There are several subtypes of medulloblastoma, including:

* Winged-helix transcription factor (WHCT) medulloblastoma
* Sonic hedgehog (SHH) medulloblastoma
* Group 3 medulloblastoma
* Group 4 medulloblastoma

Each subtype has a different genetic profile and may require different treatment approaches.

Medulloblastoma is a rare cancer, but it is the most common type of pediatric brain cancer. With current treatments, the prognosis for medulloblastoma is generally good, especially for children who are diagnosed early and receive appropriate treatment. However, the cancer can recur in some cases, and ongoing research is focused on improving treatment outcomes and finding new, less toxic therapies for this disease.

A thymus neoplasm is a type of cancer that originates in the thymus gland, which is located in the chest behind the sternum and is responsible for the development and maturation of T-lymphocytes (T-cells) of the immune system.

Types of Thymus Neoplasms

There are several types of thymus neoplasms, including:

1. Thymoma: A slow-growing tumor that is usually benign but can sometimes be malignant.
2. Thymic carcinoma: A more aggressive type of cancer that is less common than thymoma.
3. Thymic lymphoma: A type of cancer that arises from the T-cells in the thymus gland and can be either B-cell or T-cell derived.

Symptoms of Thymus Neoplasms

The symptoms of thymus neoplasms can vary depending on the location and size of the tumor, but they may include:

1. Chest pain or discomfort
2. Coughing or shortness of breath
3. Fatigue or fever
4. Swelling in the neck or face
5. Weight loss or loss of appetite

Diagnosis of Thymus Neoplasms

The diagnosis of a thymus neoplasm typically involves a combination of imaging tests such as chest X-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, as well as a biopsy to confirm the presence of cancer cells.

Treatment of Thymus Neoplasms

The treatment of thymus neoplasms depends on the type and stage of the cancer, but may include:

1. Surgery to remove the tumor
2. Radiation therapy to kill any remaining cancer cells
3. Chemotherapy to destroy cancer cells
4. Targeted therapy to specific molecules involved in the growth and progression of the cancer.

Prognosis of Thymus Neoplasms

The prognosis for thymus neoplasms depends on the type and stage of the cancer at the time of diagnosis. In general, the earlier the cancer is detected and treated, the better the prognosis.

Prevention of Thymus Neoplasms

There is no known way to prevent thymus neoplasms, as they are rare and can occur in people of all ages. However, early detection and treatment of the cancer can improve the chances of a successful outcome.

Current Research on Thymus Neoplasms

Researchers are currently studying new treatments for thymus neoplasms, such as targeted therapies and immunotherapy, which use the body's own immune system to fight cancer. Additionally, researchers are working to develop better diagnostic tests to detect thymus neoplasms at an earlier stage, when they are more treatable.

Conclusion

Thymus neoplasms are rare and complex cancers that require specialized care and treatment. While the prognosis for these cancers can be challenging, advances in diagnosis and treatment have improved outcomes for many patients. Researchers continue to study new treatments and diagnostic tools to improve the chances of a successful outcome for those affected by thymus neoplasms.

Transitional cell carcinoma typically affects older adults, with the average age at diagnosis being around 70 years. Men are more likely to be affected than women, and the risk of developing TCC increases with age and exposure to certain environmental factors such as smoking and exposure to certain chemicals.

The symptoms of TCC can vary depending on the location and stage of the cancer, but may include:

* Blood in the urine (hematuria)
* Painful urination
* Frequent urination
* Pain in the lower abdomen or back

If left untreated, TCC can spread to other parts of the body, including the lymph nodes, liver, and bones. Treatment options for TCC may include surgery, chemotherapy, and immunotherapy, and the prognosis depends on the stage and location of the cancer at the time of diagnosis.

Preventive measures to reduce the risk of developing TCC include maintaining a healthy diet and lifestyle, avoiding smoking and excessive alcohol consumption, and regular screening for bladder cancer. Early detection and treatment can improve the prognosis for patients with TCC.

Most nasopharyngeal neoplasms are rare and tend to affect children and young adults more frequently than older adults. The most common types of nasopharyngeal neoplasms include:

1. Nasopharyngeal carcinoma (NPC): This is the most common type of malignant nasopharyngeal neoplasm and tends to affect young adults in Southeast Asia more frequently than other populations.
2. Adenoid cystic carcinoma: This is a rare, slow-growing tumor that usually affects the nasopharynx and salivary glands.
3. Metastatic squamous cell carcinoma: This is a type of cancer that originates in another part of the body (usually the head and neck) and spreads to the nasopharynx.
4. Lymphoma: This is a type of cancer that affects the immune system and can occur in the nasopharynx.
5. Benign tumors: These include benign growths such as papillomas, fibromas, and meningiomas.

Symptoms of nasopharyngeal neoplasms can vary depending on the size and location of the tumor but may include:

* Difficulty swallowing
* Nosebleeds
* Headaches
* Facial pain or numbness
* Trouble breathing through the nose
* Hoarseness or voice changes
* Enlarged lymph nodes in the neck

Diagnosis of nasopharyngeal neoplasms usually involves a combination of imaging tests such as CT or MRI scans, endoscopy (insertion of a flexible tube with a camera into the nose and throat), and biopsy (removal of a small sample of tissue for examination under a microscope).

Treatment of nasopharyngeal neoplasms depends on the type, size, location, and stage of the tumor but may include:

* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules on cancer cells

Prognosis for nasopharyngeal neoplasms varies depending on the type and stage of the tumor but in general, early detection and treatment improve the chances of a successful outcome.

Flushing can also be a side effect of certain medications, such as beta-blockers, aspirin, and some antidepressants. In addition, flushing can be a sign of an underlying condition that affects blood flow or blood vessels, such as Raynaud's disease or lupus.

Treatment for flushing will depend on the underlying cause. For example, if flushing is caused by an allergic reaction, medications such as antihistamines may be prescribed. If the flushing is caused by a medical condition, treatment will focus on managing that condition. In some cases, lifestyle changes such as avoiding triggers, wearing protective clothing, and using cool compresses can help reduce flushing.

It is important to seek medical attention if flushing is severe, persistent, or accompanied by other symptoms such as fever, chest pain, or difficulty breathing. Your healthcare provider can diagnose the underlying cause of flushing and recommend appropriate treatment.

Precancerous changes in the uterine cervix are called dysplasias, and they can be detected by a Pap smear, which is a routine screening test for women. If dysplasia is found, it can be treated with cryotherapy (freezing), laser therapy, or cone biopsy, which removes the affected cells.

Cervical cancer is rare in developed countries where Pap screening is widely available, but it remains a common cancer in developing countries where access to healthcare and screening is limited. The human papillomavirus (HPV) vaccine has been shown to be effective in preventing cervical precancerous changes and cancer.

Cervical cancer can be treated with surgery, radiation therapy, or chemotherapy, depending on the stage and location of the cancer. The prognosis for early-stage cervical cancer is good, but advanced-stage cancer can be difficult to treat and may have a poor prognosis.

The following are some types of uterine cervical neoplasms:

1. Adenocarcinoma in situ (AIS): This is a precancerous condition that occurs when glandular cells on the surface of the cervix become abnormal and grow out of control.
2. Cervical intraepithelial neoplasia (CIN): This is a precancerous condition that occurs when abnormal cells are found on the surface of the cervix. There are several types of CIN, ranging from mild to severe.
3. Squamous cell carcinoma: This is the most common type of cervical cancer and arises from the squamous cells that line the cervix.
4. Adnexal carcinoma: This is a rare type of cervical cancer that arises from the glands or ducts near the cervix.
5. Small cell carcinoma: This is a rare and aggressive type of cervical cancer that grows rapidly and can spread quickly to other parts of the body.
6. Micropapillary uterine carcinoma: This is a rare type of cervical cancer that grows in a finger-like shape and can be difficult to diagnose.
7. Clear cell carcinoma: This is a rare type of cervical cancer that arises from clear cells and can be more aggressive than other types of cervical cancer.
8. Adenocarcinoma: This is a type of cervical cancer that arises from glandular cells and can be less aggressive than squamous cell carcinoma.
9. Sarcoma: This is a rare type of cervical cancer that arises from the connective tissue of the cervix.

The treatment options for uterine cervical neoplasms depend on the stage and location of the cancer, as well as the patient's overall health and preferences. The following are some common treatments for uterine cervical neoplasms:

1. Hysterectomy: This is a surgical procedure to remove the uterus and may be recommended for early-stage cancers or precancerous changes.
2. Cryotherapy: This is a minimally invasive procedure that uses liquid nitrogen to freeze and destroy abnormal cells in the cervix.
3. Laser therapy: This is a minimally invasive procedure that uses a laser to remove or destroy abnormal cells in the cervix.
4. Cone biopsy: This is a surgical procedure to remove a small cone-shaped sample of tissue from the cervix to diagnose and treat early-stage cancers or precancerous changes.
5. Radiation therapy: This is a non-surgical treatment that uses high-energy rays to kill cancer cells and may be recommended for more advanced cancers or when the cancer has spread to other parts of the body.
6. Chemotherapy: This is a non-surgical treatment that uses drugs to kill cancer cells and may be recommended for more advanced cancers or when the cancer has spread to other parts of the body.
7. Immunotherapy: This is a non-surgical treatment that uses drugs to stimulate the immune system to fight cancer cells and may be recommended for more advanced cancers or when other treatments have failed.
8. Targeted therapy: This is a non-surgical treatment that uses drugs to target specific genes or proteins that contribute to cancer growth and development and may be recommended for more advanced cancers or when other treatments have failed.

It is important to note that the choice of treatment will depend on the stage and location of the cancer, as well as the patient's overall health and preferences. Patients should discuss their treatment options with their doctor and develop a personalized plan that is right for them.

Teratocarcinomas can arise from any of the three layers of germ cells: the spermatogonia, the oögonia, or the primordial germ cells. These tumors are often characterized by a mixture of normal and abnormal tissue, including skin, gastrointestinal tract, and other organs. They can also contain teratomy, which is the presence of immature tissue resembling embryonic tissue.

The diagnosis of teratocarcinoma is based on a combination of clinical, radiological, and pathological findings. Treatment options for teratocarcinoma depend on the location, size, and aggressiveness of the tumor, as well as the patient's age and overall health. Surgery is usually the first line of treatment, followed by radiation therapy or chemotherapy if necessary.

In summary, teratocarcinoma is a rare and complex type of cancer that arises from germ cells and can be either malignant or benign. It is characterized by a mixture of normal and abnormal tissue and requires careful diagnosis and treatment planning to ensure the best possible outcome for the patient.

Types of Drug Eruptions:

1. Maculopapular exanthema (MPE): This is a common type of drug eruption characterized by flat, red patches on the skin that may be accompanied by small bumps or hives. MPE typically occurs within 1-2 weeks of starting a new medication and resolves once the medication is discontinued.
2. Stevens-Johnson syndrome (SJS): This is a more severe type of drug eruption that can cause blisters, skin sloughing, and mucosal lesions. SJS typically occurs within 2-4 weeks of starting a new medication and can be life-threatening in some cases.
3. Toxic epidermal necrolysis (TEN): This is a severe, life-threatening type of drug eruption that can cause widespread skin death and mucosal lesions. TEN typically occurs within 2-4 weeks of starting a new medication and requires immediate hospitalization and treatment.

Causes of Drug Eruptions:

1. Allergic reactions to medications: This is the most common cause of drug eruptions. The body's immune system overreacts to certain medications, leading to skin symptoms.
2. Adverse effects of medications: Certain medications can cause skin symptoms as a side effect, even if the person is not allergic to them.
3. Infections: Bacterial, fungal, or viral infections can cause drug eruptions, particularly if the medication is used to treat the infection.
4. Autoimmune disorders: Certain autoimmune disorders, such as lupus or rheumatoid arthritis, can increase the risk of developing drug eruptions.

Diagnosis and Treatment of Drug Eruptions:

1. Medical history and physical examination: A thorough medical history and physical examination are essential to diagnose a drug eruption. The healthcare provider will look for patterns of skin symptoms that may be related to a specific medication.
2. Skin biopsy: In some cases, a skin biopsy may be necessary to confirm the diagnosis of a drug eruption and to rule out other conditions.
3. Medication history: The healthcare provider will ask about all medications taken by the patient, including over-the-counter medications and supplements.
4. Treatment: Depending on the severity of the drug eruption, treatment may include stopping the offending medication, administering corticosteroids or other immunosuppressive medications, and providing supportive care to manage symptoms such as itching, pain, and infection. In severe cases, hospitalization may be necessary.
5. Monitoring: Patients with a history of drug eruptions should be closely monitored by their healthcare provider when starting new medications, and any changes in their skin should be reported promptly.

Prevention of Drug Eruptions:

1. Allergy testing: Before starting a new medication, the healthcare provider may perform allergy testing to determine the patient's sensitivity to specific medications.
2. Medication history: The healthcare provider should take a thorough medication history to identify potential allergens and avoid prescribing similar medications that may cause an adverse reaction.
3. Gradual introduction of new medications: When starting a new medication, it is recommended to introduce the medication gradually in small doses to monitor for any signs of an adverse reaction.
4. Monitoring: Patients should be closely monitored when starting new medications, and any changes in their skin or symptoms should be reported promptly to their healthcare provider.
5. Avoiding certain medications: In some cases, it may be necessary to avoid certain medications that are more likely to cause a drug eruption based on the patient's medical history and other factors.

Conclusion:

Drug eruptions can present with various symptoms and can be challenging to diagnose. A thorough medical history and physical examination are essential to diagnose a drug eruption. Treatment depends on the severity of the reaction and may include stopping the offending medication, administering corticosteroids, and providing supportive care. Prevention is key, and healthcare providers should be aware of potential allergens and take steps to minimize the risk of adverse reactions. By being vigilant and proactive, healthcare providers can help prevent drug eruptions and ensure the best possible outcomes for their patients.

There are several possible causes of thrombocytopenia, including:

1. Immune-mediated disorders such as idiopathic thrombocytopenic purpura (ITP) or systemic lupus erythematosus (SLE).
2. Bone marrow disorders such as aplastic anemia or leukemia.
3. Viral infections such as HIV or hepatitis C.
4. Medications such as chemotherapy or non-steroidal anti-inflammatory drugs (NSAIDs).
5. Vitamin deficiencies, especially vitamin B12 and folate.
6. Genetic disorders such as Bernard-Soulier syndrome.
7. Sepsis or other severe infections.
8. Disseminated intravascular coagulation (DIC), a condition where blood clots form throughout the body.
9. Postpartum thrombocytopenia, which can occur in some women after childbirth.

Symptoms of thrombocytopenia may include easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding from injuries or surgical sites. Treatment options depend on the underlying cause but may include platelet transfusions, steroids, immunosuppressive drugs, and in severe cases, surgery.

In summary, thrombocytopenia is a condition characterized by low platelet counts that can increase the risk of bleeding and bruising. It can be caused by various factors, and treatment options vary depending on the underlying cause.

Examples of neoplasms, glandular and epithelial include:

* Adenomas: These are benign tumors that arise from glandular tissue. Examples include colon adenomas and prostate adenomas.
* Carcinomas: These are malignant tumors that arise from glandular or epithelial tissue. Examples include breast carcinoma, lung carcinoma, and ovarian carcinoma.
* Sarcomas: These are malignant tumors that arise from connective tissue. Examples include soft tissue sarcoma and bone sarcoma.

The diagnosis of neoplasms, glandular and epithelial is typically made through a combination of imaging tests such as X-rays, CT scans, MRI scans, and PET scans, along with a biopsy to confirm the presence of cancer cells. Treatment options for these types of neoplasms depend on the location, size, and stage of the tumor, but may include surgery, chemotherapy, radiation therapy, or a combination of these.

Overall, the term "neoplasms, glandular and epithelial" refers to a wide range of tumors that arise from glandular or epithelial tissue, and can be either benign or malignant. These types of neoplasms are common and can affect many different parts of the body.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

Hematologic neoplasms refer to abnormal growths or tumors that affect the blood, bone marrow, or lymphatic system. These types of cancer can originate from various cell types, including red blood cells, white blood cells, platelets, and lymphoid cells.

There are several subtypes of hematologic neoplasms, including:

1. Leukemias: Cancers of the blood-forming cells in the bone marrow, which can lead to an overproduction of immature or abnormal white blood cells, red blood cells, or platelets. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
2. Lymphomas: Cancers of the immune system, which can affect the lymph nodes, spleen, liver, or other organs. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
3. Multiple myeloma: A cancer of the plasma cells in the bone marrow that can lead to an overproduction of abnormal plasma cells.
4. Myeloproliferative neoplasms: Cancers that affect the blood-forming cells in the bone marrow, leading to an overproduction of red blood cells, white blood cells, or platelets. Examples include polycythemia vera and essential thrombocythemia.
5. Myelodysplastic syndromes: Cancers that affect the blood-forming cells in the bone marrow, leading to an underproduction of normal blood cells.

The diagnosis of hematologic neoplasms typically involves a combination of physical examination, medical history, laboratory tests (such as complete blood counts and bone marrow biopsies), and imaging studies (such as CT scans or PET scans). Treatment options for hematologic neoplasms depend on the specific type of cancer, the severity of the disease, and the overall health of the patient. These may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapy with drugs that specifically target cancer cells.

Some common types of gastrointestinal neoplasms include:

1. Gastric adenocarcinoma: A type of stomach cancer that starts in the glandular cells of the stomach lining.
2. Colorectal adenocarcinoma: A type of cancer that starts in the glandular cells of the colon or rectum.
3. Esophageal squamous cell carcinoma: A type of cancer that starts in the squamous cells of the esophagus.
4. Small intestine neuroendocrine tumors: Tumors that start in the hormone-producing cells of the small intestine.
5. Gastrointestinal stromal tumors (GISTs): Tumors that start in the connective tissue of the GI tract.

The symptoms of gastrointestinal neoplasms can vary depending on the location and size of the tumor, but they may include:

* Abdominal pain or discomfort
* Changes in bowel habits (such as diarrhea or constipation)
* Weight loss
* Fatigue
* Nausea and vomiting

If you have any of these symptoms, it is important to see a doctor for further evaluation and diagnosis. A gastrointestinal neoplasm can be diagnosed through a combination of endoscopy (insertion of a flexible tube into the GI tract to visualize the inside), imaging tests (such as CT or MRI scans), and biopsy (removal of a small sample of tissue for examination under a microscope).

Treatment options for gastrointestinal neoplasms depend on the type, location, and stage of the tumor, but they may include:

* Surgery to remove the tumor
* Chemotherapy (use of drugs to kill cancer cells)
* Radiation therapy (use of high-energy X-rays or other particles to kill cancer cells)
* Targeted therapy (use of drugs that target specific molecules involved in cancer growth and development)
* Supportive care (such as pain management and nutritional support)

The prognosis for gastrointestinal neoplasms varies depending on the type and stage of the tumor, but in general, early detection and treatment improve outcomes. If you have been diagnosed with a gastrointestinal neoplasm, it is important to work closely with your healthcare team to develop a personalized treatment plan and follow up regularly for monitoring and adjustments as needed.

The symptoms of T-cell leukemia can vary depending on the severity of the disease, but they may include:

* Fatigue
* Weakness
* Frequent infections
* Easy bruising or bleeding
* Swollen lymph nodes
* Pain in the bones or joints
* Headaches
* Confusion or seizures (in severe cases)

T-cell leukemia is diagnosed through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment typically involves chemotherapy and/or radiation therapy to kill cancer cells and restore the body's normal production of blood cells. In some cases, bone marrow transplantation may be recommended.

The prognosis for T-cell leukemia varies depending on the patient's age and overall health, as well as the aggressiveness of the disease. However, with current treatments, the 5-year survival rate is around 70% for children and adolescents, and around 40% for adults.

It's important to note that T-cell leukemia is relatively rare compared to other types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL). However, it can be a very aggressive and difficult-to-treat form of cancer, and patients with T-cell leukemia often require intensive treatment and close follow-up care.

The exact cause of vitiligo is still unknown, but it is believed to involve a combination of genetic and environmental factors. In people with vitiligo, the immune system mistakenly attacks and destroys melanocytes, leading to a loss of skin pigmentation. The disease can also be triggered by physical or emotional stress, sun exposure, and certain medications.

The symptoms of vitiligo can vary in severity and progression. They may include:

1. White patches on the skin, which can appear suddenly or gradually over time.
2. Loss of skin pigmentation in specific areas, such as the face, hands, or limbs.
3. Thinning or loss of hair on affected areas.
4. Premature whitening or graying of the hair.
5. Itching, pain, or sensitivity in the affected areas.
6. Emotional distress and reduced quality of life due to the visible appearance of the disease.

There is no cure for vitiligo, but various treatments can help manage the symptoms and slow down its progression. These may include:

1. Topical corticosteroids to reduce inflammation and suppress the immune system.
2. Topical immunomodulators to suppress the immune system and promote skin repigmentation.
3. Narrowband ultraviolet B (UVB) phototherapy to slow down the progression of the disease and improve skin appearance.
4. Psoralen photochemotherapy to promote skin repigmentation and reduce inflammation.
5. Surgical skin grafting or blister grafting to cover small areas of depigmentation.
6. Camouflage makeup to cover the affected areas and improve self-esteem.

In addition to these treatments, it is essential for patients with vitiligo to protect their skin from the sun by using broad-spectrum sunscreens, wearing protective clothing, and seeking shade when the sun is strongest.

Early diagnosis and appropriate treatment can help improve the quality of life for patients with vitiligo. However, the emotional and psychological impact of the disease should not be underestimated, and patients may require long-term support and counseling to cope with the challenges of living with this condition.

In LLCB, the B cells undergo a mutation that causes them to become cancerous and multiply rapidly. This can lead to an overproduction of these cells in the bone marrow, causing the bone marrow to become crowded and unable to produce healthy red blood cells, platelets, and white blood cells.

LLCB is typically a slow-growing cancer, and it can take years for symptoms to develop. However, as the cancer progresses, it can lead to a range of symptoms including fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes.

LLCB is typically diagnosed through a combination of physical examination, blood tests, bone marrow biopsy, and imaging studies such as X-rays or CT scans. Treatment options for LLCB include chemotherapy, radiation therapy, and in some cases, stem cell transplantation.

Overall, while LLCB is a serious condition, it is typically slow-growing and can be managed with appropriate treatment. With current treatments, many people with LLCB can achieve long-term remission and a good quality of life.

NETs can be benign (non-cancerous) or malignant (cancerous). Malignant NETs can spread to other parts of the body through a process called metastasis, which can lead to serious health complications.

The symptoms of NETs vary depending on their location and size, but may include:

* Abdominal pain or discomfort
* Diarrhea or constipation
* Fatigue
* Weakness
* Shortness of breath
* Skin changes such as flushing or sweating
* Headaches
* Seizures

The diagnosis of NETs is based on a combination of imaging tests such as CT scans, MRI scans, and PET scans, as well as biopsy samples. Treatment options for NETs depend on the type, size, location, and stage of the tumor, but may include:

* Medications to slow or stop hormone production
* Chemotherapy to shrink the tumor
* Radiation therapy to kill cancer cells
* Surgery to remove the tumor

Overall, NETs are rare and can be challenging to diagnose and treat. However, with advances in medical technology and ongoing research, there are more effective treatment options available for patients with NETs.

There are several subtypes of astrocytoma, including:

1. Low-grade astrocytoma: These tumors grow slowly and are less aggressive. They can be treated with surgery, radiation therapy, or chemotherapy.
2. High-grade astrocytoma: These tumors grow more quickly and are more aggressive. They are often resistant to treatment and may recur after initial treatment.
3. Anaplastic astrocytoma: These are the most aggressive type of astrocytoma, growing rapidly and spreading to other parts of the brain.
4. Glioblastoma (GBM): This is the most common and deadliest type of primary brain cancer, accounting for 55% of all astrocytomas. It is highly aggressive and resistant to treatment, often recurring after initial surgery, radiation, and chemotherapy.

The symptoms of astrocytoma depend on the location and size of the tumor. Common symptoms include headaches, seizures, weakness or numbness in the arms or legs, and changes in personality or behavior.

Astrocytomas are diagnosed through a combination of imaging tests such as MRI or CT scans, and tissue biopsy. Treatment options vary depending on the type and location of the tumor, but may include surgery, radiation therapy, chemotherapy, or a combination of these.

The prognosis for astrocytoma varies based on the subtype and location of the tumor, as well as the patient's age and overall health. In general, low-grade astrocytomas have a better prognosis than high-grade tumors. However, even with treatment, the survival rate for astrocytoma is generally lower compared to other types of cancer.

There are several types of inflammatory breast neoplasms, including:

1. Inflammatory carcinoma of the breast: This is the most common type of inflammatory breast neoplasm and is characterized by a thickened, reddened skin that may have small lumps or nodules.
2. Paget's disease of the nipple: This type of cancer starts in the ducts of the nipple and can cause crusting, scaling, and itching of the nipple.
3. Inflammatory phyllodes tumor: This is a rare type of breast tumor that is characterized by a thickened, fibrous tissue in the breast.
4. Pyogenic granuloma of the breast: This is a benign (non-cancerous) tumor that can mimic inflammatory breast neoplasms and is caused by bacterial infection.

The symptoms of inflammatory breast neoplasms can include:

* Redness, swelling, and warmth of the breast
* Thickening and texture changes of the skin
* Painless lumps or nodules
* Nipple discharge or crusting
* Itching or scaling of the skin

The diagnosis of inflammatory breast neoplasms is based on a combination of clinical examination, imaging studies (such as mammography and ultrasound), and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these.

Inflammatory breast neoplasms are rare and can be challenging to diagnose and treat. However, with early detection and appropriate treatment, many women with these tumors can achieve long-term survival and a good quality of life.

The diagnosis of GVHD is based on a combination of clinical findings, laboratory tests, and biopsies. Treatment options include immunosuppressive drugs, corticosteroids, and in severe cases, stem cell transplantation reversal or donor lymphocyte infusion.

Prevention of GVHD includes selecting the right donor, using conditioning regimens that minimize damage to the recipient's bone marrow, and providing appropriate immunosuppression after transplantation. Early detection and management of GVHD are critical to prevent long-term complications and improve survival rates.

The carcinogenesis process of PDAC usually starts with the accumulation of genetic mutations in the pancreatic duct cells, which progressively leads to the formation of a premalignant lesion called PanIN (pancreatic intraepithelial neoplasia). Over time, these lesions can develop into invasive adenocarcinoma, which is PDAC.

The main risk factor for developing PDAC is smoking, but other factors such as obesity, diabetes, and family history of pancreatic cancer also contribute to the development of the disease. Symptoms of PDAC are often non-specific and late-stage, which makes early diagnosis challenging.

The treatment options for PDAC are limited, and the prognosis is generally poor. Surgery is the only potentially curative treatment, but only a small percentage of patients are eligible for surgical resection due to the locally advanced nature of the disease at the time of diagnosis. Chemotherapy, radiation therapy, and targeted therapies are used to palliate symptoms and improve survival in non-surgical cases.

PDAC is an aggressive and lethal cancer, and there is a need for better diagnostic tools and more effective treatment strategies to improve patient outcomes.

In the medical field, fatigue is often evaluated using a combination of physical examination, medical history, and laboratory tests to determine its underlying cause. Treatment for fatigue depends on the underlying cause, but may include rest, exercise, stress management techniques, and medication.

Some common causes of fatigue in the medical field include:

1. Sleep disorders, such as insomnia or sleep apnea
2. Chronic illnesses, such as diabetes, heart disease, or arthritis
3. Infections, such as the flu or a urinary tract infection
4. Medication side effects
5. Poor nutrition or hydration
6. Substance abuse
7. Chronic stress
8. Depression or anxiety
9. Hormonal imbalances
10. Autoimmune disorders, such as thyroiditis or lupus.

Fatigue can also be a symptom of other medical conditions, such as:

1. Anemia
2. Hypoglycemia (low blood sugar)
3. Hypothyroidism (underactive thyroid)
4. Hyperthyroidism (overactive thyroid)
5. Chronic fatigue syndrome
6. Fibromyalgia
7. Vasculitis
8. Cancer
9. Heart failure
10. Liver or kidney disease.

It is important to seek medical attention if fatigue is severe, persistent, or accompanied by other symptoms such as fever, pain, or difficulty breathing. A healthcare professional can diagnose and treat the underlying cause of fatigue, improving overall quality of life.

Examples of hematologic diseases include:

1. Anemia - a condition where there are not enough red blood cells or hemoglobin in the body.
2. Leukemia - a type of cancer that affects the bone marrow and blood, causing an overproduction of immature white blood cells.
3. Lymphoma - a type of cancer that affects the lymphatic system, including the bone marrow, spleen, and lymph nodes.
4. Thalassemia - a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.
5. Sickle cell disease - a genetic disorder that affects the production of hemoglobin, causing red blood cells to become sickle-shaped and prone to breaking down.
6. Polycythemia vera - a rare disorder where there is an overproduction of red blood cells.
7. Myelodysplastic syndrome - a condition where the bone marrow produces abnormal blood cells that do not mature properly.
8. Myeloproliferative neoplasms - a group of conditions where the bone marrow produces excessive amounts of blood cells, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
9. Deep vein thrombosis - a condition where a blood clot forms in a deep vein, often in the leg or arm.
10. Pulmonary embolism - a condition where a blood clot travels to the lungs and blocks a blood vessel, causing shortness of breath, chest pain, and other symptoms.

These are just a few examples of hematologic diseases, but there are many others that can affect the blood and bone marrow. Treatment options for these diseases can range from watchful waiting and medication to surgery, chemotherapy, and stem cell transplantation. It is important to seek medical attention if you experience any symptoms of hematologic disease, as early diagnosis and treatment can improve outcomes.

There are several key features of inflammation:

1. Increased blood flow: Blood vessels in the affected area dilate, allowing more blood to flow into the tissue and bringing with it immune cells, nutrients, and other signaling molecules.
2. Leukocyte migration: White blood cells, such as neutrophils and monocytes, migrate towards the site of inflammation in response to chemical signals.
3. Release of mediators: Inflammatory mediators, such as cytokines and chemokines, are released by immune cells and other cells in the affected tissue. These molecules help to coordinate the immune response and attract more immune cells to the site of inflammation.
4. Activation of immune cells: Immune cells, such as macrophages and T cells, become activated and start to phagocytose (engulf) pathogens or damaged tissue.
5. Increased heat production: Inflammation can cause an increase in metabolic activity in the affected tissue, leading to increased heat production.
6. Redness and swelling: Increased blood flow and leakiness of blood vessels can cause redness and swelling in the affected area.
7. Pain: Inflammation can cause pain through the activation of nociceptors (pain-sensing neurons) and the release of pro-inflammatory mediators.

Inflammation can be acute or chronic. Acute inflammation is a short-term response to injury or infection, which helps to resolve the issue quickly. Chronic inflammation is a long-term response that can cause ongoing damage and diseases such as arthritis, asthma, and cancer.

There are several types of inflammation, including:

1. Acute inflammation: A short-term response to injury or infection.
2. Chronic inflammation: A long-term response that can cause ongoing damage and diseases.
3. Autoimmune inflammation: An inappropriate immune response against the body's own tissues.
4. Allergic inflammation: An immune response to a harmless substance, such as pollen or dust mites.
5. Parasitic inflammation: An immune response to parasites, such as worms or fungi.
6. Bacterial inflammation: An immune response to bacteria.
7. Viral inflammation: An immune response to viruses.
8. Fungal inflammation: An immune response to fungi.

There are several ways to reduce inflammation, including:

1. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs).
2. Lifestyle changes, such as a healthy diet, regular exercise, stress management, and getting enough sleep.
3. Alternative therapies, such as acupuncture, herbal supplements, and mind-body practices.
4. Addressing underlying conditions, such as hormonal imbalances, gut health issues, and chronic infections.
5. Using anti-inflammatory compounds found in certain foods, such as omega-3 fatty acids, turmeric, and ginger.

It's important to note that chronic inflammation can lead to a range of health problems, including:

1. Arthritis
2. Diabetes
3. Heart disease
4. Cancer
5. Alzheimer's disease
6. Parkinson's disease
7. Autoimmune disorders, such as lupus and rheumatoid arthritis.

Therefore, it's important to manage inflammation effectively to prevent these complications and improve overall health and well-being.

The symptoms of retinoblastoma can vary depending on the location and size of the tumor, but may include:

* A white or colored mass in one eye
* Redness or swelling of the eye
* Sensitivity to light
* Blurred vision or vision loss
* Crossed eyes (strabismus)
* Eye pain or discomfort

Retinoblastoma is usually diagnosed with a combination of physical examination, imaging tests such as ultrasound and MRI, and genetic testing. Treatment options depend on the stage and location of the tumor, but may include:

* Chemotherapy to shrink the tumor before surgery
* Surgery to remove the tumor and/or the affected eye (enucleation)
* Radiation therapy to kill any remaining cancer cells
* Targeted therapy with drugs that specifically target cancer cells

The prognosis for retinoblastoma depends on the stage of the disease at diagnosis. If the tumor is confined to one eye and has not spread to other parts of the body, the 5-year survival rate is high (around 90%). However, if the tumor has spread to other parts of the body (known as metastatic retinoblastoma), the prognosis is much poorer.

Retinoblastoma can be inherited in an autosomal dominant pattern, meaning that a single copy of the mutated RB1 gene is enough to cause the condition. Families with a history of retinoblastoma may undergo genetic testing and counseling to determine their risk of developing the disease.

Ewing's sarcoma is a rare and aggressive type of cancer that affects the bones and soft tissues of the body. It primarily occurs in the pelvis, spine, and limbs. This malignancy usually develops in children and young adults between the ages of 10 and 30.

Ewing's sarcoma is caused by a genetic mutation in the EWS gene, which is responsible for regulating cell growth and division. The mutated gene leads to uncontrollable cell proliferation, resulting in the formation of a tumor.

The symptoms of Ewing's sarcoma vary depending on the location of the tumor but can include pain, swelling, limited mobility, and broken bones. Diagnosis is usually made through a combination of imaging tests such as X-rays, CT scans, and PET scans, along with a biopsy to confirm the presence of cancer cells.

Treatment for Ewing's sarcoma typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery is used to remove the tumor and any affected tissue, while chemotherapy and radiation therapy are used to kill any remaining cancer cells. The prognosis for Ewing's sarcoma varies depending on the stage and location of the cancer but can be improved with early diagnosis and appropriate treatment.

Neoplasms, plasma cell, are tumors that arise from plasma cells and can be either benign or malignant. They are relatively rare and tend to affect older adults.

Symptoms of neoplasms, plasma cell, include bone pain, tiredness, fever, and weight loss. Treatment options vary depending on the type and stage of the tumor but may include chemotherapy, radiation therapy, or surgery.

Neoplasms, plasma cells are classified as either extramedullary (outside the bone marrow) or intramedullary (within the bone marrow). The most common type of plasma cell neoplasm is multiple myeloma, which is a malignant tumor that affects the bone marrow and can cause bone pain, infections, and other complications.

Common types of genital neoplasms in females include:

1. Vulvar intraepithelial neoplasia (VIN): A precancerous condition that affects the vulva, the external female genital area.
2. Cervical dysplasia: Precancerous changes in the cells of the cervix, which can progress to cancer if left untreated.
3. Endometrial hyperplasia: Abnormal growth of the uterine lining, which can sometimes develop into endometrial cancer.
4. Endometrial adenocarcinoma: Cancer that arises in the glands of the uterine lining.
5. Ovarian cancer: Cancer that originates in the ovaries.
6. Vaginal cancer: Cancer that occurs in the vagina.
7. Cervical cancer: Cancer that occurs in the cervix.
8. Uterine leiomyosarcoma: A rare type of cancer that occurs in the uterus.
9. Uterine clear cell carcinoma: A rare type of cancer that occurs in the uterus.
10. Mesothelioma: A rare type of cancer that affects the lining of the abdominal cavity, including the female reproductive organs.

Treatment for genital neoplasms in females depends on the type and stage of the disease, and may include surgery, radiation therapy, chemotherapy, or a combination of these. Early detection and treatment are important to improve outcomes and reduce the risk of complications.

Types of mouth neoplasms include:

1. Oral squamous cell carcinoma (OSCC): This is the most common type of mouth cancer, accounting for about 90% of all cases. It usually occurs on the tongue, lips, or floor of the mouth.
2. Verrucous carcinoma: This type of cancer is slow-growing and typically affects the gums or the outer surface of the tongue.
3. Adenoid cystic carcinoma: This type of cancer is rare and usually affects the salivary glands. It can infiltrate surrounding tissues and cause significant destruction of nearby structures.
4. Mucoepidermoid carcinoma: This type of cancer is relatively rare and occurs most commonly on the tongue or the floor of the mouth. It can be benign or malignant, and its behavior varies depending on the type.
5. Melanotic neuroectodermal tumor: This is a rare type of cancer that affects the melanocytes (pigment-producing cells) in the mouth. It typically occurs in the tongue or the lips.

Symptoms of mouth neoplasms can include:

* A sore or ulcer that does not heal
* A lump or mass in the mouth
* Bleeding or pain in the mouth
* Difficulty swallowing or speaking
* Numbness or tingling in the mouth

Diagnosis of mouth neoplasms typically involves a combination of physical examination, imaging studies (such as X-rays or CT scans), and biopsy. Treatment options vary depending on the type and severity of the cancer, but may include surgery, radiation therapy, chemotherapy, or a combination of these. Early detection and treatment are important for improving outcomes in patients with mouth neoplasms.

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

Characteristics of Medullary Carcinoma:

1. Location: Medullary carcinoma typically arises in the inner substance of the breast, near the milk ducts and blood vessels.
2. Growth pattern: The cancer cells grow in a nodular or sheet-like pattern, with a clear boundary between the tumor and the surrounding normal tissue.
3. Cellular features: The cancer cells are typically large and polygonal, with prominent nucleoli and a pale, pinkish cytoplasm.
4. Lymphocytic infiltration: There is often a significant amount of lymphocytic infiltration surrounding the tumor, which can give it a "spiculated" or "heterogeneous" appearance.
5. Grade: Medullary carcinoma is generally a low-grade cancer, meaning that the cells are slow-growing and less aggressive than those of other types of breast cancer.
6. Hormone receptors: Medullary carcinoma is often hormone receptor-positive, meaning that the cancer cells have estrogen or progesterone receptors on their surface.
7. Her2 status: The cancer cells are typically Her2-negative, meaning that they do not overexpress the Her2 protein.

Prognosis and Treatment of Medullary Carcinoma:

The prognosis for medullary carcinoma is generally good, as it tends to be a slow-growing and less aggressive type of breast cancer. The 5-year survival rate for medullary carcinoma is around 80-90%.

Treatment for medullary carcinoma typically involves surgery, such as a lumpectomy or mastectomy, followed by radiation therapy and/or hormone therapy. Chemotherapy is sometimes used in addition to these treatments, especially if the cancer has spread to the lymph nodes or other parts of the body.

It's important for women with medullary carcinoma to work closely with their healthcare team to develop a personalized treatment plan that takes into account their unique needs and circumstances. With appropriate treatment, many women with medullary carcinoma can achieve long-term survival and a good quality of life.

Neuroectodermal tumors are relatively rare, accounting for only about 1-2% of all childhood cancers. However, they are a significant cause of morbidity and mortality in children and young adults. These tumors can be benign or malignant, and their behavior and clinical presentation can vary widely depending on the specific type and location of the tumor.

Some common types of neuroectodermal tumors include:

1. Medulloblastoma: This is a type of brain cancer that develops in the cerebellum, typically in children under the age of 10. It is the most common type of pediatric brain cancer and accounts for about 75% of all childhood brain tumors.
2. PNET (Primitive Neuroectodermal Tumor): This is a type of brain tumor that can occur in various parts of the central nervous system, including the brain, spinal cord, and peripheral nerves. PNETs are rare and tend to affect older children and young adults.
3. AT/RT (Askin Tumor/Rhabdoid Tumor): This is a type of brain tumor that typically occurs in infants and young children. It is a rare and aggressive form of cancer that can arise in various parts of the central nervous system.
4. Craniopharyngioma: This is a type of benign tumor that develops near the pituitary gland in the brain. It is relatively rare and tends to affect children and young adults.
5. Ganglioglioma: This is a type of brain tumor that arises from the fusion of ganglion cells and glial cells. It is a rare and benign tumor that can occur in various parts of the central nervous system.

The clinical presentation of neuroectodermal tumors can vary depending on their location, size, and type. Common symptoms include headaches, seizures, vomiting, and changes in behavior or cognitive function. Diagnosis is typically made through a combination of imaging studies (such as MRI or CT scans) and tissue biopsy.

Treatment for neuroectodermal tumors depends on the specific type and location of the tumor, as well as the age and overall health of the patient. Surgery is often the first line of treatment, followed by radiation therapy and/or chemotherapy. In some cases, a combination of these treatments may be necessary to achieve the best possible outcome.

The prognosis for neuroectodermal tumors can vary depending on the specific type and location of the tumor, as well as the age and overall health of the patient. In general, the prognosis for these types of tumors is generally better for children than for adults. With prompt and appropriate treatment, many patients with neuroectodermal tumors can achieve long-term survival and a good quality of life.

Vomiting can be caused by a variety of factors, such as:

1. Infection: Viral or bacterial infections can inflame the stomach and intestines, leading to vomiting.
2. Food poisoning: Consuming contaminated or spoiled food can cause vomiting.
3. Motion sickness: Traveling by car, boat, plane, or other modes of transportation can cause motion sickness, which leads to vomiting.
4. Alcohol or drug overconsumption: Drinking too much alcohol or taking certain medications can irritate the stomach and cause vomiting.
5. Pregnancy: Hormonal changes during pregnancy can cause nausea and vomiting, especially during the first trimester.
6. Other conditions: Vomiting can also be a symptom of other medical conditions such as appendicitis, pancreatitis, and migraines.

When someone is vomiting, they may experience:

1. Nausea: A feeling of queasiness or sickness in the stomach.
2. Abdominal pain: Crampy or sharp pain in the abdomen.
3. Diarrhea: Loose, watery stools.
4. Dehydration: Loss of fluids and electrolytes.
5. Headache: A throbbing headache can occur due to dehydration.
6. Fatigue: Weakness and exhaustion.

Treatment for vomiting depends on the underlying cause, but may include:

1. Fluid replacement: Drinking fluids to replenish lost electrolytes and prevent dehydration.
2. Medications: Anti-inflammatory drugs or antibiotics may be prescribed to treat infections or other conditions causing vomiting.
3. Rest: Resting the body and avoiding strenuous activities.
4. Dietary changes: Avoiding certain foods or substances that trigger vomiting.
5. Hospitalization: In severe cases of vomiting, hospitalization may be necessary to monitor and treat underlying conditions.

It is important to seek medical attention if the following symptoms occur with vomiting:

1. Severe abdominal pain.
2. Fever above 101.5°F (38.6°C).
3. Blood in vomit or stools.
4. Signs of dehydration, such as excessive thirst, dark urine, or dizziness.
5. Vomiting that lasts for more than 2 days.
6. Frequent vomiting with no relief.

There are several types of thyroid neoplasms, including:

1. Thyroid nodules: These are abnormal growths or lumps that can develop in the thyroid gland. Most thyroid nodules are benign (non-cancerous), but some can be malignant (cancerous).
2. Thyroid cancer: This is a type of cancer that develops in the thyroid gland. There are several types of thyroid cancer, including papillary, follicular, and medullary thyroid cancer.
3. Thyroid adenomas: These are benign tumors that develop in the thyroid gland. They are usually non-cancerous and do not spread to other parts of the body.
4. Thyroid cysts: These are fluid-filled sacs that can develop in the thyroid gland. They are usually benign and do not cause any symptoms.

Thyroid neoplasms can be caused by a variety of factors, including genetic mutations, exposure to radiation, and certain medical conditions, such as thyroiditis (inflammation of the thyroid gland).

Symptoms of thyroid neoplasms can include:

* A lump or swelling in the neck
* Pain in the neck or throat
* Difficulty swallowing or breathing
* Hoarseness or voice changes
* Weight loss or fatigue

Diagnosis of thyroid neoplasms usually involves a combination of physical examination, imaging tests (such as ultrasound or CT scans), and biopsies. Treatment depends on the type and severity of the neoplasm, and can include surgery, radiation therapy, and medications.

SCLC typically starts in the bronchi of the lungs and can spread quickly to other parts of the body, such as the brain, liver, and bones. It is often found in later stages and is associated with a poorer prognosis than non-small cell lung cancer (NSCLC).

There are two main types of SCLC:

1. Limited-stage SCLC: This type of SCLC is limited to one lung and has not spread to other parts of the body.
2. Extensive-stage SCLC: This type of SCLC has spread beyond one lung and may have spread to other parts of the body.

Symptoms of SCLC include:

* Coughing
* Chest pain
* Shortness of breath
* Weight loss
* Fatigue

Diagnosis of SCLC is typically made through a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, and a biopsy to confirm the presence of cancer cells. Treatment options for SCLC include:

1. Chemotherapy: This is the primary treatment for SCLC and may be used alone or in combination with radiation therapy.
2. Radiation therapy: This may be used alone or in combination with chemotherapy to treat SCLC.
3. Surgery: In some cases, surgery may be possible to remove the tumor and affected tissue.
4. Clinical trials: These may be available for patients with SCLC to access new and innovative treatments.

Overall, SCLC is a highly aggressive form of lung cancer that requires prompt and accurate diagnosis and treatment to improve outcomes.

Types of Intestinal Neoplasms:

1. Adenomas: These are benign tumors that grow on the inner lining of the intestine. They can become malignant over time if left untreated.
2. Carcinomas: These are malignant tumors that develop in the inner lining of the intestine. They can be subdivided into several types, including colon cancer and rectal cancer.
3. Lymphoma: This is a type of cancer that affects the immune system and can occur in the intestines.
4. Leiomyosarcomas: These are rare malignant tumors that develop in the smooth muscle layers of the intestine.

Causes and Risk Factors:

The exact cause of intestinal neoplasms is not known, but several factors can increase the risk of developing these growths. These include:

1. Age: The risk of developing intestinal neoplasms increases with age.
2. Family history: Having a family history of colon cancer or other intestinal neoplasms can increase the risk of developing these growths.
3. Inflammatory bowel disease: People with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are at higher risk of developing intestinal neoplasms.
4. Genetic mutations: Certain genetic mutations can increase the risk of developing intestinal neoplasms.
5. Diet and lifestyle factors: A diet high in fat and low in fiber, as well as lack of physical activity, may increase the risk of developing intestinal neoplasms.

Symptoms:

Intestinal neoplasms can cause a variety of symptoms, including:

1. Abdominal pain or discomfort
2. Changes in bowel habits, such as diarrhea or constipation
3. Blood in the stool
4. Weight loss
5. Fatigue
6. Loss of appetite

Diagnosis:

To diagnose intestinal neoplasms, a doctor may perform several tests, including:

1. Colonoscopy: A colonoscope is inserted through the rectum and into the colon to visualize the inside of the colon and detect any abnormal growths.
2. Biopsy: A small sample of tissue is removed from the colon and examined under a microscope for cancer cells.
3. Imaging tests: Such as X-rays, CT scans, or MRI scans to look for any abnormalities in the colon.
4. Blood tests: To check for certain substances in the blood that are associated with intestinal neoplasms.

Treatment:

The treatment of intestinal neoplasms depends on the type and location of the growth, as well as the stage of the cancer. Treatment options may include:

1. Surgery: To remove the tumor and any affected tissue.
2. Chemotherapy: To kill any remaining cancer cells with drugs.
3. Radiation therapy: To kill cancer cells with high-energy X-rays or other forms of radiation.
4. Targeted therapy: To use drugs that target specific molecules on cancer cells to kill them.
5. Immunotherapy: To use drugs that stimulate the immune system to fight cancer cells.

Prognosis:

The prognosis for intestinal neoplasms depends on several factors, including the type and stage of the cancer, the location of the growth, and the effectiveness of treatment. In general, early detection and treatment improve the prognosis, while later-stage cancers have a poorer prognosis.

Complications:

Intestinal neoplasms can cause several complications, including:

1. Obstruction: The tumor can block the normal flow of food through the intestine, leading to abdominal pain and other symptoms.
2. Bleeding: The tumor can cause bleeding in the intestine, which can lead to anemia and other complications.
3. Perforation: The tumor can create a hole in the wall of the intestine, leading to peritonitis (inflammation of the lining of the abdomen) and other complications.
4. Metastasis: The cancer cells can spread to other parts of the body, such as the liver or lungs, and cause further complications.
5. Malnutrition: The tumor can make it difficult for the body to absorb nutrients, leading to malnutrition and other health problems.

Prevention:

There is no sure way to prevent intestinal neoplasms, but there are several steps that may help reduce the risk of developing these types of cancer. These include:

1. Avoiding known risk factors: Avoiding known risk factors such as smoking, excessive alcohol consumption, and a diet high in processed meat can help reduce the risk of developing intestinal neoplasms.
2. Maintaining a healthy diet: Eating a balanced diet that is high in fruits, vegetables, and whole grains can help keep the intestines healthy and may reduce the risk of cancer.
3. Exercise regularly: Regular exercise can help maintain a healthy weight, improve digestion, and may reduce the risk of developing intestinal neoplasms.
4. Managing chronic conditions: Managing chronic conditions such as inflammatory bowel disease, diabetes, and obesity can help reduce the risk of developing intestinal neoplasms.
5. Screening tests: Regular screening tests such as colonoscopy, CT scan, or barium enema can help detect precancerous polyps or early-stage cancer, allowing for early treatment and prevention of advanced disease.

Early detection and diagnosis are crucial for effective treatment and survival rates for intestinal neoplasms. If you have any of the risk factors or symptoms mentioned above, it is essential to consult a doctor as soon as possible. A thorough examination and diagnostic tests can help determine the cause of your symptoms and recommend appropriate treatment.

Benign pleural neoplasms include:

1. Pleomorphic adenoma: A rare, slow-growing tumor that usually occurs in the soft tissues of the chest wall.
2. Pneumoschisis: A condition where there is a tear or separation in the membrane that lines the lung, which can cause air to leak into the pleural space and create a benign tumor.
3. Pleural plaques: Calcified deposits that form in the pleura as a result of inflammation or injury.

Malignant pleural neoplasms include:

1. Mesothelioma: A rare and aggressive cancer that originates in the pleura, usually caused by exposure to asbestos.
2. Lung cancer: Cancer that spreads to the pleura from another part of the body, such as the lungs.
3. Metastatic tumors: Tumors that have spread to the pleura from another part of the body, such as the breast or colon.

Pleural neoplasms can cause a variety of symptoms, including chest pain, shortness of breath, coughing, and fatigue. Diagnosis is typically made through a combination of imaging tests, such as CT scans and PET scans, and a biopsy to confirm the presence of cancerous cells. Treatment options for pleural neoplasms depend on the type and stage of the tumor, and may include surgery, chemotherapy, and radiation therapy.

There are several types of diarrhea, including:

1. Acute diarrhea: This type of diarrhea is short-term and usually resolves on its own within a few days. It can be caused by a viral or bacterial infection, food poisoning, or medication side effects.
2. Chronic diarrhea: This type of diarrhea persists for more than 4 weeks and can be caused by a variety of conditions, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or celiac disease.
3. Diarrhea-predominant IBS: This type of diarrhea is characterized by frequent, loose stools and abdominal pain or discomfort. It can be caused by a variety of factors, including stress, hormonal changes, and certain foods.
4. Infectious diarrhea: This type of diarrhea is caused by a bacterial, viral, or parasitic infection and can be spread through contaminated food and water, close contact with an infected person, or by consuming contaminated food.

Symptoms of diarrhea may include:

* Frequent, loose, and watery stools
* Abdominal cramps and pain
* Bloating and gas
* Nausea and vomiting
* Fever and chills
* Headache
* Fatigue and weakness

Diagnosis of diarrhea is typically made through a physical examination, medical history, and laboratory tests to rule out other potential causes of the symptoms. Treatment for diarrhea depends on the underlying cause and may include antibiotics, anti-diarrheal medications, fluid replacement, and dietary changes. In severe cases, hospitalization may be necessary to monitor and treat any complications.

Prevention of diarrhea includes:

* Practicing good hygiene, such as washing hands frequently and thoroughly, especially after using the bathroom or before preparing food
* Avoiding close contact with people who are sick
* Properly storing and cooking food to prevent contamination
* Drinking safe water and avoiding contaminated water sources
* Avoiding raw or undercooked meat, poultry, and seafood
* Getting vaccinated against infections that can cause diarrhea

Complications of diarrhea can include:

* Dehydration: Diarrhea can lead to a loss of fluids and electrolytes, which can cause dehydration. Severe dehydration can be life-threatening and requires immediate medical attention.
* Electrolyte imbalance: Diarrhea can also cause an imbalance of electrolytes in the body, which can lead to serious complications.
* Inflammation of the intestines: Prolonged diarrhea can cause inflammation of the intestines, which can lead to abdominal pain and other complications.
* Infections: Diarrhea can be a symptom of an infection, such as a bacterial or viral infection. If left untreated, these infections can lead to serious complications.
* Malnutrition: Prolonged diarrhea can lead to malnutrition and weight loss, which can have long-term effects on health and development.

Treatment of diarrhea will depend on the underlying cause, but may include:

* Fluid replacement: Drinking plenty of fluids to prevent dehydration and replace lost electrolytes.
* Anti-diarrheal medications: Over-the-counter or prescription medications to slow down bowel movements and reduce diarrhea.
* Antibiotics: If the diarrhea is caused by a bacterial infection, antibiotics may be prescribed to treat the infection.
* Rest: Getting plenty of rest to allow the body to recover from the illness.
* Dietary changes: Avoiding certain foods or making dietary changes to help manage symptoms and prevent future episodes of diarrhea.

It is important to seek medical attention if you experience any of the following:

* Severe diarrhea that lasts for more than 3 days
* Diarrhea that is accompanied by fever, blood in the stool, or abdominal pain
* Diarrhea that is severe enough to cause dehydration or electrolyte imbalances
* Diarrhea that is not responding to treatment

Prevention of diarrhea includes:

* Good hand hygiene: Washing your hands frequently, especially after using the bathroom or before preparing food.
* Safe food handling: Cooking and storing food properly to prevent contamination.
* Avoiding close contact with people who are sick.
* Getting vaccinated against infections that can cause diarrhea, such as rotavirus.

Overall, while diarrhea can be uncomfortable and disruptive, it is usually a minor illness that can be treated at home with over-the-counter medications and plenty of fluids. However, if you experience severe or persistent diarrhea, it is important to seek medical attention to rule out any underlying conditions that may require more formal treatment.

Benign splenic neoplasms:

1. Splenic hamartoma: A rare benign tumor that usually occurs in children and young adults. It is made up of immature cells and can cause symptoms such as abdominal pain, fever, and anemia.
2. Splenic cyst: A fluid-filled sac that can develop in the spleen, often causing no symptoms unless it becomes infected or ruptures.
3. Splenic hemangioma: A benign tumor made up of blood vessels that can cause abdominal pain and discomfort.

Malignant splenic neoplasms:

1. Lymphoma: Cancer of the immune system that can affect the spleen, causing symptoms such as fever, fatigue, and weight loss.
2. Leukemia: Cancer of the blood cells that can cause an overgrowth of abnormal white blood cells in the bone marrow and other organs, including the spleen.
3. Splenic marginal zone lymphoma: A rare type of cancer that affects the marginal zone of the spleen, causing symptoms such as abdominal pain, fatigue, and weight loss.
4. Splenic diffuse large B-cell lymphoma: An aggressive form of lymphoma that can cause symptoms such as fever, night sweats, and weight loss.

The diagnosis of splenic neoplasms is based on a combination of imaging studies such as CT scans or PET scans, blood tests, and biopsies. Treatment options vary depending on the type and stage of the tumor and may include surgery, chemotherapy, or radiation therapy.

Lymphatic metastasis occurs when cancer cells enter the lymphatic vessels and are carried through the lymphatic system to other parts of the body. This can happen through several mechanisms, including:

1. Direct invasion: Cancer cells can invade the nearby lymphatic vessels and spread through them.
2. Lymphatic vessel embolization: Cancer cells can block the flow of lymphatic fluid and cause the formation of a clot-like structure, which can trap cancer cells and allow them to grow.
3. Lymphatic vessel invasion: Cancer cells can infiltrate the walls of lymphatic vessels and spread through them.

Lymphatic metastasis is a common mechanism for the spread of cancer, particularly in the breast, melanoma, and other cancers that have a high risk of lymphatic invasion. The presence of lymphatic metastasis in a patient's body can indicate a more aggressive cancer and a poorer prognosis.

Treatment for lymphatic metastasis typically involves a combination of surgery, chemotherapy, and radiation therapy. Surgery may be used to remove any affected lymph nodes or other tumors that have spread through the lymphatic system. Chemotherapy may be used to kill any remaining cancer cells, while radiation therapy may be used to shrink the tumors and relieve symptoms.

In summary, lymphatic metastasis is a common mechanism for the spread of cancer through the body, particularly in cancers that originate in organs with a high lymphatic drainage. Treatment typically involves a combination of surgery, chemotherapy, and radiation therapy to remove or shrink the tumors and relieve symptoms.

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

Adenofibromas are usually slow-growing and do not spread to other parts of the body. They may be small and firm or large and soft to the touch. They can be skin-colored or pink, and they may have a rough surface.

The cause of adenofibroma is not known, but it is thought to arise from abnormal growth of sweat gland cells. It is usually diagnosed by a dermatologist or a pathologist who examines a sample of the tumor under a microscope.

Treatment for adenofibroma is usually not necessary unless the tumor is causing symptoms or is cosmetically bothersome. In these cases, surgical removal of the tumor may be recommended. Complete removal of the tumor is usually possible, and the prognosis is excellent.

Sources:

* American Academy of Dermatology: Adenofibroma: Overview and Treatment Options
* Mayo Clinic: Adenofibroma: Symptoms and Causes
* Skin Cancer Foundation: Adenofibroma: Diagnosis and Treatment

The two main types of lymphoid leukemia are:

1. Acute Lymphoblastic Leukemia (ALL): This type of leukemia is most commonly seen in children, but it can also occur in adults. It is characterized by a rapid increase in the number of immature white blood cells in the blood and bone marrow.
2. Chronic Lymphocytic Leukemia (CLL): This type of leukemia usually affects older adults and is characterized by the gradual buildup of abnormal white blood cells in the blood, bone marrow, and lymph nodes.

Symptoms of lymphoid leukemia include fatigue, fever, night sweats, weight loss, and swollen lymph nodes. Treatment options for lymphoid leukemia can vary depending on the type of cancer and the severity of symptoms, but may include chemotherapy, radiation therapy, or bone marrow transplantation.

The disease is named after the Swedish physician Jan G. Waldenström, who first described it in 1944. It is also known as lymphoplasmacytic lymphoma or IgM multoculullarity.

The exact cause of Waldenström macroglobulinemia is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. The condition usually affects older adults and is more common in males than females.

Symptoms of Waldenström macroglobulinemia can include:

* Fatigue
* Weight loss
* Enlargement of the liver and spleen
* Swelling in the legs, ankles, and hands
* Pain in the bones or joints
* Increased risk of infections
* Numbness or tingling in the hands and feet

The diagnosis of Waldenström macroglobulinemia is based on a combination of physical examination, blood tests, and imaging studies. Treatment options include chemotherapy, immunomodulatory drugs, and stem cell transplantation. The prognosis for the disease varies depending on the severity of the symptoms and the response to treatment.

Overall, Waldenström macroglobulinemia is a rare and complex condition that requires careful management by a team of healthcare professionals. With appropriate treatment, many patients with this condition can experience long-term remission and improved quality of life.

Exanthema is often used interchangeably with the term "rash," but it specifically refers to a type of rash that is accompanied by other symptoms such as fever, headache, or joint pain. Exanthematous rashes can be contagious and may require treatment with antiviral or antibacterial medications, depending on the underlying cause.

Some common types of exanthema include:

* Measles: a highly contagious viral infection that causes a characteristic rash and other symptoms such as fever and cough.
* Roseola: a viral infection that causes a high fever followed by a rash.
* Fifth disease: a mild viral infection that causes a rash on the face and body.
* Hand, foot and mouth disease: a viral infection that causes a rash on the hands, feet, and mouth.

It's important to note that exanthema can be a symptom of various conditions, so it's important to seek medical attention if you or your child experiences a rash with other symptoms, especially if it's accompanied by fever, headache, or joint pain. A healthcare professional can diagnose the underlying cause and recommend appropriate treatment.

Myeloid leukemia can be classified into several subtypes based on the type of cell involved and the degree of maturity of the abnormal cells. The most common types of myeloid leukemia include:

1. Acute Myeloid Leukemia (AML): This is the most aggressive form of myeloid leukemia, characterized by a rapid progression of immature cells that do not mature or differentiate into normal cells. AML can be further divided into several subtypes based on the presence of certain genetic mutations or chromosomal abnormalities.
2. Chronic Myeloid Leukemia (CML): This is a slower-growing form of myeloid leukemia, characterized by the presence of a genetic abnormality known as the Philadelphia chromosome. CML is typically treated with targeted therapies or bone marrow transplantation.
3. Myelodysplastic Syndrome (MDS): This is a group of disorders characterized by the impaired development of immature blood cells in the bone marrow. MDS can progress to AML if left untreated.
4. Chronic Myelomonocytic Leukemia (CMML): This is a rare form of myeloid leukemia that is characterized by the accumulation of immature monocytes in the blood and bone marrow. CMML can be treated with chemotherapy or bone marrow transplantation.

The symptoms of myeloid leukemia can vary depending on the subtype and severity of the disease. Common symptoms include fatigue, weakness, fever, night sweats, and weight loss. Diagnosis is typically made through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment options for myeloid leukemia can include chemotherapy, targeted therapies, bone marrow transplantation, and supportive care to manage symptoms and prevent complications. The prognosis for myeloid leukemia varies depending on the subtype of the disease and the patient's overall health. With current treatments, many patients with myeloid leukemia can achieve long-term remission or even be cured.

Benign CNS neoplasms include:

1. Meningiomas: These are the most common type of benign CNS tumor, arising from the meninges (the membranes covering the brain and spinal cord).
2. Acoustic neuromas: These tumors arise from the nerve cells that connect the inner ear to the brain.
3. Pineal gland tumors: These are rare tumors that occur in the pineal gland, a small gland located in the brain.
4. Craniopharyngiomas: These are rare tumors that arise from the remnants of the embryonic pituitary gland and can cause a variety of symptoms including headaches, vision loss, and hormonal imbalances.

Malignant CNS neoplasms include:

1. Gliomas: These are the most common type of malignant CNS tumor and arise from the supporting cells of the brain called glial cells. Examples of gliomas include astrocytomas, oligodendrogliomas, and medulloblastomas.
2. Lymphomas: These are cancers of the immune system that can occur in the CNS.
3. Melanomas: These are rare tumors that arise from the pigment-producing cells of the skin and can spread to other parts of the body, including the CNS.
4. Metastatic tumors: These are tumors that have spread to the CNS from other parts of the body, such as the breast, lung, or colon.

The diagnosis and treatment of central nervous system neoplasms depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment. In general, gliomas have a poorer prognosis than other types of CNS tumors, with five-year survival rates ranging from 30% to 60%. Lymphomas and melanomas have better prognoses, with five-year survival rates of up to 80%. Metastatic tumors have a more guarded prognosis, with five-year survival rates depending on the primary site of the cancer.

In summary, central nervous system neoplasms are abnormal growths of tissue in the brain and spinal cord that can cause a variety of symptoms and can be benign or malignant. The diagnosis and treatment of these tumors depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment, but in general, gliomas have a poorer prognosis than other types of CNS tumors.

There are several types of retinal neoplasms, including:

1. Retinal angiomatosis: This is a benign tumor that grows new blood vessels in the retina.
2. Retinal astrocytoma: This is a malignant tumor that arises from the supportive cells of the retina called astrocytes.
3. Retinal melanoma: This is a malignant tumor that arises from the pigment-producing cells of the retina called melanocytes. It is the most common type of primary intraocular cancer (cancer that originates in the eye).
4. Retinal osteochondroma: This is a benign tumor that grows from the supporting tissue of the retina.
5. Retinal sarcoma: This is a malignant tumor that arises from the connective tissue of the retina.

Retinal neoplasms can cause a variety of symptoms, including:

1. Blurred vision
2. Distorted vision
3. Flashes of light
4. Floaters (specks or cobwebs in your vision)
5. Eye pain
6. Redness and swelling of the eye
7. Sensitivity to light
8. Difficulty seeing colors

If you experience any of these symptoms, it is important to see an eye doctor as soon as possible for a comprehensive examination. Retinal neoplasms can be diagnosed through a combination of physical examination, imaging tests such as ultrasound and MRI, and laboratory tests such as blood tests.

Treatment options for retinal neoplasms depend on the type and location of the tumor, as well as the severity of the symptoms. Some common treatment options include:

1. Observation: Small, benign tumors may not require immediate treatment and can be monitored with regular eye exams to see if they grow or change over time.
2. Photocoagulation: This is a procedure that uses laser light to damage the tumor and prevent it from growing further. It can be used to treat retinal melanoma and other types of retinal neoplasms.
3. Cryotherapy: This is a procedure that uses extreme cold to freeze and destroy the tumor. It can be used to treat retinal sarcoma and other types of retinal neoplasms.
4. Surgery: In some cases, surgery may be necessary to remove the tumor. This can involve removing the affected eye (enucleation) or removing only the tumor and a small amount of surrounding tissue (vitrectomy).
5. Chemotherapy: This is a treatment that uses drugs to kill cancer cells. It may be used in combination with other treatments, such as photocoagulation or surgery, to treat retinal neoplasms.

It is important to note that early detection and treatment of retinal neoplasms can help preserve vision and improve outcomes. If you experience any symptoms of a retinal tumor, such as blurred vision, flashes of light, or floaters, it is important to see an eye doctor as soon as possible for an evaluation.

The prognosis for mantle-cell lymphoma is generally poor, with a five-year survival rate of approximately 40%. Treatment options include chemotherapy, immunotherapy, and autologous stem-cell transplantation. The disease often recurs after initial therapy, and subsequent treatments may be less effective.

Mantle-cell lymphoma can be difficult to distinguish from other types of non-Hodgkin lymphoma, such as follicular lymphoma or diffuse large B-cell lymphoma, and a correct diagnosis is important for determining appropriate treatment.

Slide: Mantle Cell Lymphoma (Image courtesy of Nephron/Wikimedia Commons)

The symptoms of malignant pleural effusion can vary depending on the location and size of the tumor and the amount of fluid accumulated. Common symptoms include:

* Chest pain or discomfort
* Shortness of breath (dyspnea)
* Coughing up blood or pink, frothy liquid (hemoptysis)
* Fatigue
* Weight loss
* Night sweats
* Fevers

A diagnosis of malignant pleural effusion is typically made based on a combination of physical examination findings, medical imaging studies such as chest X-rays or CT scans, and laboratory tests to evaluate the fluid drained from the pleural space.

Treatment for malignant pleural effusion depends on the underlying cause and may include:

* Chemotherapy to shrink the tumor and reduce fluid buildup
* Radiation therapy to target cancer cells in the chest
* Surgery to remove the cancerous tissue or drain the fluid
* Pain management medications to relieve chest pain and discomfort.

Synonyms: Castration-resistant prostatic neoplasm, Hormone-refractory prostate cancer, Androgen-independent prostate cancer

Example sentence: "The patient's prostate cancer had progressed to castration-resistant prostatic neoplasms, and he was experiencing severe bone pain despite undergoing multiple treatments."

Erythroleukemia typically affects adults in their 50s and 60s, although it can occur at any age. Symptoms may include fever, night sweats, weight loss, and fatigue. The cancer cells can spread to other parts of the body, including the spleen, liver, and lymph nodes.

Erythroleukemia is diagnosed through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment typically involves chemotherapy and/or radiation therapy to kill cancer cells and restore normal blood cell production. In some cases, a bone marrow transplant may be necessary. The prognosis for erythroleukemia is generally poor, with a five-year survival rate of about 20%.

Erythroleukemia is classified as an acute leukemia, meaning it progresses rapidly and can lead to life-threatening complications if left untreated. It is important for patients to receive prompt and appropriate treatment to improve their chances of survival and quality of life.

Adult T-cell leukemia/lymphoma (ATLL) is a rare type of cancer that affects the immune system. It is caused by the human T-lymphotropic virus type 1 (HTLV-1), which is transmitted through breastfeeding or blood transfusions. ATLL typically affects adults and can cause a range of symptoms, including fever, fatigue, weight loss, and swollen lymph nodes.

If you suspect that you or someone you know may have ATLL, it is important to seek medical attention as soon as possible. A healthcare provider will perform a physical examination and order diagnostic tests to determine if HTLV-1 is present in the body. Diagnostic tests for ATLL may include blood tests, imaging studies, and biopsies.

There are several treatment options available for ATLL, including chemotherapy, radiation therapy, and bone marrow transplantation. The choice of treatment will depend on the stage and severity of the disease, as well as the patient's overall health. In some cases, a combination of treatments may be used to achieve the best possible outcome.

Unfortunately, the prognosis for ATLL is poor, with a five-year survival rate of less than 30%. However, early detection and treatment can improve the chances of survival. It is important to note that there is currently no cure for ATLL, but ongoing research is exploring new treatments and therapies to improve outcomes for patients with this disease.

In conclusion, ATLL is a rare and aggressive form of cancer that affects the immune system. It is caused by the HTLV-1 virus and can progress slowly over several years before symptoms appear. If you suspect that you or someone you know may have ATLL, it is important to seek medical attention as soon as possible for proper diagnosis and treatment. While the prognosis is poor, early detection and treatment can improve survival rates. Ongoing research is exploring new treatments and therapies to improve outcomes for patients with ATLL.

The term "serous" refers to the fact that the tumor produces a fluid-filled cyst, which typically contains a clear, serous (watery) liquid. The cancer cells are typically found in the outer layer of the ovary, near the surface of the organ.

Cystadenocarcinoma, serous is the most common type of ovarian cancer, accounting for about 50-60% of all cases. It is often diagnosed at an advanced stage, as it can be difficult to detect in its early stages. Symptoms may include abdominal pain, bloating, and changes in bowel or bladder habits.

Treatment for cystadenocarcinoma, serous usually involves a combination of surgery and chemotherapy. Surgery may involve removing the uterus, ovaries, and other affected tissues, followed by chemotherapy to kill any remaining cancer cells. In some cases, radiation therapy may also be used.

Prognosis for cystadenocarcinoma, serous varies depending on the stage of the cancer at diagnosis. Women with early-stage disease have a good prognosis, while those with advanced-stage disease have a poorer outlook. However, overall survival rates have improved in recent years due to advances in treatment and screening.

In summary, cystadenocarcinoma, serous is a type of ovarian cancer that originates in the lining of the ovary and grows slowly over time. It can be difficult to detect in its early stages, but treatment typically involves surgery and chemotherapy. Prognosis varies depending on the stage of the cancer at diagnosis.

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.

The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Night sweats
* Weight loss
* Abdominal pain or discomfort
* Itching

The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.

Peripheral neuroectodermal tumors are those that occur outside of the CNS, typically in the peripheral nervous system (PNS). Examples of peripheral neuroectodermal tumors include:

1. Neuroblastoma: a type of cancer that develops in nerve tissue outside of the brain and spinal cord.
2. Ganglioneuroma: a rare type of tumor that occurs in the peripheral nervous system, typically in the abdomen or extremities.
3. Plexiform neuroectodermal tumor: a rare type of tumor that occurs in the peripheral nervous system, typically in the limbs.
4. Malignant peripheral nerve sheath tumors (MPNST): a type of cancer that develops in the covering of nerves outside of the CNS.

These tumors are rare and can be difficult to diagnose and treat. They often have a poor prognosis, but with early detection and appropriate treatment, outcomes can improve. Treatment options may include surgery, chemotherapy, and radiation therapy.

There are several types of leukocyte disorders, including:

1. Leukemia: a malignancy of the blood cells that can affect any type of blood cell, including white blood cells.
2. Neutropenia: a condition characterized by a low number of neutrophils (a type of white blood cell) in the blood.
3. Monocytopenia: a condition characterized by a low number of monocytes (a type of white blood cell) in the blood.
4. Lymphopenia: a condition characterized by a low number of lymphocytes (a type of white blood cell) in the blood.
5. Leukopenia: a condition characterized by a low number of all types of white blood cells in the blood.
6. Thalassemia: a genetic disorder that affects the production of hemoglobin, which is necessary for red blood cells to carry oxygen in the body.
7. Fanconi anemia: a rare genetic disorder that affects the production of white blood cells and increases the risk of cancer and other health problems.
8. Diamond-Blackfan anemia: a rare genetic disorder that affects the production of red blood cells and can also lead to neutropenia and other complications.
9. Chronic granulomatous disease (CGD): a condition caused by a defect in the production of a type of white blood cell called a granulocyte, which makes it difficult for the body to fight off infections.
10. Chediak-Higashi syndrome: a rare genetic disorder that affects the production of white blood cells and increases the risk of infections and other health problems.

Treatment for leukocyte disorders depends on the specific condition and may include medications, blood transfusions, or bone marrow transplantation. In some cases, the only effective treatment is a bone marrow transplant.

Inherited bone marrow failure syndromes (IBMFS) are a group of rare genetic disorders that affect the bone marrow's ability to produce blood cells, including red blood cells, white blood cells, and platelets. These disorders can lead to anemia, neutropenia, thrombocytopenia, and an increased risk of infections and cancer.

The following are some of the most common inherited bone marrow failure syndromes:

1. Fanconi anemia: a rare genetic disorder that affects the production of white blood cells and increases the risk of cancer and other health problems.
2. Diamond-Blackfan anemia: a rare genetic disorder that affects the production of red blood cells and can also lead to neutropenia and other complications.
3. Chronic granulomatous disease (CGD): a condition caused by a defect in the production of a type of white blood cell called a granulocyte, which makes it difficult for the body to fight off infections.
4. Chediak-Higashi syndrome: a rare genetic disorder that affects the production of white blood cells and increases the risk of infection and other health problems.
5. X-linked sideroblastic anemia (XLSA): a rare genetic disorder that affects the production of red blood cells and can also lead to neutropenia and other complications.
6. Leukocyte adhesion deficiency (LAD): a rare genetic disorder that affects the production of white blood cells and increases the risk of infection.
7. Wiskott-Aldrich syndrome: a rare genetic disorder that affects the production of white blood cells and increases the risk of infection and other health problems.
8. X-linked agammaglobulinemia (XLA): a rare genetic disorder that affects the production of antibodies and increases the risk of infections.
9. Common variable immunodeficiency (CVID): a condition caused by a defect in the production of antibodies, which makes it difficult for the body to fight off infections.
10. Ataxia-telangiectasia (AT): a rare genetic disorder that affects the production of immune cells and increases the risk of cancer and other health problems.

It is important to note that these are just a few examples of primary immunodeficiency diseases and there are many more types of disorders that can affect the immune system. Each type of primary immunodeficiency disease has its own set of symptoms and may require different treatments.

There are several types of drug-related side effects and adverse reactions, including:

1. Common side effects: These are side effects that are commonly experienced by patients taking a particular medication. Examples include nausea, dizziness, and fatigue.
2. Serious side effects: These are side effects that can be severe or life-threatening. Examples include allergic reactions, liver damage, and bone marrow suppression.
3. Adverse events: These are any unwanted or harmful effects that occur during the use of a medication, including side effects and other clinical events such as infections or injuries.
4. Drug interactions: These are interactions between two or more drugs that can cause harmful side effects or reduce the effectiveness of one or both drugs.
5. Side effects caused by drug abuse: These are side effects that occur when a medication is taken in larger-than-recommended doses or in a manner other than as directed. Examples include hallucinations, seizures, and overdose.

It's important to note that not all side effects and adverse reactions are caused by the drug itself. Some may be due to other factors, such as underlying medical conditions, other medications being taken, or environmental factors.

To identify and manage drug-related side effects and adverse reactions, healthcare providers will typically ask patients about any symptoms they are experiencing, perform physical exams, and review the patient's medical history and medication list. In some cases, additional tests may be ordered to help diagnose and manage the problem.

Overall, it's important for patients taking medications to be aware of the potential for side effects and adverse reactions, and to report any symptoms or concerns to their healthcare provider promptly. This can help ensure that any issues are identified and addressed early, minimizing the risk of harm and ensuring that the patient receives the best possible care.

Examples of Immunologic Deficiency Syndromes include:

1. Primary Immunodeficiency Diseases (PIDDs): These are a group of genetic disorders that affect the immune system's ability to function properly. Examples include X-linked agammaglobulinemia, common variable immunodeficiency, and severe combined immunodeficiency.
2. Acquired Immunodeficiency Syndrome (AIDS): This is a condition that results from the human immunodeficiency virus (HIV) infection, which destroys CD4 cells, a type of immune cell that fights off infections.
3. Immune Thrombocytopenic Purpura (ITP): This is an autoimmune disorder that causes the immune system to attack and destroy platelets, which are blood cells that help the blood to clot.
4. Autoimmune Disorders: These are conditions in which the immune system mistakenly attacks and damages healthy cells and tissues in the body. Examples include rheumatoid arthritis, lupus, and multiple sclerosis.
5. Immunosuppressive Therapy-induced Immunodeficiency: This is a condition that occurs as a side effect of medications used to prevent rejection in organ transplant patients. These medications can suppress the immune system, increasing the risk of infections.

Symptoms of Immunologic Deficiency Syndromes can vary depending on the specific disorder and the severity of the immune system dysfunction. Common symptoms include recurrent infections, fatigue, fever, and swollen lymph nodes. Treatment options for these syndromes range from medications to suppress the immune system to surgery or bone marrow transplantation.

In summary, Immunologic Deficiency Syndromes are a group of disorders that result from dysfunction of the immune system, leading to recurrent infections and other symptoms. There are many different types of these syndromes, each with its own set of symptoms and treatment options.

Leukemic infiltration refers to the abnormal growth and spread of cancer cells (leukemia) into normal tissues, organs, or bones. It is a common feature of many types of leukemia, including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL).

Leukemic infiltration can cause a range of symptoms, including pain, swelling, and difficulty with movement or function. In severe cases, it can also lead to life-threatening complications such as organ failure or sepsis.

The diagnosis of leukemic infiltration typically involves a combination of physical examination, medical history, laboratory tests (such as blood and bone marrow studies), and imaging studies (such as X-rays, CT scans, or PET scans). Treatment options for leukemic infiltration depend on the specific type of leukemia and the severity of the infiltration, but may include chemotherapy, radiation therapy, immunotherapy, or bone marrow transplantation.

Overall, leukemic infiltration is a serious condition that can have significant impacts on quality of life and survival. Early detection and prompt treatment are important for achieving the best possible outcomes.

Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin's lymphoma that was first identified in 1985. It typically affects the skin, particularly the legs, and can present with symptoms such as swelling, redness, and itching. Less common sites include the lymph nodes, liver, spleen, bone marrow, or gastrointestinal tract.

Symptoms of ALCL may also include fever, night sweats, weight loss, fatigue, and swollen lymph nodes. The cancer cells are typically large and have an "anaplastic" appearance under a microscope, with prominent nucleoli and abundant cytoplasm.

Treatment for ALCL usually involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary. The prognosis for ALCL varies depending on the stage and location of the cancer, but overall it is considered to be a relatively rare and aggressive form of non-Hodgkin's lymphoma.

In summary, anaplastic large cell lymphoma (ALCL) is a rare and aggressive subtype of non-Hodgkin's lymphoma that primarily affects the skin, but can also involve other lymphoid tissues and organs. It is characterized by large, anaplastic cells with prominent nucleoli and abundant cytoplasm, and typically presents with symptoms such as swelling, redness, itching, fever, night sweats, weight loss, and fatigue. Treatment usually involves chemotherapy, radiation therapy, or a combination of both, and the prognosis varies depending on the stage and location of the cancer.

Some common types of nervous system neoplasms include:

1. Brain tumors: These are abnormal growths that develop in the brain, including gliomas (such as glioblastoma), meningiomas, and acoustic neuromas.
2. Spinal cord tumors: These are abnormal growths that develop in the spinal cord, including astrocytomas, oligodendrogliomas, and metastatic tumors.
3. Nerve sheath tumors: These are abnormal growths that develop in the covering of nerves, such as neurofibromas and schwannomas.
4. Pineal gland tumors: These are abnormal growths that develop in the pineal gland, a small endocrine gland located in the brain.

Symptoms of nervous system neoplasms can vary depending on their location and size, but may include headaches, seizures, weakness or numbness in the arms or legs, and changes in vision, speech, or balance. Diagnosis is typically made through a combination of imaging studies (such as MRI or CT scans) and tissue biopsy. Treatment options vary depending on the type and location of the tumor, but may include surgery, radiation therapy, and chemotherapy.

In summary, nervous system neoplasms are abnormal growths that can develop in the brain, spinal cord, and nerves, and can have a significant impact on the body. Diagnosis and treatment require a comprehensive approach, involving a team of medical professionals with expertise in neurology, neurosurgery, radiation oncology, and other related specialties.

Some common types of eye neoplasms include:

1. Uveal melanoma: This is a malignant tumor that develops in the uvea, the middle layer of the eye. It is the most common primary intraocular cancer in adults and can spread to other parts of the body if left untreated.
2. Retinoblastoma: This is a rare type of cancer that affects children and develops in the retina. It is usually diagnosed before the age of 5 and is highly treatable with surgery, chemotherapy, and radiation therapy.
3. Conjunctival melanoma: This is a malignant tumor that develops in the conjunctiva, the thin membrane that covers the white part of the eye. It is more common in older adults and can be treated with surgery and/or radiation therapy.
4. Ocular sarcomas: These are rare types of cancer that develop in the eye tissues, including the retina, optic nerve, and uvea. They can be benign or malignant and may require surgical removal or radiation therapy.
5. Secondary intraocular tumors: These are tumors that metastasize (spread) to the eye from other parts of the body, such as breast cancer or lung cancer.

The symptoms of eye neoplasms can vary depending on their location and type, but may include:

* Blurred vision
* Eye pain or discomfort
* Redness or inflammation in the eye
* Sensitivity to light
* Floaters (specks or cobwebs in vision)
* Flashes of light
* Abnormal pupil size or shape

Early detection and treatment of eye neoplasms are important to preserve vision and prevent complications. Diagnosis is typically made through a combination of physical examination, imaging tests such as ultrasound or MRI, and biopsy (removing a small sample of tissue for examination under a microscope). Treatment options may include:

* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to destroy cancer cells with medication
* Observation and monitoring if the tumor is slow-growing or benign

It's important to seek medical attention if you experience any unusual symptoms in your eye, as early detection and treatment can improve outcomes.

Uveal neoplasms can cause a variety of symptoms, including blurred vision, flashes of light, floaters, and eye pain. These tumors can also cause inflammation and swelling in the eye, which can lead to glaucoma or other complications.

Diagnosis of uveal neoplasms typically involves a combination of physical examination, imaging tests such as ultrasound and MRI, and biopsy. Treatment options for uveal neoplasms depend on the type and location of the tumor, as well as the severity of the disease. Surgery is often the first line of treatment for these tumors, and may involve removal of the affected tissue or the entire eye. Radiation therapy and chemotherapy may also be used in some cases.

Overall, uveal neoplasms are serious conditions that can have a significant impact on vision and eye health. Early diagnosis and treatment are key to improving outcomes for patients with these tumors.

Anorexia can have serious physical and emotional consequences, including:

* Malnutrition and nutrient deficiencies
* Osteoporosis and bone loss
* Heart problems and low blood pressure
* Hormonal imbalances
* Depression, anxiety, and other mood disorders
* Social isolation and difficulties in relationships

There are two main types of anorexia:

* Restrictive type: Characterized by restrictive eating habits and a fear of gaining weight.
* Binge/purge type: Characterized by episodes of binge eating followed by purging behaviors, such as vomiting or using laxatives.

Treatment for anorexia typically involves a combination of psychotherapy, nutrition counseling, and medication. Family-based therapy, cognitive-behavioral therapy, and interpersonal psychotherapy are some of the common approaches used to treat anorexia. Medications such as antidepressants and anti-anxiety drugs may also be prescribed to help manage symptoms.

In conclusion, anorexia is a complex and serious eating disorder that can have long-lasting physical and emotional consequences. It is important to seek professional help if symptoms persist or worsen over time. With appropriate treatment, individuals with anorexia can recover and lead a healthy and fulfilling life.

Neoplasm micrometastasis is a common phenomenon in many types of cancer, including breast cancer, lung cancer, and melanoma. The presence of micrometastases can indicate that the cancer has a higher risk of recurrence and can be a factor in determining the course of treatment.

The detection and characterization of neoplasm micrometastasis is an area of ongoing research in the field of pathology, with new techniques such as digital image analysis and next-generation sequencing being developed to improve the accuracy and speed of diagnosis. The prognostic and therapeutic implications of neoplasm micrometastasis are also being studied, as they may have important implications for cancer treatment and patient outcomes.

The term splenomegaly is used to describe any condition that results in an increase in the size of the spleen, regardless of the underlying cause. This can be caused by a variety of factors, such as infection, inflammation, cancer, or genetic disorders.

Splenomegaly can be diagnosed through a physical examination, where the doctor may feel the enlarged spleen during an abdominal palpation. Imaging tests, such as ultrasound, computed tomography (CT) scans, or magnetic resonance imaging (MRI), may also be used to confirm the diagnosis and evaluate the extent of the splenomegaly.

Treatment for splenomegaly depends on the underlying cause. For example, infections such as malaria or mononucleosis are treated with antibiotics, while cancerous conditions may require surgical intervention or chemotherapy. In some cases, the spleen may need to be removed, a procedure known as splenectomy.

In conclusion, splenomegaly is an abnormal enlargement of the spleen that can be caused by various factors and requires prompt medical attention for proper diagnosis and treatment.

Examples of soft tissue neoplasms include:

1. Lipoma: a benign tumor composed of fat cells.
2. Fibroma: a benign tumor composed of fibrous tissue.
3. Leiomyoma: a benign tumor composed of smooth muscle tissue.
4. Synovial sarcoma: a malignant tumor that arises in the soft tissues surrounding joints.
5. Rhabdomyosarcoma: a malignant tumor that arises in the skeletal muscles.
6. Neurofibroma: a benign tumor that arises in the nerve tissue.

Soft tissue neoplasms can occur in various parts of the body, including the extremities (arms and legs), trunk, and head and neck. They can be diagnosed through a combination of imaging studies such as X-rays, CT scans, MRI scans, and biopsy.

Treatment for soft tissue neoplasms depends on the type, size, location, and aggressiveness of the tumor, as well as the patient's overall health. Benign tumors may not require treatment, while malignant tumors may be treated with surgery, radiation therapy, or chemotherapy.

A rare and aggressive type of cancer that affects the connective tissue cells of the body, including blood vessels, lymph nodes, and soft tissue. It is caused by the human herpesvirus 8 (HHV-8) and is more common in people with weakened immune systems, such as those with HIV/AIDS.

Symptoms:

* Painless lumps or lesions on the skin or mouth
* Fatigue
* Weight loss
* Night sweats

Diagnosis:

* Biopsy of affected tissue
* Imaging tests, such as CT scans or MRI

Treatment:

* Chemotherapy to shrink the tumors
* Radiation therapy to kill cancer cells
* Surgery to remove the affected tissue

Prognosis:

* Poor, especially in people with HIV/AIDS

Etymology:

* Named after the Hungarian-born Jewish doctor, Georg Kaposi, who first described the condition in 1872.

Endometrial neoplasms are abnormal growths or tumors that develop in the lining of the uterus, known as the endometrium. These growths can be benign (non-cancerous) or malignant (cancerous). The most common type of endometrial neoplasm is endometrial hyperplasia, which is a condition where the endometrium grows too thick and can become cancerous if left untreated. Other types of endometrial neoplasms include endometrial adenocarcinoma, which is the most common type of uterine cancer, and endometrial sarcoma, which is a rare type of uterine cancer that develops in the muscle or connective tissue of the uterus.

Endometrial neoplasms can be caused by a variety of factors, including hormonal imbalances, genetic mutations, and exposure to certain chemicals or radiation. Risk factors for developing endometrial neoplasms include obesity, early onset of menstruation, late onset of menopause, never being pregnant or having few or no full-term pregnancies, and taking hormone replacement therapy or other medications that can increase estrogen levels.

Symptoms of endometrial neoplasms can include abnormal vaginal bleeding, painful urination, and pelvic pain or discomfort. Treatment for endometrial neoplasms depends on the type and stage of the condition, and may involve surgery, radiation therapy, chemotherapy, or hormone therapy. In some cases, a hysterectomy (removal of the uterus) may be necessary.

In summary, endometrial neoplasms are abnormal growths that can develop in the lining of the uterus and can be either benign or malignant. They can be caused by a variety of factors and can cause symptoms such as abnormal bleeding and pelvic pain. Treatment depends on the type and stage of the condition, and may involve surgery, radiation therapy, chemotherapy, or hormone therapy.

Types of Esophageal Neoplasms:

1. Barrett's Esophagus: This is a precancerous condition that occurs when the cells lining the esophagus undergo abnormal changes, increasing the risk of developing esophageal cancer.
2. Adenocarcinoma: This is the most common type of esophageal cancer, accounting for approximately 70% of all cases. It originates in the glands that line the esophagus.
3. Squamous Cell Carcinoma: This type of cancer accounts for about 20% of all esophageal cancers and originates in the squamous cells that line the esophagus.
4. Other rare types: Other rare types of esophageal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Causes and Risk Factors:

1. Gastroesophageal reflux disease (GERD): Long-standing GERD can lead to the development of Barrett's esophagus, which is a precancerous condition that increases the risk of developing esophageal cancer.
2. Obesity: Excess body weight is associated with an increased risk of developing esophageal cancer.
3. Diet: A diet high in processed meats and low in fruits and vegetables may increase the risk of developing esophageal cancer.
4. Alcohol consumption: Heavy alcohol consumption is a known risk factor for esophageal cancer.
5. Smoking: Cigarette smoking is a major risk factor for esophageal cancer.
6. Family history: Having a family history of esophageal cancer or other cancers may increase an individual's risk.
7. Age: The risk of developing esophageal cancer increases with age, with most cases occurring in people over the age of 50.
8. Other medical conditions: Certain medical conditions, such as achalasia, may increase the risk of developing esophageal cancer.

Symptoms and Diagnosis:

1. Dysphagia (difficulty swallowing): This is the most common symptom of esophageal cancer, and can be caused by a narrowing or blockage of the esophagus due to the tumor.
2. Chest pain or discomfort: Pain in the chest or upper back can be a symptom of esophageal cancer.
3. Weight loss: Losing weight without trying can be a symptom of esophageal cancer.
4. Coughing or hoarseness: If the tumor is obstructing the airway, it can cause coughing or hoarseness.
5. Fatigue: Feeling tired or weak can be a symptom of esophageal cancer.
6. Diagnosis: A diagnosis of esophageal cancer is typically made through a combination of endoscopy, imaging tests (such as CT scans), and biopsies.

Treatment Options:

1. Surgery: Surgery is the primary treatment for esophageal cancer, and can involve removing the tumor and some surrounding tissue, or removing the entire esophagus and replacing it with a section of stomach or intestine.
2. Chemotherapy: Chemotherapy involves using drugs to kill cancer cells, and is often used in combination with surgery to treat esophageal cancer.
3. Radiation therapy: Radiation therapy uses high-energy X-rays to kill cancer cells, and can be used alone or in combination with surgery or chemotherapy.
4. Targeted therapy: Targeted therapy drugs are designed to target specific molecules that are involved in the growth and spread of cancer cells, and can be used in combination with other treatments.

Prognosis and Survival Rate:

1. The prognosis for esophageal cancer is generally poor, with a five-year survival rate of around 20%.
2. Factors that can improve the prognosis include early detection, small tumor size, and absence of spread to lymph nodes or other organs.
3. The overall survival rate for esophageal cancer has not improved much over the past few decades, but advances in treatment have led to a slight increase in survival time for some patients.

Lifestyle Changes and Prevention:

1. Avoiding tobacco and alcohol: Tobacco and alcohol are major risk factors for esophageal cancer, so avoiding them can help reduce the risk of developing the disease.
2. Maintaining a healthy diet: Eating a balanced diet that is high in fruits, vegetables, and whole grains can help protect against esophageal cancer.
3. Managing obesity: Obesity is a risk factor for esophageal cancer, so maintaining a healthy weight through diet and exercise can help reduce the risk of developing the disease.
4. Reducing exposure to pollutants: Exposure to certain chemicals and pollutants, such as pesticides and asbestos, has been linked to an increased risk of esophageal cancer. Avoiding these substances can help reduce the risk of developing the disease.
5. Getting regular screening: Regular screening for Barrett's esophagus, a precancerous condition that can develop in people with gastroesophageal reflux disease (GERD), can help detect and treat esophageal cancer early, when it is most treatable.

Current Research and Future Directions:

1. Targeted therapies: Researchers are working on developing targeted therapies that can specifically target the genetic mutations that drive the growth of esophageal cancer cells. These therapies may be more effective and have fewer side effects than traditional chemotherapy.
2. Immunotherapy: Immunotherapy, which uses the body's immune system to fight cancer, is being studied as a potential treatment for esophageal cancer. Researchers are working on developing vaccines and other immunotherapies that can help the body recognize and attack cancer cells.
3. Precision medicine: With the help of advanced genomics and precision medicine, researchers are working to identify specific genetic mutations that drive the growth of esophageal cancer in each patient. This information can be used to develop personalized treatment plans that are tailored to the individual patient's needs.
4. Early detection: Researchers are working on developing new methods for early detection of esophageal cancer, such as using machine learning algorithms to analyze medical images and detect signs of cancer at an early stage.
5. Lifestyle modifications: Studies have shown that lifestyle modifications, such as quitting smoking and maintaining a healthy diet, can help reduce the risk of developing esophageal cancer. Researchers are working on understanding the specific mechanisms by which these modifications can help prevent the disease.

In conclusion, esophageal cancer is a complex and aggressive disease that is often diagnosed at an advanced stage. However, with advances in technology, research, and treatment options, there is hope for improving outcomes for patients with this disease. By understanding the risk factors, early detection methods, and current treatments, as well as ongoing research and future directions, we can work towards a future where esophageal cancer is more manageable and less deadly.

Symptoms of cerebellar neoplasms can include:

* Headaches
* Nausea and vomiting
* Dizziness and loss of balance
* Weakness or paralysis in the arms or legs
* Coordination problems and difficulty walking
* Double vision or other visual disturbances
* Speech difficulties
* Seizures

Cerebellar neoplasms can be caused by genetic mutations, exposure to radiation, or viral infections. They can also occur spontaneously without any known cause.

Diagnosis of cerebellar neoplasms usually involves a combination of imaging tests such as CT or MRI scans, and tissue sampling through biopsy. Treatment options for cerebellar neoplasms depend on the type, size, and location of the tumor, as well as the patient's overall health.

Treatment options may include:

* Surgery to remove the tumor
* Radiation therapy to kill remaining cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules that are involved in the growth and spread of the tumor.

Prognosis for cerebellar neoplasms varies depending on the type, size, and location of the tumor, as well as the patient's overall health. In general, the prognosis is better for patients with benign tumors that are located in the outer layers of the cerebellum, and worse for those with malignant tumors that are located in the deeper layers.

Overall, cerebellar neoplasms are a complex and rare type of brain tumor that require specialized care and treatment from a team of medical professionals.

The exact cause of cachexia is not fully understood, but it is thought to be related to a combination of factors such as inflammation, hormonal imbalances, and changes in metabolism. Treatment for cachexia often focuses on addressing the underlying cause of the wasting, such as managing cancer or HIV/AIDS, as well as providing nutritional support and addressing any related complications.

In the medical field, cachexia is a serious condition that requires careful management to improve quality of life and outcomes for patients. It is important for healthcare providers to be aware of the signs and symptoms of cachexia and to provide appropriate treatment and support to affected individuals.

The different types of Neurotoxicity Syndromes include:

1. Organophosphate-induced neurotoxicity: This syndrome is caused by exposure to organophosphate pesticides, which can damage the nervous system and cause symptoms such as headaches, dizziness, and memory loss.
2. Heavy metal neurotoxicity: Exposure to heavy metals, such as lead, mercury, and arsenic, can damage the nervous system and cause symptoms such as tremors, muscle weakness, and cognitive impairment.
3. Pesticide-induced neurotoxicity: This syndrome is caused by exposure to pesticides, which can damage the nervous system and cause symptoms such as headaches, dizziness, and memory loss.
4. Solvent-induced neurotoxicity: Exposure to solvents, such as toluene and benzene, can damage the nervous system and cause symptoms such as memory loss, difficulty with concentration, and mood changes.
5. Medication-induced neurotoxicity: Certain medications, such as antidepressants and antipsychotics, can damage the nervous system and cause symptoms such as tremors, muscle rigidity, and cognitive impairment.
6. Environmental neurotoxicity: Exposure to environmental toxins, such as air pollution and pesticides, can damage the nervous system and cause symptoms such as headaches, dizziness, and memory loss.
7. Neurodegenerative disease-induced neurotoxicity: Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, can cause neurotoxicity and lead to symptoms such as cognitive decline, memory loss, and motor dysfunction.
8. Traumatic brain injury-induced neurotoxicity: Traumatic brain injury can cause neurotoxicity and lead to symptoms such as cognitive impairment, memory loss, and mood changes.
9. Stroke-induced neurotoxicity: A stroke can cause neurotoxicity and lead to symptoms such as weakness or paralysis on one side of the body, difficulty with speech and language, and memory loss.
10. Neurodevelopmental disorder-induced neurotoxicity: Neurodevelopmental disorders, such as autism spectrum disorder, can cause neurotoxicity and lead to symptoms such as cognitive impairment, social withdrawal, and repetitive behaviors.

It is important to note that these are just a few examples of the many different types of neurotoxicity that can occur, and that each type may have its own unique set of causes, symptoms, and treatments. If you suspect that you or someone you know may be experiencing neurotoxicity, it is important to seek medical attention as soon as possible in order to receive an accurate diagnosis and appropriate treatment.

The symptoms of meningeal neoplasms vary depending on the location, size, and type of tumor. Common symptoms include headaches, seizures, weakness or numbness in the arms or legs, and changes in vision, memory, or behavior. As the tumor grows, it can compress or displaces the brain tissue, leading to increased intracranial pressure and potentially life-threatening complications.

There are several different types of meningeal neoplasms, including:

1. Meningioma: This is the most common type of meningeal neoplasm, accounting for about 75% of all cases. Meningiomas are usually benign and grow slowly, but they can sometimes be malignant.
2. Metastatic tumors: These are tumors that have spread to the meninges from another part of the body, such as the lung or breast.
3. Lymphoma: This is a type of cancer that affects the immune system and can spread to the meninges.
4. Melanotic neuroectodermal tumors (MNTs): These are rare, malignant tumors that usually occur in children and young adults.
5. Hemangiopericytic hyperplasia: This is a rare, benign condition characterized by an overgrowth of blood vessels in the meninges.

The diagnosis of meningeal neoplasms is based on a combination of clinical symptoms, physical examination findings, and imaging studies such as CT or MRI scans. A biopsy may be performed to confirm the diagnosis and determine the type of tumor.

Treatment options for meningeal neoplasms depend on the type, size, and location of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment, and may involve removing as much of the tumor as possible or using a laser to ablate (destroy) the tumor cells. Radiation therapy and chemotherapy may also be used in combination with surgery to treat malignant meningeal neoplasms.

Prognosis for meningeal neoplasms varies depending on the type of tumor and the patient's overall health. In general, early diagnosis and treatment improve the prognosis, while later-stage tumors may have a poorer outcome.

Source: Dorland's Medical Dictionary, 32nd edition.

There are several types of GISTs, including:

1. Gastrointestinal stromal tumor (GIST): This is the most common type of GIST, accounting for about 90% of all cases. It typically occurs in the stomach or small intestine and can range in size from a few millimeters to several centimeters.
2. Leiomyoma: This type of GIST is made up of smooth muscle cells and is more common in women than men.
3. Leioyobbroma: This type of GIST is a rare variant of leiomyoma that contains both smooth muscle cells and glands.
4. Mucormyxoid fibroma: This type of GIST is rare and typically occurs in the small intestine. It is made up of mucin-producing cells and has a better prognosis than other types of GISTs.
5. Secondary gastrointestinal stromal tumors (SGISTs): These are GISTs that occur in other parts of the body, such as the liver or peritoneum, as a result of the spread of cancer cells from the primary tumor in the digestive system.

The symptoms of GISTs can vary depending on the location and size of the tumor, but may include:

* Abdominal pain or discomfort
* Nausea and vomiting
* Diarrhea or constipation
* Fatigue
* Weight loss
* Feeling full after eating only a small amount of food (early satiety)

GISTs are usually diagnosed using a combination of imaging tests such as CT scans, MRI scans, and PET scans, and a biopsy to confirm the presence of cancer cells. Treatment for GISTs may include:

* Surgery to remove the tumor
* Chemotherapy to kill any remaining cancer cells
* Targeted therapy with drugs that specifically target the KIT or PDGFRA genes, which are mutated in many GISTs.

The prognosis for GISTs is generally good if the tumor is completely removed by surgery, but if the tumor cannot be removed or has spread to other parts of the body, the prognosis is poorer. The specific treatment and prognosis will depend on the type of GIST, its location, and the severity of the symptoms.

The common types of reoviridae infections include:

1. Rotavirus infection: This is the most common cause of diarrhea in children under five years old worldwide. It can lead to dehydration, hospitalization, and even death in severe cases.
2. Calicivirus infection: This virus is responsible for norovirus, which is the leading cause of gastroenteritis outbreaks in the United States and other countries. It can cause symptoms such as diarrhea, vomiting, and stomach cramps.
3. Aichivirus infection: This virus was first identified in 2013 and has been linked to outbreaks of gastroenteritis in the United States and Europe. The symptoms of this infection are similar to those caused by norovirus.
4. Cysticercosis: This is a parasitic infection that occurs when the larvae of the pork tapeworm (Taenia solium) infect the human brain, eyes, or muscles. It can cause symptoms such as seizures, headaches, and vision problems.
5. Orbivirus infection: This virus is responsible for diseases such as bluetongue and epizootic hemorrhagic fever, which affects animals such as sheep, goats, and cattle. It can also be transmitted to humans through the bite of an infected midge insect.

Reoviridae infections are usually diagnosed based on symptoms, medical history, and laboratory tests such as PCR (polymerase chain reaction) or ELISA (enzyme-linked immunosorbent assay). Treatment of these infections depends on the specific type of virus and the severity of the symptoms.

Prevention measures for Reoviridae infections include good hygiene practices such as washing hands regularly, cooking food thoroughly, and avoiding close contact with people who are sick. Vaccines are also available for some types of Reoviridae infections, such as the rotavirus vaccine that is given to infants to protect against gastroenteritis.

Peripheral Nervous System Diseases can result from a variety of causes, including:

1. Trauma or injury
2. Infections such as Lyme disease or HIV
3. Autoimmune disorders such as Guillain-Barré syndrome
4. Genetic mutations
5. Tumors or cysts
6. Toxins or poisoning
7. Vitamin deficiencies
8. Chronic diseases such as diabetes or alcoholism

Some common Peripheral Nervous System Diseases include:

1. Neuropathy - damage to the nerves that can cause pain, numbness, and weakness in the affected areas.
2. Multiple Sclerosis (MS) - an autoimmune disease that affects the CNS and PNS, causing a range of symptoms including numbness, weakness, and vision problems.
3. Peripheral Neuropathy - damage to the nerves that can cause pain, numbness, and weakness in the affected areas.
4. Guillain-Barré syndrome - an autoimmune disorder that causes muscle weakness and paralysis.
5. Charcot-Marie-Tooth disease - a group of inherited disorders that affect the nerves in the feet and legs, leading to muscle weakness and wasting.
6. Friedreich's ataxia - an inherited disorder that affects the nerves in the spine and limbs, leading to coordination problems and muscle weakness.
7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - an autoimmune disorder that causes inflammation of the nerves, leading to pain, numbness, and weakness in the affected areas.
8. Amyotrophic Lateral Sclerosis (ALS) - a progressive neurological disease that affects the nerve cells responsible for controlling voluntary muscle movement, leading to muscle weakness, atrophy, and paralysis.
9. Spinal Muscular Atrophy - an inherited disorder that affects the nerve cells responsible for controlling voluntary muscle movement, leading to muscle weakness and wasting.
10. Muscular Dystrophy - a group of inherited disorders that affect the nerve cells responsible for controlling voluntary muscle movement, leading to muscle weakness and wasting.

It's important to note that this is not an exhaustive list and there may be other causes of muscle weakness. If you are experiencing persistent or severe muscle weakness, it is important to see a healthcare professional for proper evaluation and diagnosis.

The symptoms of lymphoma, T-cell, cutaneous can vary depending on the location and severity of the cancer, but may include:

* Red, scaly patches or lesions on the skin
* Itching, burning, or pain on the skin
* Swollen lymph nodes
* Fever
* Fatigue

Lymphoma, T-cell, cutaneous is a relatively rare type of cancer, and it can be difficult to diagnose. A doctor will typically perform a biopsy (removing a small sample of tissue from the affected area) to confirm the diagnosis. Treatment options may include:

* Topical medications (applied directly to the skin)
* Phototherapy (exposure to specific wavelengths of light)
* Chemotherapy (using drugs to kill cancer cells)
* Radiation therapy (using high-energy radiation to kill cancer cells)
* Targeted therapy (using drugs or other substances to target specific molecules on cancer cells)

Overall, the prognosis for lymphoma, T-cell, cutaneous is generally good, especially if the cancer is caught early and treated effectively. However, it can be a challenging condition to treat, and patients may experience significant discomfort and disfigurement.

1. Parvovirus (Parvo): A highly contagious viral disease that affects dogs of all ages and breeds, causing symptoms such as vomiting, diarrhea, and severe dehydration.
2. Distemper: A serious viral disease that can affect dogs of all ages and breeds, causing symptoms such as fever, coughing, and seizures.
3. Rabies: A deadly viral disease that affects dogs and other animals, transmitted through the saliva of infected animals, and causing symptoms such as aggression, confusion, and paralysis.
4. Heartworms: A common condition caused by a parasitic worm that infects the heart and lungs of dogs, leading to symptoms such as coughing, fatigue, and difficulty breathing.
5. Ticks and fleas: These external parasites can cause skin irritation, infection, and disease in dogs, including Lyme disease and tick-borne encephalitis.
6. Canine hip dysplasia (CHD): A genetic condition that affects the hip joint of dogs, causing symptoms such as arthritis, pain, and mobility issues.
7. Osteosarcoma: A type of bone cancer that affects dogs, often diagnosed in older dogs and causing symptoms such as lameness, swelling, and pain.
8. Allergies: Dog allergies can cause skin irritation, ear infections, and other health issues, and may be triggered by environmental factors or specific ingredients in their diet.
9. Gastric dilatation-volvulus (GDV): A life-threatening condition that occurs when a dog's stomach twists and fills with gas, causing symptoms such as vomiting, pain, and difficulty breathing.
10. Cruciate ligament injuries: Common in active dogs, these injuries can cause joint instability, pain, and mobility issues.

It is important to monitor your dog's health regularly and seek veterinary care if you notice any changes or abnormalities in their behavior, appetite, or physical condition.

Source: National Cancer Institute (www.cancer.gov)

The above definition is given by the National Cancer Institute, which is an authoritative source of information on cancer and lymphoma. It provides a concise overview of follicular lymphoma, including its characteristics, diagnosis, treatment options, and prognosis. The definition includes key terms such as "slow-growing," "B cells," "lymph nodes," and "five-year survival rate," which are important to understand when discussing this type of cancer.

There are different types of fever, including:

1. Pyrexia: This is the medical term for fever. It is used to describe a body temperature that is above normal, usually above 38°C (100.4°F).
2. Hyperthermia: This is a more severe form of fever, where the body temperature rises significantly above normal levels.
3. Febrile seizure: This is a seizure that occurs in children who have a high fever.
4. Remittent fever: This is a type of fever that comes and goes over a period of time.
5. Intermittent fever: This is a type of fever that recurs at regular intervals.
6. Chronic fever: This is a type of fever that persists for an extended period of time, often more than 3 weeks.

The symptoms of fever can vary depending on the underlying cause, but common symptoms include:

* Elevated body temperature
* Chills
* Sweating
* Headache
* Muscle aches
* Fatigue
* Loss of appetite

In some cases, fever can be a sign of a serious underlying condition, such as pneumonia, meningitis, or sepsis. It is important to seek medical attention if you or someone in your care has a fever, especially if it is accompanied by other symptoms such as difficulty breathing, confusion, or chest pain.

Treatment for fever depends on the underlying cause and the severity of the symptoms. In some cases, medication such as acetaminophen (paracetamol) or ibuprofen may be prescribed to help reduce the fever. It is important to follow the recommended dosage instructions carefully and to consult with a healthcare professional before giving medication to children.

In addition to medication, there are other ways to help manage fever symptoms at home. These include:

* Drinking plenty of fluids to stay hydrated
* Taking cool baths or using a cool compress to reduce body temperature
* Resting and avoiding strenuous activities
* Using over-the-counter pain relievers, such as acetaminophen (paracetamol) or ibuprofen, to help manage headache and muscle aches.

Preventive measures for fever include:

* Practicing good hygiene, such as washing your hands frequently and avoiding close contact with people who are sick
* Staying up to date on vaccinations, which can help prevent certain infections that can cause fever.

The definition of DILI has been revised several times over the years, but the most recent definition was published in 2013 by the International Consortium for DILI Research (ICDCR). According to this definition, DILI is defined as:

"A clinically significant alteration in liver function that is caused by a medication or other exogenous substance, and is not related to underlying liver disease. The alteration may be biochemical, morphological, or both, and may be acute or chronic."

The ICDCR definition includes several key features of DILI, including:

1. Clinically significant alteration in liver function: This means that the liver damage must be severe enough to cause symptoms or signs of liver dysfunction, such as jaundice, nausea, vomiting, or abdominal pain.
2. Caused by a medication or other exogenous substance: DILI is triggered by exposure to certain drugs or substances that are not related to underlying liver disease.
3. Not related to underlying liver disease: This means that the liver damage must not be caused by an underlying condition such as hepatitis B or C, alcoholic liver disease, or other genetic or metabolic disorders.
4. May be acute or chronic: DILI can occur as a sudden and severe injury (acute DILI) or as a slower and more insidious process (chronic DILI).

The ICDCR definition provides a standardized way of defining and diagnosing DILI, which is important for clinicians and researchers to better understand the cause of liver damage in patients who are taking medications. It also helps to identify the drugs or substances that are most likely to cause liver injury and to develop strategies for preventing or treating DILI.

There are two main types of hemolysis:

1. Intravascular hemolysis: This type occurs within the blood vessels and is caused by factors such as mechanical injury, oxidative stress, and certain infections.
2. Extravascular hemolysis: This type occurs outside the blood vessels and is caused by factors such as bone marrow disorders, splenic rupture, and certain medications.

Hemolytic anemia is a condition that occurs when there is excessive hemolysis of RBCs, leading to a decrease in the number of healthy red blood cells in the body. This can cause symptoms such as fatigue, weakness, pale skin, and shortness of breath.

Some common causes of hemolysis include:

1. Genetic disorders such as sickle cell anemia and thalassemia.
2. Autoimmune disorders such as autoimmune hemolytic anemia (AIHA).
3. Infections such as malaria, babesiosis, and toxoplasmosis.
4. Medications such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood thinners.
5. Bone marrow disorders such as aplastic anemia and myelofibrosis.
6. Splenic rupture or surgical removal of the spleen.
7. Mechanical injury to the blood vessels.

Diagnosis of hemolysis is based on a combination of physical examination, medical history, and laboratory tests such as complete blood count (CBC), blood smear examination, and direct Coombs test. Treatment depends on the underlying cause and may include supportive care, blood transfusions, and medications to suppress the immune system or prevent infection.

There are many different approaches to weight loss, and what works best for one person may not work for another. Some common strategies for weight loss include:

* Caloric restriction: Reducing daily caloric intake to create a calorie deficit that promotes weight loss.
* Portion control: Eating smaller amounts of food and avoiding overeating.
* Increased physical activity: Engaging in regular exercise, such as walking, running, swimming, or weightlifting, to burn more calories and build muscle mass.
* Behavioral modifications: Changing habits and behaviors related to eating and exercise, such as keeping a food diary or enlisting the support of a weight loss buddy.

Weight loss can have numerous health benefits, including:

* Improved blood sugar control
* Reduced risk of heart disease and stroke
* Lowered blood pressure
* Improved joint health and reduced risk of osteoarthritis
* Improved sleep quality
* Boosted mood and reduced stress levels
* Increased energy levels

However, weight loss can also be challenging, and it is important to approach it in a healthy and sustainable way. Crash diets and other extreme weight loss methods are not effective in the long term and can lead to nutrient deficiencies and other negative health consequences. Instead, it is important to focus on making sustainable lifestyle changes that can be maintained over time.

Some common misconceptions about weight loss include:

* All weight loss methods are effective for everyone.
* Weight loss should always be the primary goal of a fitness or health program.
* Crash diets and other extreme weight loss methods are a good way to lose weight quickly.
* Weight loss supplements and fad diets are a reliable way to achieve significant weight loss.

The most effective ways to lose weight and maintain weight loss include:

* Eating a healthy, balanced diet that is high in nutrient-dense foods such as fruits, vegetables, whole grains, lean proteins, and healthy fats.
* Engaging in regular physical activity, such as walking, running, swimming, or weight training.
* Getting enough sleep and managing stress levels.
* Aiming for a gradual weight loss of 1-2 pounds per week.
* Focusing on overall health and wellness rather than just the number on the scale.

It is important to remember that weight loss is not always linear and can vary from week to week. It is also important to be patient and consistent with your weight loss efforts, as it can take time to see significant results.

Overall, weight loss can be a challenging but rewarding process, and it is important to approach it in a healthy and sustainable way. By focusing on overall health and wellness rather than just the number on the scale, you can achieve a healthy weight and improve your overall quality of life.

The exact cause of hepatoblastoma is not known, but it is believed to be linked to genetic mutations that occur during fetal development. Children with certain congenital conditions, such as Beckwith-Wiedemann syndrome, are at higher risk of developing hepatoblastoma. The symptoms of hepatoblastoma can include abdominal pain, weight loss, and jaundice (yellowing of the skin and eyes), but in many cases, the cancer may not cause any noticeable symptoms until it has reached an advanced stage.

Hepatoblastoma is diagnosed through a combination of imaging tests, such as ultrasound, CT scans, and MRI, and a biopsy to confirm the presence of cancer cells. Treatment typically involves surgery to remove the affected lobe of the liver, followed by chemotherapy to kill any remaining cancer cells. In some cases, a liver transplant may be necessary if the cancer has spread too far or if the child's liver is not functioning properly. The prognosis for hepatoblastoma depends on several factors, including the stage of the cancer at diagnosis and the effectiveness of treatment. With current treatments, the 5-year survival rate for children with hepatoblastoma is around 70%.

Osteolysis can be caused by several factors, including:

1. Infection: Bacterial or fungal infections can cause osteolysis by secreting enzymes that break down bone tissue.
2. Inflammation: Chronic inflammation can lead to the destruction of bone tissue, causing osteolysis.
3. Tumors: Malignant tumors like multiple myeloma or osteosarcoma can cause osteolysis by producing enzymes that destroy bone tissue.
4. Degenerative conditions: Conditions like osteoporosis, rheumatoid arthritis, and Paget's disease can lead to osteolysis due to the gradual breakdown of bone tissue.

Symptoms of osteolysis may include:

1. Bone pain or tenderness
2. Fractures or fracture risk
3. Limited mobility or stiffness in affected joints
4. Swelling or redness in the affected area
5. Difficulty healing from injuries or infections

Treatment for osteolysis depends on the underlying cause and may include:

1. Antibiotics to treat infections
2. Pain management with medication or physical therapy
3. Surgery to repair or replace damaged bone tissue
4. Orthotics or assistive devices to support affected joints
5. Medications to slow down or stop bone loss, such as bisphosphonates or denosumab

In conclusion, osteolysis is a condition where there is a gradual loss or destruction of bone tissue, leading to a decrease in bone density and structural integrity. It can be caused by various factors, including infection, inflammation, tumors, and degenerative conditions. Treatment depends on the underlying cause and may include antibiotics, pain management, surgery, orthotics, and medications to slow down or stop bone loss.

Rectal neoplasms refer to abnormal growths or tumors that occur in the rectum, which is the lower part of the digestive system. These growths can be benign (non-cancerous) or malignant (cancerous).

Types of Rectal Neoplasms:

There are several types of rectal neoplasms, including:

1. Adenoma: A benign growth that is usually found in the colon and rectum. It is a common precursor to colorectal cancer.
2. Carcinoma: A malignant tumor that arises from the epithelial cells lining the rectum. It is the most common type of rectal cancer.
3. Rectal adenocarcinoma: A type of carcinoma that originates in the glandular cells lining the rectum.
4. Rectal squamous cell carcinoma: A type of carcinoma that originates in the squamous cells lining the rectum.
5. Rectal melanoma: A rare type of carcinoma that originates in the pigment-producing cells (melanocytes) of the rectum.

Causes and Risk Factors:

The exact causes of rectal neoplasms are not known, but several factors can increase the risk of developing these growths. These include:

1. Age: The risk of developing rectal neoplasms increases with age, with most cases occurring in people over the age of 50.
2. Family history: Having a family history of colorectal cancer or polyps can increase the risk of developing rectal neoplasms.
3. Inflammatory bowel disease: People with inflammatory bowel disease, such as ulcerative colitis and Crohn's disease, are at higher risk of developing rectal neoplasms.
4. Diet: A diet high in fat and low in fiber may increase the risk of developing rectal neoplasms.
5. Lifestyle factors: Factors such as smoking, obesity, and lack of physical activity may also increase the risk of developing rectal neoplasms.

Symptoms:

The symptoms of rectal neoplasms can vary depending on the type and location of the growth. Some common symptoms include:

1. Blood in the stool
2. Changes in bowel movements (such as diarrhea or constipation)
3. Abdominal pain or discomfort
4. Weakness and fatigue
5. Loss of appetite

Diagnosis:

To diagnose rectal neoplasms, a doctor may perform several tests, including:

1. Digital rectal exam (DRE): A doctor will insert a gloved finger into the rectum to feel for any abnormalities.
2. Colonoscopy: A flexible tube with a camera and light on the end is inserted through the anus and into the rectum to examine the inside of the rectum and colon for polyps or other abnormalities.
3. Imaging tests: Such as X-rays, CT scans, or MRI scans to visualize the growth and determine its location and size.
4. Biopsy: A sample of tissue is removed from the rectum and examined under a microscope for cancer cells.

Treatment:

The treatment of rectal neoplasms depends on the type, location, and stage of the growth. Some common treatments include:

1. Polypectomy: Removal of polyps through a colonoscopy or surgery.
2. Local excision: Surgical removal of the tumor and a small amount of surrounding tissue.
3. Radiation therapy: High-energy beams are used to kill cancer cells.
4. Chemotherapy: Drugs are used to kill cancer cells.
5. Immunotherapy: A treatment that uses the body's immune system to fight cancer.

Prognosis:

The prognosis for rectal neoplasms depends on the type, location, and stage of the growth. In general, the earlier the diagnosis and treatment, the better the prognosis. However, some types of rectal neoplasms can be more aggressive and difficult to treat, and may have a poorer prognosis.

Prevention:

There is no sure way to prevent rectal neoplasms, but there are several screening tests that can help detect them early, including:

1. Colonoscopy: A test in which a flexible tube with a camera and light on the end is inserted into the rectum and colon to examine for polyps or cancer.
2. Fecal occult blood test (FOBT): A test that checks for blood in the stool.
3. Flexible sigmoidoscopy: A test similar to a colonoscopy, but only examines the lower part of the colon and rectum.
4. Digital rectal exam (DRE): An examination of the rectum using a gloved finger to feel for any abnormalities.

It is important to talk to your doctor about your risk for rectal neoplasms and any screening tests that may be appropriate for you. Early detection and treatment can improve the prognosis for these types of growths.

These isolated molecules are screened via in-vitro assays to measure their effects in standardized paradigms designed to select ... Many efforts to discover cancer therapeutic drugs focus on the screening of novel biomolecules produced and isolated from ... Kalkitoxin was originally isolated from Lyngbya majuscula as an effort to collect new molecules for testing as antitumor or ... One of the first tests of kalkitoxin tumor-selective cytotoxicity used an in-vitro assay to test solid tumor selectivity of ...
... drug screening assays, antitumor MeSH E05.337.550.200.800 - tumor stem cell assay MeSH E05.337.550.200.900 - xenograft model ... drug screening assays, antitumor MeSH E05.200.500.388.930 - tumor stem cell assay MeSH E05.200.500.410 - electroporation MeSH ... multiphasic screening MeSH E05.318.308.250.580.580 - neonatal screening MeSH E05.318.308.250.580.925 - vision screening MeSH ... antitumor assays MeSH E05.337.550.200.900.830 - subrenal capsule assay MeSH E05.337.550.400 - microbial sensitivity tests MeSH ...
Using a line of CD4+ T cells that they had made, they developed an assay to screen drugs for their ability to protect CD4+ T ... leading to the development of the antitumor agent 6-mercaptopurine. Jerome Horwitz of the Barbara Ann Karmanos Cancer Institute ... another drug that had shown effective anti-HIV activity in the laboratory. This initial trial of AZT proved that the drug could ... Drugs with non-standard legal status, Articles with changed EBI identifier, ECHA InfoCard ID from Wikidata, Drug has EMA link, ...
Studies related to antitumor antibiotics. Part V. Reactions of mitomycin C with DNA examined by ethidium fluorescence assay. ... Microbial drug discovery: 80 years of progress. J Antibiot. 62:5-16. Lown JW, Begetter A, Johnson D, Morgan AR. 1976. ... Research on Antibiotic Screening in Japan over the Last Decade: A Producing Microorganisms Approach. Actinomycetologica. 9:100- ... Many natural compounds have led to the discovery of drugs used to treat human disease. Out of the 22,500 biologically active ...
It enhances antitumor activity of some other drugs such as vincristine. Dactolisib seems to inhibit effectively both wild-type ... New mTOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both mTOR ... Thus, this data is based on preclinical assays, based on in vitro cultured tumor cell lines, which suggest that the effects of ... Compared with drugs that inhibit either mTORC1 or PI3K, these drugs have the benefit of inhibiting mTORC1, mTORC2, and all the ...
"Performance of Interferon-Gamma Release Assays for Tuberculosis Screening in Pediatric Inflammatory Bowel Disease". Journal of ... Many 5-ASA drugs have been developed with the aim of delivering the active compound to the large intestine to maintain ... July 2018). "A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With ... A series of drugs in development looks to disrupt the inflammation process by selectively targeting an ion channel in the ...
Applying the revised screen led to the discovery of the potent biological activity of ciclosporin on 31 January 1972. This drug ... Guided by Stähelin's in-vitro and in-vivo assays, they found the active compound responsible for the good antitumor activity of ... Stähelin's invention of this procedure initiated an innovative screening system for discovering immunosuppressant drugs lacking ... This screening process was first used in the pharmacology department in January 1970, before Jean F. Borel joined Stähelin's ...
Also, amanitin-based antibody-drug conjugates using an anti-Her2 antibody such as trastuzumab showed high antitumor activity in ... Urine screening is generally most useful within 48 hours of ingestion. Treatment is mainly supportive (gastric lavage, ... As early as the 1980s, antibody-based assays (immunoassays) were developed for amanitin (but more often recognize amatoxins as ... "What are antibody-drug conjugates?". ADC Review / Journal of Antibody-drug Conjugates. ISSN 2327-0152. Retrieved 26 May 2017. ...
It was discovered in 1966 by M. E. Wall and M. C. Wani in systematic screening of natural products for anticancer drugs. It was ... M.E. Wall; M.C.Wani; C.E. Cook; K.H.Palmer; A.I.McPhail; G.A.Sim (1966). "Plant antitumor agents. I. The isolation and ... Replacement in any position results in much less potent compound than parent compound in other cytotoxicity assay. The E-ring ... Drugs not assigned an ATC code, ECHA InfoCard ID from Wikidata, Drugs with no legal status, Drugboxes which contain changes to ...
These reagents are therefore important for future drug and vaccine development. Immudex developed a CMV Dextramer® assay for ... MHC tetramers are used in studies of pathogen immunity and vaccine development, in evaluation of antitumor responses, in ... covering a broad range of epitopes to assist with screening and monitoring CMV progression in future clinical settings. MHC ... Tetramer assays are used for single-cell phenotyping and cell counting, and offer an important advantage over other methods, ...
2007). "Preclinical antitumor activity of a novel folate-targeted dual drug conjugate". Mol. Pharm. 4 (5): 659-67. doi:10.1021/ ... Because novel FR-targeted therapies are now being tested clinically, having the ability to screen patients for FR-positive ... These include an invasive tissue-based immunohistochemical assay, and a non-invasive radiodiagnostic approach. The latter ... Targeted drug therapy is advantageous because it deposits the drug at the specific location where it can be most useful in ...
October 2014). "In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug ... Many ligand binding assays require a filtration step to separate bound and unbound ligands before screening. A method called ... Ligand binding assays are used primarily in pharmacology to provide an indication of drug affinity across a wide range of GPCRs ... 2009). Ligand-binding assays development, validation, and implementation in the drug development arena. Hoboken, N.J.: John ...
"Such cell cultures can lead to new insights into cell and organ function and be used for drug screening". A kidney-on-a-chip ... October 2018). "Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine ... based biomimetic liver tumor-on-a-chip proved to be a suitable design for further anti-tumor studies. Zhou et al. analyzed ... Fan Y, Nguyen DT, Akay Y, Xu F, Akay M (May 2016). "Engineering a Brain Cancer Chip for High-throughput Drug Screening". ...
In vitro assays have shown them both to be selective AR agonists and that they inhibit proliferation of several prostate cancer ... Screening of chemical libraries for AR blockers led to the discovery of the first antiandrogen, cyproterone. An acetate group ... These drugs may therefore be effective as a second-line therapy for refractory prostate cancer previously treated with ... "Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study". Lancet. 375 (9724): 1437-46. doi: ...
... technical barriers to screening natural products in high-throughput assays]. The growing appreciation of functional assays and ... One example of successful use of this strategy is the screening for antitumor agents by the National Cancer Institute, which ... It is unlikely that a perfect drug candidate will emerge from these early screening runs. One of the first steps is to screen ... Zheng W, Thorne N, McKew JC (November 2013). "Phenotypic screens as a renewed approach for drug discovery". Drug Discovery ...
"In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities". Mol Cancer Ther ... microtubule gliding assays, single molecule motility assays, and optical trap assays. In microtubule gliding assays, kinesins ... Drugs that specifically inhibit only human Kinesin-5 are alternatives to the taxanes and vinc alkaloids that target ... In single molecule motility assays, velocities for Kinesin-5 were similar to those seen in microtubule gliding assays, and the ...
... rationale and design of screening assays, and the application of such assays for screening of natural product extracts and the ... Antisense drugs are based on the fact that antisense RNA hybridizes with and inactivates mRNA. These drugs are short sequences ... SLR14 improved antitumor efficacy of anti-PD1 antibody over single-agent treatment. SLR14 was absorbed by CD11b+ myeloid cells ... Sahin U, Karikó K, Türeci Ö (October 2014). "mRNA-based therapeutics--developing a new class of drugs". Nature Reviews. Drug ...
Male and female animals underwent a standardized phenotypic screen to determine the effects of deletion. Additional screens ... Yeast three-hybrid assays have shown that this protein binds to the stem loops within the 3'UTR of the POLB mRNA, however the ... and drug resistance. The mitochondrial DNA of mammalian cells is constantly under attack from oxygen radicals released during ... impact on sensitivity towards antitumor agents". Oncogene. 20 (43): 6181-7. doi:10.1038/sj.onc.1204743. PMID 11593426. ...
When anticancer drugs such as doxorubicin accumulate in microvesicles, the drug's cellular levels decrease. This can ultimately ... Several tumor markers accessible as proteins in blood or urine have been used to screen and diagnose various types of cancer. ... Circulating microvesicles isolated from cardiac surgery patients were found to be thrombogenic in both in vitro assays and in ... Like other EVs, they have been implicated in numerous physiologic processes, including anti-tumor effects, tumor immune ...
... so researchers collect samples from around the world to analyze and evaluate in drug discovery screens or bioassays. This ... June 2020). Assay Guidance Manual. Bethesda: Eli Lilly & Company and the National Center for Advancing Translational Sciences. ... Other natural products derived from marine animals and under investigation as possible therapies include the antitumour agents ... Drug Discovery - Is Mother Nature still the number one source for promising new drugs? Patrick GL (2013). "12.4.2: Medical ...
2008). Analogous successful use of IMC to determine the effects of antitumor drugs on tumor cells in culture within a few hours ... If absolute data are required (e.g. quantity of product produced by a process), then assays can be conducted in parallel on ... This is especially useful for comparative screening-e.g. the effects of different combinations of material composition and/or ... Also, IMC not only documents the general metabolic decline over time due to the drugs, but also the overall frequency of worm ...
Drug-Drug Interaction with Acetaminophen Involving Phase I and Phase II Metabolites". Chemical Research in Toxicology. 20 (10 ... "Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals". Toxicology. 195 (2-3): 177-86. ... "Effects of combined treatment with niftolide and low doses of antitumor estrogen preparation, chlorotrianizene, on rat prostate ... Evidence for Complex I Inhibition and Mitochondrial Dysfunction Using Toxicogenomic Screening". Chemical Research in Toxicology ...
Ther Drug Monit. 36 (1): 93-99. doi:10.1097/FTD.0b013e3182a04fc7. PMID 24061446. S2CID 21072472. "ARK Methotrexate Assay". Ark ... DNA-Interactive Alkylating Agents and Antitumour Platinum-Based Drugs". The Cancer Handbook. John Wiley & Sons, Ltd. doi: ... and hence it has been recommended that the babies be screened. Between 30 and 40 percent of people undergoing chemotherapy ... drug-to-drug interactions, genetics, and obesity, which have major impacts on the actual concentration of the drug in the ...
... and drug screening applications. Using MitoBloCK-6 and/or PluriSIn # 1 the differentiated progenitor cells can be further ... iPSCs have been shown to support the development of all-iPSC mice using a tetraploid (4n) embryo, the most stringent assay for ... They augment anti-tumor responses by producing interferon-gamma (IFN-γ). The approach of collection, reprogramming/ ... of drugs, and toxicity testing of various drugs. The tissue grown from iPSCs, placed in the "chimeric" embryos in the early ...
"Abraxane Drug Information Archived 2005-05-26 at the Wayback Machine." Food and Drug Administration. January 7, 2005. Retrieved ... In general, in vitro assays involving microtubules, such as motility assays, rely on paclitaxel to maintain microtubule ... The discovery of paclitaxel began in 1962 as a result of a NCI-funded screening program. A number of years later it was ... Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (May 1971). "Plant antitumor agents. VI. The isolation and structure of taxol ...
... survivin was expressed in all 60 different human tumour lines used in the National Cancer Institute's cancer drug-screening ... In vitro assays and other tests were also performed to validate the idea of the occurrence of an actual immune response to ... "Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies". Leuk. ... A. Cellular T Cell Response The first evidence of survivin-specific CTL recognition and killing was shown in an assay wherein ...
Quintavalle M, Elia L, Price JH, Heynen-Genel S, Courtneidge SA (July 2011). "A cell-based high-content screening assay reveals ... Cdk5 has been proved to be directly linked with drug abuse. We know that drugs act in the reward system, reaching their action ... Cdk5 is involved in tumor proliferation, migration, angiogenesis and also chemotherapy resistance and anti-tumor immunity. It ... Hence, its relation to drug abuse and more specifically to the reward system, which is triggered by the consumption of drugs. ...
Micronuclei assays can help in early detection of pre-malignant and malignant lesions, thereby improving survival and reducing ... A high concentration of cytotoxic drugs in the tumor and regional lymph nodes is also retained by PRV111 shown in human studies ... There are a variety of screening devices such as toluidine blue, brush biopsy, or fluorescence imaging, however, there is no ... PRV111, a nanotechnology-based system for local delivery of cisplatin loaded chitosan particles induces anti-tumor responses in ...
Drugs Controller General of India is the head of department of the Central Drugs Standard Control Organization of the ... Pregnant women are often screened for continued resistance to rubella. The human papillomavirus vaccine is recommended in the U ... van Oirschot JT, Gielkens AL, Moormann RJ, Berns AJ (June 1990). "Marker vaccines, virus protein-specific antibody assays and ... "Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in ...
Some cationic drugs, such as chloroquine and sertraline, are known as lysosomotropic drugs. These drugs are weak bases that ... During a screen seeking to identify microbial secondary metabolites whose activity mimicked that of two cardiac glycosides, ... In a rabbit contractility assay, bafilomycin was used to pre-treat isolated rabbit aorta. The lipophilic agent xylometazoline, ... Bafilomycins exhibit a wide range of biological activity, including anti-tumor, anti-parasitic, immunosuppressant and anti- ...
One screen of single-gene knockouts identified 48 transcription factors (about 20% of all non-essential transcription factors) ... However, 833 of the genes assayed changed behavior between the wild type and mutant cells, indicating that these genes are ... have tried to invent the synthetic Cdk4/6 inhibitor as Cdk4/6 has been characterized to be a therapeutic target for anti-tumor ... are targeted in cancer therapy as the DNA is relatively exposed during cell division and hence susceptible to damage by drugs ...
This assay evaluates the final dilution that may cause a viral infection in 50% of inoculated eggs. This EID50 assay is used to ... This was shown in a mouse model of renal cancer, in which the anti-tumor effect of SeV was suppressed by reducing the number of ... Drug Discovery. 6 (12): 975-90. doi:10.1038/nrd2422. PMC 7097588. PMID 18049472. S2CID 583709. Albini A, Marchisone C, Del ... Sendai Fluorescence Reporter system that allows to screen cells for finding those that are permissive for Sendai virus ...
A number of similar analogues were found and assayed. Structurally similar series of c-Met inhibitors in which a phenolic hinge ... "Orphan Drug Designation". Merck KGaA, Darmstadt, Germany (Press release). 20 November 2019. Retrieved 8 November 2020. (CS1 ... "The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach", Bioorganic & ... offered the first proof that relatively selective c-Met inhibitors could be identified and that the inhibition leads to an anti ...
"Daffodil drug's major investment". BBC News. 29 October 2008. Archived from the original on 2008-11-02. Retrieved 2014-10-08. ... These bulbs contain pretazettine, an active antitumor compound. Narcissus products have received a variety of other uses. The ... In Singer (1846) "Wordsworth's Daffodils" (Skip any introductory screen). Wordsworth Trust. Archived from the original on 2014- ... "Detection of Narcissus Latent Virus Isolates Using One-Step Rt-Pcr Assay" (PDF). Journal of Horticultural Research. 21 (1): 11- ...
... antitumor antibiotic - Antiviral drug - anxiolytic - APC - APC vaccine - APC8015 - apheresis - aplastic anemia - aplidine - ... CA 19-9 assay - CA-125 - CA-125 test - cachexia - calcitonin - calcitriol - CAM - Campath-1H - camptothecin - camptothecin ... screening mammogram - Scutellaria barbata - SDX-102 - SDX-105 - second primary cancer - second-line therapy - second-look ... drug tolerance - dry orgasm - DTGM fusion protein - ductal carcinoma - ductal carcinoma in situ - ductal lavage - Dukes' ...
Robertson H, Langdon WY, Thien CB, Bowtell DD (November 1997). "A c-Cbl yeast two hybrid screen reveals interactions with 14-3- ... Vidal M, Liu WQ, Gril B, Assayag F, Poupon MF, Garbay C (2004). "[Design of new anti-tumor agents interrupting deregulated ... VanderNoot VA, Fitzpatrick FA (September 1995). "Competitive binding assay of src homology domain 3 interactions between 5- ... SH3 domain-mediated protein-protein interaction blocking drug". Oncogene. 21 (13): 2037-50. doi:10.1038/sj.onc.1205271. PMID ...
OR drug resistance, neoplasm. OR drug screening assays, antitumor. OR early detection of cancer. OR gene expression regulation ... OR antitumor [tw]. OR antitumors [tw]. OR antitumour [tw]. OR antitumours [tw]. OR apudoma [tw]. OR apudomas [tw]. OR ... OR Anti cancer Drugs [ta]. OR Anticancer Agents Med Chem [ta]. OR Anticancer Drug Des [ta]. OR Anticancer Res [ta]. OR Asia Pac ... OR Drug Resist Updat [ta]. OR Eksp Onkol [ta]. OR Endocr Relat Cancer [ta]. OR Eur J Cancer B Oral Oncol [ta]. OR Eur J Cancer ...
Drug Screening Assays, Antitumor / methods * Gemcitabine * Humans * Mice * Models, Biological * Mutation * Organoids / drug ... Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids Nat ... Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify ...
Drug Screening Assays, Antitumor. Myzak MC, W Dashwood M, Orner GA, Ho E, Dashwood RH. 2006. Sulforaphane inhibits histone ... Curr Drug Targets. 7(4):443-52.. Myzak MC, Ho E, Dashwood RH. 2006. Dietary agents as histone deacetylase inhibitors.. Mol ... Dose-Response Relationship, Drug. Myzak MC, Carr AC. 2002. Myeloperoxidase-dependent caspase-3 activation and apoptosis in HL- ...
Drug Screening Assays, Antitumor Actions. * Search in PubMed * Search in MeSH * Add to Search ... In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and ... The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry. Wang J, Tao J, Jia S, Wang M ... Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Holloway ...
Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Salicylanilides/chemical synthesis; Salicylanilides/ ... Using a series of well-established HSP60/10 biochemical screens and cell-viability assays, we identified 24 inhibitors (14%) ... Cell Proliferation/drug effects; Cell Survival/drug effects; Chaperonin 10/antagonists & inhibitors*; Chaperonin 10/metabolism ... Apoptosis/drug effects; Benzoxazoles/chemical synthesis; Benzoxazoles/chemistry; Benzoxazoles/pharmacology*; ...
Anti-Cancer Drug Screens Anticancer Drug Sensitivity Tests Antitumor Drug Screening Assays Antitumor Drug Screens Cancer Drug ... Drug Evaluation, Preclinical [E05.337.550] * Drug Screening Assays, Antitumor [E05.337.550.200] * Tumor Stem Cell Assay [ ... Drug Screening Tests, Tumor-Specific Dye Exclusion Assays, Antitumor Tumor-Specific Drug Screening Tests Previous Indexing. ... Drug Screening Assays, Antitumor [E01.370.225.500.388] * Tumor Stem Cell Assay [E01.370.225.500.388.930] ...
... molecular target-based screening assays. Biosynthetic approaches are considered within the scope of the RFA. The development or ... Strategies also encompass creative methods to maximize antitumor selectivity. GROUP. See NCDDG below. LABORATORY PROGRAM. A ... Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, edited by: B. Teicher, Humana Press ... an Investigational New Drug Application [INDA] to the United States Food and Drug Administration) of any invention resulting ...
D12.776.92.500.462 Drug Screening Assays, Antitumor E1.370.225.500.388 E5.242.388 Dysuria C23.888.942.325 C23.888.942.343.274 ... E5.240.550 Plaque Assay E1.370.225.875.970.790 (Replaced for 2012 by Viral Plaque Assay) Plastic Embedding E1.370.225.500. ... Drug E2.319.267.641 Insulin D6.472.699.587.740.625 D6.472.699.587.200.500.625 D12.644.548.586.740.625 D12.644.548.586.200.500. ... E5.478.594.700 Radioimmunoprecipitation Assay E1.450.495.410.380.825 E1.370.225.812.735.840 E1.450.495.410.700.825 E5.200. ...
Drug Screening Assays, Antitumor, Fluorescence Polarization, HSP90 Heat-Shock Proteins, Humans, Isoxazoles, Mice, Mice, Nude, ... Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of ... Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of ... Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of ...
Figure 1: Suggested screening flowchart in the discovery of anti-CSC agents with tumorsphere assay. The source of primary ... The results from in vivo anti-tumor efficacy of the selected anti-CSC agents or the identified CSC-specific antigens could be ... Keywords: cancer stem cells, tumorsphere, targeting therapy, drug screening. Received: June 11, 2015 Accepted: October 14, 2015 ... We believe that tumorsphere assay based-drug discovery of anti-cancer agents will provide more translatable results compared ...
Anti-Cancer Drug Screens Anticancer Drug Sensitivity Tests Antitumor Drug Screening Assays Antitumor Drug Screens Cancer Drug ... Drug Evaluation, Preclinical [E05.337.550] * Drug Screening Assays, Antitumor [E05.337.550.200] * Tumor Stem Cell Assay [ ... Drug Screening Tests, Tumor-Specific Dye Exclusion Assays, Antitumor Tumor-Specific Drug Screening Tests Previous Indexing. ... Drug Screening Assays, Antitumor [E01.370.225.500.388] * Tumor Stem Cell Assay [E01.370.225.500.388.930] ...
Drug Screening Assays, Antitumor MeSH DeCS ID:. 23045 Unique ID:. D014407 Documents indexed in the Virtual Health Library (VHL ... DE drug effects. EN enzymology. IM immunology. ME metabolism. MI microbiology. PA pathology. PH physiology. PS parasitology. RE ...
synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. Structural-based ... Dose-Response Relationship, Drug * Drug Design * Drug Screening Assays, Antitumor * Flavins * Humans ... Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase ... The results of the Annexin-V/PI apoptotic assay demonstrated that many compounds induced significantly early (89-146%) and a ...
Tumor-Specific Drug Screening Tests See Drug Screening Assays, Antitumor Tumoricidal Activities, Immunologic See Cytotoxicity, ...
We performed in silico drug screening for candidate drugs that could reprogram the gene expression signature of PC3CR cells. ... The WST assay revealed that VP16 had a significant antitumor effect on PC3CR cells. PC3CR cells exhibited significantly higher ... The in vivo effect of the drug combination was tested in xenograft mice models. We identified etoposide (VP16) as a promising ... The results of this study will contribute to the development of novel diagnostic markers and drug targets for PCa under hypoxia ...
These cells are used for VIRUS CULTIVATION and antitumor drug screening assays.. ... Dose-Response Relationship, Drug. The relationship between the dose of an administered drug and the response of the organism to ... Chemicals and Drugs78. RNA, MessengerInterleukin-8KeratinsMembrane ProteinsCadherinsNF-kappa BMucinsZonula Occludens-1 Protein ... Development of a lung model utilizing human alveolar epithelial cells for evaluating aerosol drug delivery. In Respiratory Drug ...
Drug Screening Assays, Antitumor. *Erythrocytes. *Ethanol. *Exons. *Female. *Fermentation. *Formaldehyde. *Formates. * ...
In January 2007, after the new assay was licensed by the Food and Drug Administration (FDA), other centers began screening ... Saulnier Sholler GL, Kalkunte S, Greenlaw C, McCarten K, Forman E. Antitumor activity of nifurtimox observed in a patient with ... and with other assays used to screen for T. cruzi antibodies (10). In addition, when a screening assay is used in a population ... Donors with reactive screening assay results require further clinical diagnostic testing to verify T. cruzi infection and to ...
Assay to Screen Anti-metastatic Drugs *Read more about Assay to Screen Anti-metastatic Drugs ... Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells. ... The assay is useful for screening compounds that specifically inhibit pathways involved in mammary carcinoma and can improve ... A drug delivery platform that could deliver therapeutic agents directly to the brain is needed, and could have wide ranging ...
Drug Screening Assays, Antitumor. *Electroporation. *Enzyme-Linked Immunospot Assay. *Histocytochemistry. *Histocytological ... and increased uptake by cells of drugs, molecular probes, and DNA. ...
Xenograft Model Antitumor Assays UI - D023041 MN - E5.337.550.200.900 MN - E5.624.850 MS - In vivo methods of screening ... They can be used for vaccines (VACCINES, VIROSOME), drug delivery, or gene transfer. AN - when used as a vehicle in drug ther, ... for TUMOR XENOGRAFT ASSAY use SUBRENAL CAPSULE ASSAY (1988-2000) BX - Tumor Xenograft Assay BX - Xenograft Antitumor Assays MH ... Local Lymph Node Assay UI - D023441 MN - E1.370.750.450 MN - E1.450.495.750.450 MS - The local lymph node assay (LLNA) is an ...
... which can profoundly alter anti-tumor drug activity. To address this major limitation, we have developed assays (e.g. the tumor ... Conventional anti-cancer drug screening is typically performed in the absence of accessory cells (e.g. stromal cells) of the ... absence of non-malignant stromal cells or drug treatment. These assays have allowed us to identify that neoplastic cells from ... Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. ...
D12.776.92.500.462 Drug Screening Assays, Antitumor E1.370.225.500.388 E5.242.388 Dysuria C23.888.942.325 C23.888.942.343.274 ... E5.240.550 Plaque Assay E1.370.225.875.970.790 (Replaced for 2012 by Viral Plaque Assay) Plastic Embedding E1.370.225.500. ... Drug E2.319.267.641 Insulin D6.472.699.587.740.625 D6.472.699.587.200.500.625 D12.644.548.586.740.625 D12.644.548.586.200.500. ... E5.478.594.700 Radioimmunoprecipitation Assay E1.450.495.410.380.825 E1.370.225.812.735.840 E1.450.495.410.700.825 E5.200. ...
D12.776.92.500.462 Drug Screening Assays, Antitumor E1.370.225.500.388 E5.242.388 Dysuria C23.888.942.325 C23.888.942.343.274 ... E5.240.550 Plaque Assay E1.370.225.875.970.790 (Replaced for 2012 by Viral Plaque Assay) Plastic Embedding E1.370.225.500. ... Drug E2.319.267.641 Insulin D6.472.699.587.740.625 D6.472.699.587.200.500.625 D12.644.548.586.740.625 D12.644.548.586.200.500. ... E5.478.594.700 Radioimmunoprecipitation Assay E1.450.495.410.380.825 E1.370.225.812.735.840 E1.450.495.410.700.825 E5.200. ...
Identification of novel P2X7R antagonists by using structure-based virtual screening and cell-based assays.. Zhao Y; Chen X; ... Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity.. Zhao Y; Chen X; He C; Gao G; Chen Z; Du J. Bioorg ... Recent Pat Anticancer Drug Discov; 2019; 14(1):32-38. PubMed ID: 30652649. [TBL] ... 4. P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells.. Han Y; Bai C; He XM; Ren ...
Drug/Laboratory Interactions Cross-reactivity and false-positive urine screening tests for opiates have been reported in ... Therapeutic levels of rifampin have been shown to inhibit standard microbiological assays for serum folate and vitamin B . Thus ... Antitumor activity has also been shown with rifampin. in vitroin vitro ... To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, ...
  • Thus, pancreatic progenitor organoids and tumor organoids can be used to model PDAC and for drug screening to identify precision therapy strategies. (nih.gov)
  • The Hamburger-Salmon human tumor colony-forming assay (HTCA) was used to measure the chemosensitivity of 36 fresh tumor samples obtained during initial exploratory laparotomy from patients with newly diagnosed stage III-IV epithelial ovarian cancer who had received no prior chemotherapy or radiation therapy. (nih.gov)
  • The resulting survival data were used to estimate the IC50 (drug concentration associated with 50% inhibition of tumor colony forming units, TCFUs) of each of the platinum analogs for each of the tumor samples, as well as the estimated survival following exposure to clinically achievable drug levels (i.e. the ultrafiltrable platinum area under the plasma disappearance curve, AUC, achieved in cancer patients following administration of standard or phase II doses). (nih.gov)
  • Cancer stem cells (CSCs) are a sub-population of cells within cancer tissues with tumor initiation, drug resistance and metastasis properties. (oncotarget.com)
  • The synergy of drugs can be assayed by testing the inhibition of tumor cell growth by individual drugs and their combinations in vitro, followed by a mathematical formulation by Loewe additivity or Bliss independence [ 1 , 2 ]. (biomedcentral.com)
  • To this end, the group recently transferred its long-term experience and know-how in molecular biology of cancer in the emerging field of stem-cell biology, in order (a) to design stem cell-based vehicles for effective and specific tumor targeting and (b) to develop improved in vitro preclinical assays for quick and reliable assessing of toxicology and safety profiles of drugs. (eie.gr)
  • An archival tumor sample obtained within 1 year of screening is allowed if pre-treatment biopsy is deemed unsafe or technically not feasible. (nih.gov)
  • The major challenges of eliminating pancreatic cancer are treatment resistance and stromal barriers to optimal drug access within the tumor. (biomedcentral.com)
  • Therefore, effective molecular targeting drugs with high intra-tumor access and retention are urgently needed for managing this devastating disease in the clinic. (biomedcentral.com)
  • Furthermore, using in vivo-imaging, we found that FL118 in combination with cisplatin strongly inhibited both drug-resistant pancreatic xenograft tumor growth and metastasis. (biomedcentral.com)
  • Therefore, development of novel drugs with favorable pharmacokinetic (PK) profiles of tumor accumulation to overcome chemoresistance and the desmoplasia barrier to drug access would fulfill an unmet need for effective treatment of PDAC. (biomedcentral.com)
  • We have particular expertise in immuno-oncology, where we can help you understand the immunomodulatory effects of your drug candidates within the tumor microenvironment and/or in combination with other immune modulators, efficiently progressing your route to clinic. (conceptlifesciences.com)
  • Mixed lymphocyte reaction (MLR) assays can be used to understand the effects of biologics or small molecules on T cell activation, an important immune response in the tumor microenvironment (TME). (conceptlifesciences.com)
  • Células cultivadas in vitro procedentes de tejido neoplásico que se utilizan en el estudio de las capacidades metabólicas y proliferativas de las células tumorales, en el pronóstico de las respuestas clínicas a la quimioterapia, en la detección de nuevos agentes antitumorales y en las investigaciones biológicas básicas. (bvsalud.org)
  • Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC 50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. (port.ac.uk)
  • The in vitro anti-proliferation activity of potential agents selected from tumorsphere assay is more translatable into in vivo anti-tumorigenic activity compared with general monolayer culture. (oncotarget.com)
  • Synthesis and in vitro screening of novel N-benzyl aplysinopsin analogs as potential anticancer agents. (uams.edu)
  • The Ramsay laboratory (Peter MacCallum, Melbourne) has successfully co-cultured patient-matched rectal cancer tumouroids with tumour infiltrating lymphocytes (TILS) in a novel in vitro assay, preliminary data generated suggests this assay has the ability to predict the response of a patient to treatment with NACRT prior to instigation of neo-adjuvant therapy. (olympus-lifescience.com)
  • Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. (port.ac.uk)
  • Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. (nih.gov)
  • Besides, cytotoxic activity screening of the extracts was also carried out with view to assess the presence of antitumor activity of different extracts. (ijpsr.com)
  • Automated analysis utilising artificial neural networks is a feasible approach to expedite the processing of data generated from the cytotoxic killing assays and will improve the clinical utility of this platform to direct personalised patient therapy. (olympus-lifescience.com)
  • However, kinase assays failed to confirm the inhibition of Plk1. (nottingham.ac.uk)
  • To evaluate an investigational assay for detecting T. cruzi infection in blood donations, the American Red Cross conducted a clinical trial during August 2006--January 2007, screening 148,969 blood samples at three blood-collection centers in the United States. (cdc.gov)
  • In January 2007, after the new assay was licensed by the Food and Drug Administration (FDA), other centers began screening donors for T. cruzi . (cdc.gov)
  • The basis of our proprietary mouse assay centers around our TCR transgenic CD4+ T cells, which can be stimulated with WT-MBP to induce a fully responsive effector T cell, or with an altered ligand MBP (APL-MBP), which acts as a superagonist to generate exhausted T cells. (conceptlifesciences.com)
  • Biological or molecular targets for drug discovery and the sources and types of natural products to be investigated will be selected by the applying Group. (nih.gov)
  • Based on previous reports, we hypothesized the similarity in biological functions or genes perturbed by two drugs can determine their synergistic effects. (biomedcentral.com)
  • Applications that emphasize drug synthesis with limited biological assessments are reviewed in CBP. (nih.gov)
  • Furthermore, it was found that ST6GalNAc1, the sTn antigen synthase gene, was involved in the migration-proliferation dichotomy and drug resistance in PCa cells under hypoxia. (bvsalud.org)
  • However, patients still suffer from cancer relapse due to the occurrence of drug resistance. (biomedcentral.com)
  • However, even with such advance in cancer therapeutics, some patients still suffer from refractory responses due to the development of drug resistance. (biomedcentral.com)
  • A common feature of drug resistance is a continuous activation of drug targets or their downstream signaling pathways [ 3 ]. (biomedcentral.com)
  • On the other hand, combinatorial drug therapy may effectively circumvent the acquisition of drug resistance and optimize the efficacy of anticancer drugs. (biomedcentral.com)
  • These treatments should be highly effective but in the present scenario, adverse side effects and resistance to radiation or drug treatments have overpowered its benefits. (springeropen.com)
  • Their selective cytotoxicity to cancer cells was identified in the screening cascade. (nottingham.ac.uk)
  • The test, manufactured by Ortho-Clinical Diagnostics (Raritan, New Jersey), is an enzyme-linked immunosorbent assay (ELISA) that uses epimastigote lysate antigens for detection of antibodies to T. cruzi in serum and plasma ( 8 ). (cdc.gov)
  • use ANTIMICROBIAL CATIONIC PEPTIDES (NM) to search MICROBICIDAL CATIONIC PROTEINS 1981-2000 BX - Microbicidal Cationic Proteins FX - Blood Bactericidal Activity MH - Antiretroviral Therapy, Highly Active UI - D023241 MN - E2.319.310.75 MS - Drug regimens, for patients with HIV INFECTIONS, that aggressively supress HIV replication. (nih.gov)
  • 4. P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells. (nih.gov)
  • Because of the complexity and heterogeneity of cancers, single drug alone may not be effective enough to completely and continuously suppress the activity of critical oncogenes or pathways. (biomedcentral.com)
  • There are shared interests in chemical and biochemical aspects of drug discovery and probe development with Macromolecular Structure and Function A (MSFA) . (nih.gov)
  • Subsequent studies required for development of new treatments (e.g., formulation development, large-scale production for clinical trials, or toxicology in support of Investigational New Drug Applications, etc.) as well as the clinical trial itself, are beyond the scope of this RFA. (nih.gov)
  • Tumorsphere assay can also measure the outcome of clinical trials for potential anti-cancer agents. (oncotarget.com)
  • However, given the large number of drugs that are approved by FDA or under clinical trials, it seems to be impractical to experimentally test the synergy of all possible drug combinations, motivating the development of efficient computational methods for systematic screening and prediction of synergistic combinations. (biomedcentral.com)
  • There are more than 1500 plant derived anticancer compounds which can be developed as potential drugs are under research and about five hundred drugs are under clinical trials. (springeropen.com)
  • Thus, it is an imperative prerequisite to develop potent and less noxious drugs for fighting cancer with its ever increasing demand. (springeropen.com)
  • Together, our studies suggest that FL118 is a promising anticancer drug for further clinical development to effectively treat drug-resistant pancreatic cancer alone or in combination with other pancreatic cancer chemotherapeutic drugs. (biomedcentral.com)
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin capsules USP and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (nih.gov)
  • The results of the Annexin-V/PI apoptotic assay demonstrated that many compounds induced significantly early (89-146%) and a dramatically late (556-1180%) cell death in comparison to the vehicle control of MCF-7cells. (tamu.edu)
  • Our 96-well plate format allows for moderate-throughput screening of multiple compounds, helping you achieve fast, precise results. (conceptlifesciences.com)
  • We have developed both a murine and human exhausted CD4+ T cell assay, an important tool to test the efficacy of compounds in reversing T cell exhaustion and restoring normal effector function. (conceptlifesciences.com)
  • Our moderate-throughput assay is ideal for evaluating the efficacy of compounds able to modulate checkpoint targets on immune cells. (conceptlifesciences.com)
  • Based on the reductionist "one gene-one disease" premise [ 2 ], antitumor drugs are designed to inhibit the growth of cancer cells by targeting essential genes or pathways with high specificity and efficacy, reducing damages to the normal cells. (biomedcentral.com)
  • Organoid and three-dimensional (3D) cell culture are emerging as pivotal systems for understanding human organ development, modeling disease, screening for drug efficacy or toxicity, and investigating personalized medicine. (olympus-lifescience.com)
  • The crude carbon tetrachloride, n-hexane, and methanol extract of the plant were subjected to antimicrobial screening against 15 microorganisms such as gram-positive, gram-negative, fungi by the disc diffusion method. (ijpsr.com)
  • A technique in which electric pulses of intensity in kilovolts per centimeter and of microsecond-to-millisecond duration cause a temporary loss of the semipermeability of CELL MEMBRANES, thus leading to ion leakage, escape of metabolites, and increased uptake by cells of drugs, molecular probes, and DNA. (umassmed.edu)
  • Non-invasive imaging of cells that have been labeled non-destructively, such as with nanoemulsions or reporter genes that can be detected by molecular imaging, to monitor their location, viability, cell lineage expansion, response to drugs, movement, or other behaviors in vivo. (childrensmercy.org)
  • The DREAM challenge has confirmed the potentiality of computational methods for predicting synergistic drug combinations, while the prediction accuracy can be further improved. (biomedcentral.com)
  • Plants have a great potential for producing new drugs for human benefit. (ijpsr.com)
  • We offer activated human peripheral mononuclear cell (Human PBMC) and T cell activation assays to help you understand the interaction between your compound or biologic and the immune system, taking you to the clinic faster. (conceptlifesciences.com)
  • To test the feasibility of the hypothesis, we proposed three scoring systems: co-gene score, co-GS score, and co-gene/GS score, measuring the similarities in genes with significant expressional changes, enriched gene sets, and significantly changed genes within an enriched gene sets between a pair of drugs, respectively. (biomedcentral.com)
  • Since our method is constructed on a gene set-based analysis, in addition to synergy prediction, it provides insights into the functional relevance of drug combinations and the underlying mechanisms by which drugs achieve synergy. (biomedcentral.com)
  • Notably, the tuberculin skin test result was negative at screening before she began the TNF-αA treatment, but was now positive (20 mm), suggesting mycobacterial infection. (cdc.gov)
  • Side effects of concern are infectious diseases, which prompt the need for screening for latent mycobacterial infection before commencing treatment ( 7 ). (cdc.gov)
  • While no data are available for review, OPA has been noted as positive in the guinea pig maximization test and the mouse local lymph node assay. (nih.gov)
  • In 2005, a new commercial test for blood-donation screening for Chagas disease was developed. (cdc.gov)
  • However, FDA has not licensed a supplemental test as a confirmatory assay in blood donation screening for T. cruzi antibodies. (cdc.gov)
  • Based on summary information in Material Safety Data Sheets and statements on the internet, it appears that OPA is not mutagenic in bacterial tests, but causes chromosomal aberrations in mammalian cell assays. (nih.gov)
  • Historic drug susceptibility data was reviewed ( Table ). (cdc.gov)
  • However, manual analysis of the data generated from this assay is time consuming and limits the clinical utility of this platform. (olympus-lifescience.com)
  • Machine-based learning to develop artificial neural networks capable of analysing data produced from the killing assay has been developed to automate analysis. (olympus-lifescience.com)
  • Response to combinatorial drug therapy is optimized when a drug combination achieves greater (synergistic) effects than independent effects [ 1 ]. (biomedcentral.com)
  • Researchers want to see if a drug called NT-I7 can help a person s immune system fight KS safely and without too many side effects. (nih.gov)
  • To learn the safety and potential side effects of drug NT-I7 in people who have KS with or without HIV. (nih.gov)
  • Some screening tests will be repeated during the study. (nih.gov)
  • NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS Release Date: April 14, 1999 RFA: CA-99-010 (see reissuance RFA-CA-05-001 ) P.T. National Cancer Institute Letter of Intent Receipt Date: June 16, 1999 Application Receipt Date: July 14, 1999 This RFA is a reissuance of CA-95-020, which was published in the NIH Guide on September 22, 1995. (nih.gov)
  • PURPOSE The Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, invites applications for the continuance of the National Cooperative Drug Discovery Group (NCDDG) and National Cooperative Natural Products Drug Discovery Group (NCNPDDG) Programs for the discovery of new and more effective anticancer treatments. (nih.gov)
  • This RFA, National Cooperative Drug Discovery Groups, is related to the priority area of cancer. (nih.gov)
  • The primary focus is on fundamental studies using chemical biology and probe development approaches to illuminate pathways, often relevant to the earliest stages drug discovery. (nih.gov)
  • Applications that emphasize drug function and therapeutic potential are reviewed in DMPA, DMPB, or DMPC. (nih.gov)
  • The wide variety of polymers used in microneedle fabrication can provide a broad scope for drug delivery and other biomedical applications. (mdpi.com)
  • This method also provides a reliable platform for screening potential anti-CSC agents. (oncotarget.com)
  • It is of great need to explore potential combinatorial drug therapy since individual drug alone may not be sufficient to inhibit continuous activation of cancer-addicted genes or pathways. (biomedcentral.com)
  • We also applied the proposed method to the Connectivity Map dataset to explore more potential synergistic drug combinations. (biomedcentral.com)
  • We have thus engineered a versatile High Content Screening (HCS) device to streamline all the steps of organoid culture to exploit its potential in morphogenesis understanding. (olympus-lifescience.com)
  • The method is widely applicable to expression profiles of other drug treatments and is expected to accelerate the realization of precision cancer treatment. (biomedcentral.com)
  • This assay provides a pre-clinical platform that encapsulates the hosts immune response toward their tumour. (olympus-lifescience.com)
  • After a clinical trial in 2005 with approximately 40,000 blood donors resulted in only one repeat reactive specimen (which tested negative with RIPA) ( 8 ), the American Red Cross conducted a larger study of the new screening assay in areas where Chagas was expected to be more prevalent. (cdc.gov)
  • Blood donations collected during August 28, 2006--January 28, 2007, were tested with the screening assay for those blood donors willing to participate in the study. (cdc.gov)
  • Efficient drug delivery with minimal invasion is the prime advantage of microneedles. (mdpi.com)
  • There are shared interests in drug development with Drug and Biologic Disposition and Toxicity (DBDT) . (nih.gov)
  • extensive research is en-route to find natural aspects for control and cure of cancer. (springeropen.com)

No images available that match "drug screening assays antitumor"